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 Abstract 
Hand, Foot and Mouth Disease (HFMD) plays a major role in childhood morbidity 
and mortality in Vietnam and the Asia-Pacific region. The spectrum of severe 
disease and predictors for poor outcome are not well understood, and the 
evidence-base for management of hypertension in severe cases is lacking. 
In this thesis I describe the clinical features, their evolution over time, and the viral 
serotype/genotype findings, among 1272 HFMD cases admitted to PICU at the 
Hospital for Tropical Diseases (HTD), Ho Chi Minh City, during the the 2011-2012 
Vietnam outbreak. Fever, skin rash, and myoclonic jerks happened in the early stage 
while the more severe features, including hypertension, tachypnea, irregular 
breathing, pulmonary edema and shock occurred after day 3. Most severe features 
were associated with EV-A71 infection rather than with Coxsackieviruses (CV). 
However having mouth ulcers without skin lesions was associated with CV infection. 
The C4 genogroup of EV-A71 was associated with more severe neurological 
involvement. Risk factors present within 24 hours of PICU admission that were 
associated with subsequent deterioration to severe outcome were skin lesions and 
tachypnea, while presence of mouth ulcers alone was protective.  
I also describe the development and execution of a randomized controlled trial of a 
novel treatment, MgSO4, for severe HFMD with hypertension secondary to ANS 
dysregulation. However, only 26 of the planned 190 patients were enrolled before 
the outbreak was controlled, and with this small number we found no evidence of 
benefit in this trial. In another approach, I assessed the efficacy of MgOS4 on severe 
hypertension among 33 patients treated with open-label MgSO4 compared to 12 
patients of similar clinical severity who did not receive this intervention, and found 
a significant reduction in mean arterial pressure among the MgSO4 recipients. 
However, It is clear that with the small sample size, these data are insufficient to 
address the important question originally posed. Using our pre-prepared protocol 
as a basis, a much larger trial could be developed at short notice in the event of 
another outbreak, to properly evaluate whether MgSO4 has a role in controlling the 
blood pressure in severe HFMD. 
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Chapter 1 
INTRODUCTION 
1.1 Human enterovirus infections 
Human enterovirus infections affect many millions of people worldwide each year. 
Although they are named for their transmission route through the intestine, 
enteroviral infections have a broad range of presentations involving many organs and 
systems (e.g. fever with rash, upper respiratory infections, encephalitis, pericarditis), 
and gastrointestinal symptoms are rarely prominent. Many infections are very mild 
and may go unnoticed, but given the variety of possible signs and symptoms they are 
also on the differential diagnosis list of a wide range of illnesses, some of which can be 
very severe. One particularly important virus, poliovirus, was extensively researched in 
the twentieth century largely due to the severity of illness it caused. As a result, 
effective vaccines that were developed have been deployed globally with massive 
worldwide effort, and polio has now been virtually eradicated from both developed 
and developing countries. However, non-polio enteroviruses have received much less 
attention, and remain major causes of disease affecting a large number of people, 
especially children, around the world. Since this thesis relates to hand, foot and mouth 
disease (HFMD), the main focus of the introduction will be on non-polio enteroviruses. 
1.1.1 Virology, physical characteristics and classification  
Enteroviruses belong to the family Picomaviridae and the genus Enterovirus. The factor 
that distinguishes enteroviruses from other picornaviruses (i.e. rhinoviruses) is their 
stability in low pH environments. Enteroviruses persist in ether and alcohol solutions 
and can cause infection in pH 3-10 environment, but are inactivated at a temperature 
above 500 C [1]. All enteroviruses share these common physical and biological 
characteristics. The non-enveloped virion diameter is about 30 nm, and the icosahedral 
viral capsids are composed of four structural proteins namely viral protein (VP) 1, VP2, 
VP3 and VP4. Each capsid contains a total of about 60 structural proteins.  
The virus genome is a single stranded positive-sense RNA molecule of 7,5 kb in length. 
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This genome encodes for the structural proteins (VP1 - VP4), and nonstructural 
proteins (including RNA polymerase and protease). The protein coding region is 
flanked by the 5’ untranslated region (UTR) and the 3’UTR. The former is a highly 
conserved region across enterovirus genomes (Figure1.1). This genome starts with 
5’UTR that contain Internal Ribosome Entry Site (IRES), the protein coding region, linked 
to Virion protein (Vpg) and ends with 3’UTR that contains a pseudoknot and the poly 
(A) tail. These two play a role in starting and ending the translation and replication of 
the virus [1].  
 
 
 
 
Figure 1.1: The picornavirus genome (reproduced from [1]) 
VPg: Virion protein, UTR= Untranslated region, L= leading protein code; VP1-VP4 encode for viral capsid 
proteins; 2A, 3C and 3D encode for proteins functioning as proteins processing; 2B, 2C, 3A, 3B, 3C, and 
3D encode for proteins involving genome replication of enteroviruses.  
 
The enterovirus group originally included 72 serotypes that were identified by their 
neutralization reactions with specific antibodies, and these were classified into 5 
subgroups based on different susceptibility of the host and pathogen [2, 3]. Recently, a 
number of new serotypes have been identified by molecular biological methods, and 
the non-poliovirus enteroviruses have been reclassified into 13 species that are divided 
into 4 main human virus groups, now named EV-A, EV-B, EV-C, and EV-D, plus 6 animal 
enterovirus groups, ie. EV-E, F, G, H, I and J, and 3 rhinovirus groups (A, B, and C) based 
on the homogenous characteristics of VP1 protein encrypted RNA [4-6]. However, 
among all these, around 10 to 15 serotypes are responsible for the majority of human 
diseases, as described in Table 1.1, section 1.1.5 [7, 8]. 
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Figure 1.2: Enterovirus classification  
 (derived from http://www.picornaviridae.com/enterovirus/ev-a/ev-a.htm) 
 
 
 
 
 
 
 
 
 
 
 
 
Picornaviridae 
*: Enterovirus species E, F (former name bovine enterovirus), Enterovirus species G (former name  porcine enterovirus), H, J (former 
name simian enterovirus A) and I, are commonly seen in animals 
EV=enterovirus, CV= Coxsackievirus; SV= Simian  enterovirus; BA= baboon enterovirus 
 
Enterovirus 
CV-A 2-8, 10, 12, 14, 
16 
Enterovirus: 
E,F,G, H,I,and J* 
Rhinovirus A,B,C Enterovirus D 
(5 serotypes) 
Enterovirus A 
(25 serotypes) 
EV A-71, 76, 89, 90-
92, 114, 119-121 
Enterovirus B 
(63 serotypes) 
CV-B 1-6, CV-A9 EV-D68, 70, 94, 11 
EV-C95, 96, 99, 102, 
104, 105, 109, 
113,116-119 
Poliovirus 1,2,3 
Echovirus 1-7, 9, 11-
21, 24-27, 29-33 
Enterovirus C 
(23 serotypes) 
CV-A1, 11,13,17,19-
22, 24 
EV-B69, 73-75, 77-88, 
93, 97, 98, 100, 101, 
106, 107, 110-113 
SV 19, 43, 46, BA 13 
Serotypes 
Species 
Genus 
Family 
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1.1.2 General epidemiology of human enterovirus infections 
Enteroviruses are ubiquitous globally and circulate around the world, but different 
serotypes may be endemic in different regions. For example, while EV-A71 has caused 
large outbreaks of HFMD in the Asia-Pacific region, EV-D68 has emerged in recent 
years to cause prominent outbreaks of respiratory infections in the US and Europe [9, 
10], and Eastern Asia [11, 12]. Young children under 5 years old are usually more 
susceptible to enterovirus infection than adults. Many studies have revealed that 
enterovirus infections happen more frequently in males than in females. The male-to-
female ratio is between 1.2 and 2.5: 1 [13]. 
Transmission  
These viruses are transmitted from person to person when virus is shed from the 
gastrointestinal or respiratory tracts of an infected individual. Typically, transmission 
occurs by the faecal-oral route, but enteroviruses are also found in body secretions; for 
example EV70 was demonstrated to be present in tears, contributing to an outbreak of 
conjunctivitis in Samoa [14], while EV68 was found in respiratory secretions resulting 
in spread between patients in Cambodia and Philippines [15, 16]. 
Transmission between humans occurs both directly and indirectly. Direct transmission 
occurs when people come into immediate contact with infected material, such as 
faeces during diaper changing. Indirect transmission occurs when individuals, 
particularly children, come into contact with contaminated water, food, toys, that they 
put in their mouths. Poor hygiene, particularly failure to wash hands before meals 
contributes to this transmission cycle [12, 17-20]. Longitudinal surveys indicate that 
secondary infections occur in 53% of exposed household contacts, and confirm that 
Infants, especially those in diapers, were the main source of infection. The role of virus 
persistence in both symptomatic and asymptomatic individuals who are basically 
healthy may be important but remains to be clarified [21]. However it is clear that 
chronic viral persistence can occur in immunocompromised individuals, thus increasing 
the risk for secondary virus transmission [22-24]. 
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Relationships between serotypes, seasonality, and outbreaks  
Enteroviruses are distributed worldwide, with transmission patterns influenced by 
both season and climate. Monitoring circulating enteroviruses can be helpful to 
identify changes in the predominant serotypes, which may be accompanied by large-
scale outbreaks. For example, epidemiological surveillance reports from 2002 to 2004 
in the United States were used to examine temporal and geographic patterns of 
serotypes; the two predominant enteroviruses, echoviruses 9 and 30, which had not 
been common previously, accounted for more than half of all enterovirus detections 
during this time and the increased surveillance reports coincided with peaks in 
hospitalizations for aseptic meningitis [25].  
Reported case numbers can increase dramatically in comparison to prior/baseline 
incidence data during an outbreak [26]. Global epidemics also occur: e.g. associated 
with echovirus 10 in the end of 1950s; associated with echovirus 11 in 1979-1980; and 
an EV 70 conjunctivitis outbreak commencing in 1969. Enterovirus infections occur 
throughout the year but numbers usually increase in the warmer seasons. Published 
surveillance data show that outbreaks often happen during the summer in tropical 
countries [27], and in summer and fall in northern countries [28, 29]. Humidity is also 
thought to play a role in outbreak occurrence [27, 29, 30], and there are concerns that 
the global warming phenomenon may result in increased incidence and a wider 
geographical distribution of enterovirus infections [30, 31]. A seasonal model 
developed by a Japanese group almost exactly matched annual fluctuations in local 
case numbers and predicted that warmer climate conditions would lead to an 
increased number of herpangina (HA) and HFMD cases, simulating the impact of global 
warming [32].    
1.1.3 Pathogenesis  
Cellular invasion, replication and dissemination 
After infection via the oral route, enteroviruses replicate initially in the submucosal 
tissues of the distal pharynx and the gut, particularly the terminal ileum. Recently, they 
were also found replicating in tonsillar crypt squamous epithelium [33]. Although 
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incubation times vary depending on the virus involved and the particular clinical and  
syndrome, average times are around 3-5 days, after which fever develops in those who 
become symptomatic. During this period the virus migrates to regional lymph nodes 
and begins replicating there. Viral particles may therefore be shed before the onset of 
symptoms.  
Different enteroviruses attach to cell membranes via particular receptors, and these 
receptors are both virus and host specific, eg. P-selectin glycoprotein ligand-1 (PSGL-1), 
Scavenger receptor class B (SCARB2) are receptors for EV-A71 while Decay-accelerating 
factor (CD55) is a receptor for certain Coxsackieviruses (CV), echoviruses, and 
enterovirus 70, therefore determining host susceptibility [1]. After attachment, a 
conformational change takes place in the viral capsid proteins, resulting in formation 
of a pore in the cell membrane through which viral RNA is injected into the cell. The 
RNA un-coats rapidly and the whole process of replication is complete on average 
within 8 hours, when the cell dies and lyses to release the new viral particles (Figure 
1.3).  
 
 
 
 
 
 
 
 
 
A= Adsorption and penetration, B= translation and synthesis of viral proteins; C= Cleavage of 
the precursor protein; F= formation of viral capsid; D= negative-sense RNA replication, E= 
positive-sense RNA replication, G: Assembly; P: precursor protein, VP: viral protein 
Figure 1.3: The invasion and replication of enterovirus species  
(http://www.microbiologybook.org/virol/picorn-rep.gif) 
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After about 5 to 10 hours whole virions may be seen on electron microscopy; each 
infected cell contains around 104-105 virions, and between 0.1-10% of them are 
infectious [34, 35]. 
Knowledge about replication and dissemination of enteroviruses is based on early 
research in animal models conducted by Bodian, Sabin and others (Figure 1.4) [36, 37]. 
During the initial replication phase involving the pharynx and terminal ileum, relatively 
low level primary viremia results, following which viral spread occurs to lymph nodes 
and organs of the reticulo-endothelial system. Viral replication at these sites causes a 
secondary viremia that coincides with the onset of symptoms and with viral 
dissemination to other target organs, potentially including the central nervous system 
(CNS) that will be discussed in the next section. Infectious virus is shed from the upper 
respiratory tract for about 1-3 weeks and is eliminated in stool for 3-11 weeks [38]. 
The most infectious period for the community is around 2 weeks after infection [39].  
Invasion into the central nervous system (CNS)  
First of all, enteroviruses invade and replicate in the gastrointestinal tract, after which 
they disseminate to their target organs/tissues via specific pathways. The broad 
spectrum of neurological manifestation of enterovirus infection, including aseptic 
meningitis, brainstem encephalitis (BE) and polio-like myelitis suggest that non-polio 
entervirus, including EV-A71, can invade the CNS either through a disintegrated blood–
brain barrier or via retrograde axonal spread along cranial or peripheral nerves. Most 
previous studies of the way that enteroviruses invade the CNS were focused on the 
poliovirus that could invade into the CNS through neuromuscular junctions [40, 41]. 
However, it has demonstrated that EV-A71 enters the CNS via retrograde axonal 
transport pathways in mice [42]. Another possible pathway is through intermediary 
vehicles such as CV infected Mac-3+ mononuclear cells, or EV-A71 infected CD14+ 
cells, dendritic cells, and PBMCs; these cells have the ability to invade the CNS through 
the choroid plexus epithelium [43-45]. However, evidence to support viral entry to the 
CNS utilizing infected immune cells CNS remains limited until now. 
  
Chapter 1 
8 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.4: Bodian's classic diagram of polio pathogenesis  
(http://www-micro.msb.le.ac.uk/3035/Picornaviruses.html) 
Chapter 1 
9 
 
  
1.1.4 Immunological responses 
1.1.4.1 Innate immune response 
When viruses invade the human body, host antiviral innate immune responses are 
activated through pathogen recognition receptors such as retinoic acid-inducible gene 
(RIG-I)-like receptors (RLRs) and Toll-like receptors (TLRs) [46] or NOD-like receptors 
(NLRs) [13] that respond viral RNA as an antigen. As a result, pathways of cytokine and 
chemokine production are triggered. Both type of receptors, TLRs and RLRs, modify the 
expression of hundreds of genes encoding for a diversity of cytokines, chemokines, and 
other proteins, some of which can directly counter virus infection, e.g. Protein Kinase 
regulated by RNA (PKR) and type I interferons (T1IFNs) response which play an 
important role in regulating infection by altering tissue tropism, while NLRs may 
regulate the development of the adaptive antiviral immune [13]. Those responses have 
been revealed in vitro in some studies, eg. CV-B4 triggers TLR4 on human pancreatic 
cells, or CV-B3 activates TLR4 knockout (KO) mice, resulting in reduced virus titers and 
myocarditis. Stimulation of TLRs may increase the severity of disease, e.g. TLR4 
stimulants such as lipopolysaccharides (LPS) greatly increase the severity of CVB-
induced myocarditis, or conversely may control CVB infections, eg. TLR3-triggered 
responses protect against myocarditis associated with CV-B3 [13].  
Briefly, the innate immunity response help to start the nonspecific defense 
mechanisms immediately or within hours of an enterovirus antigen's appearance in 
the body, thence activating the system inflammation response and the adaptive 
immunity response.  
1.1.4.2 Adaptive immune responses 
Humoral immunity  
The virus triggers an immunoglobulin M (IgM) response that can be detected by the 
second day and may persist for 3 months after the onset of symptoms [47, 48] as well 
as a strong neutralizing IgG response that recognizes epitopes in the N-terminal 
segment of VP1 [13]. While immunoglobulin A (IgA), which has been found in 
enterovirus infections [49], is responsible for maintaining the local immunity barrier. 
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IgA persists in the intestinal mucous for 2-4 weeks after infection, and protects the 
host from secondary infections [50] that can occur in situations where the enterovirus 
persists in the gut for many weeks after infection [38, 51]. Immunological responses to 
enterovirus infection are quite specific in terms of serology [52]. Therefore, patient 
may develop the symptoms if they are infected later with a different serotype [53], but 
are usually asymptomatic when re-infected with the same serotype.  
Cell mediated immunity  
Together with the humoral immune response, cell mediated responses provide a 
strong barrier to protect people from viral infections. Memory T-helper 1 (Th1) CD4+ T-
cell responses specific for the three epitopes in VP1 have been identified in EV-A71-
positive individuals [54]. CD4+ T-cells may help enhance the production of strong 
neutralizing antibody responses in mice infected with CV-B3 [55]. Another study 
showed that a decrease in different regulatory T-cell populations correlates with an 
increase in EV-A71 disease severity [56]. Studies in CV-B3 infected mice have show that 
myocarditis was related to cytotoxic T cell responses [57, 58]. B cells may act as a 
reservoir for virus dissemination during persistent CVB infection [59], and hereditary or 
acquired defects in B lymphocyte function, such as X-linked deficiencies, result in the 
persistent enterovirus infections [23, 60]. 
1.1.5 Clinical manifestations of non-polio enterovirus infections 
With the success of the World Health Organization (WHO) international polio 
eradication program, clinical disease due to wild-type poliovirus is rarely seen 
nowadays [61]. However occasional vaccine-associated cases do occur following use of 
live attenuated polio vaccines; these cases are similar to wild-type infections but are 
rare. This section will therefore focus on the range of clinical manifestations seen with 
non-polio enteroviruses.  
Among this group, i.e. the non-polio enteroviruses, the vast majority of infections are 
either asymptomatic or mild undifferentiated febrile illness. Typically there is sudden 
onset of high fever that may be accompanied by symptoms such as myalgia, headache, 
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sore throat, nausea, vomiting, mild abdominal discomfort, or diarrhea. The fever 
sometimes lasts up to a week and may show a biphasic pattern (Figure 1.5) [62].  
 
 
 
 
 
 
 
 
 
 
Figure 1.5: Clinical course, viral isolation, and antibody response in enteroviral 
infection 
(Theoklis Zaoutis, and Joel D. Klein Pediatrics in Review 1998;19:183-191) 
 
In the second phase of viral dissemination, enteroviruses can cause a wide range of 
signs and symptoms with a broad spectrum of severity, ranging from high fever to life-
threatening manifestations. Clinical manifestations vary from asymptomatic disease to 
severe syndromes such as aseptic meningitis, myocarditis, and encephalitis (Table 1.1). 
These manifestations may occur alone or together [25, 63]. For example, EV-71 causes 
aseptic meningitis, encephalitis, HA, and lower respiratory tract infections. While EV68 
infection in children may produce a respiratory outbreak characterized by pneumonia 
and wheezing [12]. These clinical signs and symptoms may be indicative of disease 
progression, that may be related to the virulence of the particular serotype, and/or the 
nature of the individuals immune response to infection [64]. 
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Table 1.1: Clinical manifestations of non-polio enterovirus infections [8] 
Clinical Syndrome CV group A CV group B Echovirus Enterovirus 
Asymptomatic infection All serotypes All serotypes All serotypes  All 
serotypes  
Undifferentiated febrile 
illness  
 
All serotypes 
 
All serotypes  
 
All serotypes  
 
68, 70, 71 
Aseptic meningitis 
(often associated with 
an exanthema) 
1, 2, 3, 4, 5, 6, 7, 
8, 9, 10, 11, 14, 
16, 17, 18, 22, 
24 
1, 2, 3, 4, 5, 6 1, 2, 3, 4, 5, 6, 7, 8, 9, 
10, 11, 14, 16, 17, 18, 
20, 21, 22, 23, 24, 25, 
30, 31, 33 
70, 71 
 
Encephalitis 
2, 4, 5, 6, 7, 9, 
10, 16 
1, 2, 3, 4, 5 2, 3, 4, 6, 7, 9, 11, 14, 
17, 18, 19, 22, 25, 30, 33 
70, 71 
Acute flaccid paralysis 
(Poliomyelitis-like) 
4, 5, 6, 7, 8, 9, 
10, 11, 14, 16, 
21, 24 
1, 2, 3, 4, 5, 6 1, 2, 4, 6, 7, 9, 11, 14, 
16, 17, 18, 19, 30 
 
Myopericarditis 1, 2, 4, 5, 7, 8, 9, 
14, 16 
1, 2, 3, 4, 5, 6 1, 2, 3, 4, 6, 7, 8, 9, 11, 
14, 16, 17, 18, 22, 25, 30 
 
Pleurodynia 1, 2, 4, 6, 9, 10, 
16 
1, 2, 3, 4, 5, 6 1, 2, 3, 4, 5, 6, 7, 8, 9, 
10, 11, 12, 14, 16, 19, 
22, 25, 30 
 
Herpangina 1, 2,3, 4, 5, 6, 7, 
8, 9, 10, 16, 22 
1, 2, 3, 4, 5 6, 9, 11, 16, 17, 22, 25 71 
Hand-foot-and-mouth 
disease 
4, 5, 7, 9, 10, 16  7 71 
Exanthems 2, 4, 5, 7, 9, 10, 
16 
1, 2, 3, 4, 5 2, 4, 6, 9, 11, 16, 18, 25  
Common cold 2, 10, 21, 24 1, 2, 3, 4, 5 2, 4, 8, 9, 11, 20, 25  
Lower respiratory tract 
infections 
7, 9, 16 1, 2, 3, 4, 5 4, 8, 9, 11, 12, 14, 19, 
20, 21, 25, 30 
68, 71 
Acute hemorrhagic 
conjunctivitis 
24   70 
Generalized disease of 
the newborn 
3, 9, 16 1, 2, 3, 4, 5 3, 4, 6, 7, 9, 11, 12, 14, 
17, 18, 19, 20 
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Aseptic meningitis: CV group B viruses and Echovirus are usually the main causes of 
aseptic meningitis. Outbreaks usually associated with single serotype of echovirus 
occur every 5-12 years. 
Prodomal symptoms include fever, sore throat and headache. Meningitic signs vary 
from minor to severe, with Kernig’s sign and Brudzinski’s sign present in one-third of 
patients. The cell count in cerebrospinal fluid (CSF) is usually abnormal, with counts of 
10 to 500 cells/mm3, sometimes up to1000 cells/mm3 early in infection. At this time 
neutrophil counts may be dominant later switching to lymphocytes after a few days. 
Occasionally cell counts may be as low as 10 cells/mm3. Glucose level is normal and 
proteins are also either normal or only slightly increased in CSF. Enterovirus may be 
identified in CSF or other samples using PCR or cell culture methods. In suspected 
enterovirus meningitis cases, the sensitivity of PCR ranges from 66 to 90% on CSF, 
while the sensitivity of viral isolation ranges from 30 to 35%. But when combined with 
culture of other specimens such as throat swab, urine, faeces, the ability to detect 
virus increases.  
Admission is not necessary for all patients with aseptic meningitis. However, 
hospitalization is recommendation if patients have confusion, muscle weakness, or 
rash, since these signs may indicate that disease could progress to severe disease. 
Encephalitis: Enteroviruses, including poliovirus, accounting for 11-22% of virally 
defined encephalitis cases and 5% of clinically diagnosed cases. Thus enteroviruses 
rank fourth after other agents causing encephalitis, such as arboviruses, herpes 
simplex, and lymphocytic choriomeningitis virus [65, 66]. However, during epidemics 
this proportion is likely to rise higher. According to Cheng el al (2008), enterovirus was 
the cause of 24 % of encephalitis cases in Taiwan [63]. Many serotypes can cause 
encephalitis (Table 1.1). In some studies of HFMD in the Asia Pacific region, EV-A71 
was prominent in the etiology of a range of CNS manifestations including encephalitis 
[67, 68].  
Encephalitis is just one of several clinical features of systemic enterovirus infection in 
neonate. However, in older children and adolescents the signs and symptoms of 
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enteroviral infection are usually limited to the CNS. Clinical manifestations vary from 
stupor, lethargy, and behavioral abnormalities to convulsions, paralysis and coma. 
Focal encephalitis in children presents with localized seizures, abnormal movements, 
and/or ataxia that can mimic herpes simplex encephalitis.  
Most neonates with encephalitis caused by CV and Echovirus recover fully. Some cases 
have persistent neurological sequelae, but fatalities are rare. In contrast encephalitis 
that is associated with EV-A71 or echovirus 7 often presents a more complicated 
clinical picture. However the most concerned feature is brainstem encephalitis, since 
ANS dysregulation may happen, potentially with rapid progression to cardiopulmonary 
collapse and a fatal outcome [69, 70].  
Acute flaccid paralysis (AFP): Poliomyelitis, resulting in paralysis or weakness of one or 
more limbs has been virtually eradicated globally, except for rare reports from some 
developing countries. However, acute paralysis similar to paralytic poliomyelitis can 
occur with other serotypes of enterovirus, particularly EV-A71 and EV-D68; such 
complications have been described in outbreaks in America and Russia [71-73]. 
Recently, AFP was reported in about 10-15% of cases who had neurological 
manifestations during and HFMD outbreak in Taiwan, China [74, 75]. Huang reported 
that 4 patients had acute unilateral or bilateral flaccid paralysis with or without other 
signs of HFMD. One patient presented with a transiently atonic neurogenic bladder. 
Three of the four patients had abnormal lesions of the left anterior horn or ventral 
roots on Magnetic Resonance Imaging (MRI).  
Other clinical manifestations: Enterovirus species can also cause a range of other rare 
clinical features, such as myopericarditis, which is mostly associated with CV-B3 [76, 
77], or acute hemorrhagic conjunctivitis, which is usually associated with EV-A70 [14] 
or CV-B24 [78] (Table 1.1). Recently, EV-D68 was responsible for several outbreaks of 
lower respiratory tract disease in China [11], Japan [79] and some Western countries 
[10, 80]. 
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1.2 Hand, Foot and Mouth Disease (HFMD) 
HFMD had been described as a clinical syndrome since 1928 [81]. This disease is 
viewed as one of the common clinical manifestations of enterovirus infection and is 
usually self-limited. CV-A16 is a common causative agent, but many other 
enteroviruses, including EV-A71, can cause this disease. During the last two decades, a 
small proportion of HFMD patients have been noted to progress rapidly to severe and 
sometimes fatal outcomes. The spectrum of clinical features of HFMD has expanded 
considerably, and now includes minor conditions such as HA through to very severe 
disease, such as brainstem encephalitis, myocarditis, and pulmonary edema that may 
be fatal [64, 82, 83]. 
Children under 10 years old are usually the infectious source to other family members. 
Patients often complain of sore throat and anorexia, and after 2 days of fever may 
specifically present with small vesicles in the cheek, buccal mucosa and tongue. These 
lesions can coalesce into larger vesicles and break down to form the typical ulcers that 
are found when examining the mouth. Approximately 75% of cases present with 
specific vesicles on the palms, soles, buttocks, and also sometimes the elbows, knees, 
and genitalia. Skin biopsy of these lesions reveals inflammation in the dermis layer 
accompanied by infiltration of lymphocytes and neutrophils around small vessels in the 
epidermis layer.  
1.2.1 Global Epidemiology of HFMD 
HFMD has been a common, relatively mild pediatric disease in North America and 
Western Europe for many years. However, this epidemiology have changed recently 
[84]. In particular outbreaks of EV-A71 associated disease have been noted in the Asia 
Pacific region for the last 3 decades. In 1987, a serious outbreak of HFMD was reported 
in Hong Kong, caused by EV-A71 [85]. Then in 1997, EV-A71 was reported as the cause 
of other HFMD outbreaks in Southeast Asia such as Sarawak, Malaysia [86, 87]. In 
1998, an EV-A71 outbreak was reported in Taiwan affecting 125,000 children, with 405 
of them being very severe, particularly children under 5 years old. EV-A71 was isolated 
in 92% of the 78 deaths [88]. EV-A71 was the causative in fatal cases associated with 
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HFMD in Ho Chi Minh City, Vietnam in 2003 [89, 90]. From then onwards, HFMD has 
spread to nearly all the Asia-Pacific region (Figure 1.6). 
 
 
 
 
 
 
 
 
 
 
Figure 1.6: Distribution of HFMD around the world (updated from Health Map in May 
2017). (http://www.healthmap.org) 
HFMD is now endemic in many places but with increasing numbers of cases seen in 
summer and autumn [28]. All age groups are affected but infection rates are higher in 
children under 6 years old, especially infants, in whom infection rates are several times 
higher than in older children or adults [91-94]. For unknown reasons, males seem to 
have about 50% higher risk of infection than females. In one genetic study in Taiwan 
with different distribution of gender, HLA-A33 was related to host susceptibility to EV-
A71, but it did not show the link between this factor and gender [95]. 
1.2.2 Epidemiology of HFMD in Viet Nam  
HFMD was first reported in Viet Nam in 2003 following a series of deaths in small 
children under 3 years of age who presented with features of HFMD and deteriorated 
rapidly within 24 hours of admission [96]. EV-A71 was identified as the causal agent in 
these cases [90]. Initially HFMD cases were noted mostly in Ho Chi Minh City, but by 
2005 the disease had spread to many provinces across southern Viet Nam [89]. By 
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2008, in addition to outbreaks occurring in all provinces in southern Viet Nam, HFMD 
was also noted among children living in the central and northern regions (Vietnam CDC 
data, unpublished). Then, in a major outbreak in 2011, 164 deaths were reported 
among 106,000 children who were diagnosed clinically with HFMD across all provinces 
[97] (Figure 1.7). Later, in the HFMD outbreak of 2011-2012, about 10% of the 
encephalitis cases associated with HFMD were found to be infected by other non EV-
A71 enterovirus serotypes (unpublished data).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.7: Maps of HFMD spreading in Viet Nam from 2005 to 2011  
(based on data from Pasteur Institute [89], ProMEDmail sources, and Vietnam CDC 
(unpublished). 
 
According to 2011-2014 surveillance reports (Vietnam CDC data, unpublished), HFMD 
continued to occur endemically and was considered a common disease, with incidence 
rates varying from 76 to 171 cases, and mortality rates from 0.01 to 0.19 cases, per 
100.000 population [98]. 
2005 2008 2011 
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1.2.3 Clinical features 
HFMD: Most cases present with skin lesions or mouth ulcers only. Approximately 10-
30% of hospitalized cases progress to CNS complications, including meningitis, polio-
like paralysis, brainstem encephalitis, etc., in young children [68]. In some cases CNS 
complications, i.e. brainstem encephalitis, progress rapidly to pulmonary edema and 
cardiac failure and death finally. Most of these severe cases are infants or young 
children [69]. The clinical features vary depending on the main serotype circulating, 
the virulence of the virus, the nature of the host’s immune response, and the presence 
of co-infections (Table 1.1). 
The prodromal symptoms include low-grade fever and malaise, followed by 
papulovesicular rash involving the palms or soles of the feet and sometimes knees, 
elbows, and buttocks, often with mouth ulcers. Other dermatological manifestations 
include peri-oral rash and onychomadesis [99]. Recently, some reports have suggested 
that HFMD related to CV-A6 has a more widespread, severe, and varied rash than 
classic HFMD. In these cases a maculopapular rash with or without vesicles may appear 
on the buttocks, knees or elbows, and trunk, and needs to be distinguished from 
bullous impetigo, eczema herpeticum, vasculitis, and primary immunobullous 
disorders [99-101]. 
.  
 
 
 
 
 
Picture 1: Vesicles on the palm and maculopapular rash on the knee of HFMD patients  
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Table 1.2: Proposed clinical case definitions for HFMD/HA and associated 
complications  (WHO) [83] 
 
Disease Proposed Case Definition 
 
HFMD 
Febrile illness with papulovesicular rash on palms and soles, 
with or without vesicles/ulcers in the mouth 
 
HA 
Febrile illness with multiple oral ulcers on the posterior parts of 
the oral cavity. 
 
Aseptic meningitis 
Febrile illness with headache, vomiting and meningism 
associated with presence of more than 5 – 10 white cells per 
cubic millimeter in cerebrospinal (CSF) fluid, and negative 
results on CSF bacterial culture. 
 
Brainstem encephalitis 
Myoclonus, ataxia, nystagmus, oculomotor palsies, and bulbar 
palsy in various combinations, with or without MRI. 
In resource-limited settings, the diagnosis of brainstem 
encephalitis can be made in children with frequent myoclonic 
jerks and CSF pleocytosis. 
 
Encephalitis 
Impaired consciousness, including lethargy, drowsiness or 
coma, or seizures or myoclonus. 
 
Encephalomyelitis 
Acute onset of hyporeflexic flaccid muscle weakness with 
myoclonus, ataxia, nystagmus, oculomotor palsies and bulbar 
palsy in various combinations. 
AFP Acute onset of flaccid muscle weakness and lack of reflexes. 
Autonomic nervous 
system (ANS) 
dysregulation 
Presence of cold sweating, mottled skin, tachycardia, 
tachypnea, and hypertension. 
 
Pulmonary edema/ 
haemorrhage 
Respiratory distress with tachycardia, tachypnea, rales, and 
pink frothy secretion that develops after ANS dysregulation, 
together with a chest radiograph that shows bilateral 
pulmonary infiltrates without cardiomegaly. 
 
Cardiorespiratory 
failure 
Presence of tachycardia, respiratory distress, pulmonary 
edema, poor peripheral perfusion requiring inotropes, 
pulmonary congestion on chest radiography and reduced 
cardiac contractility on echocardiography. 
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HA: is another manifestation of HFMD that can present without skin symptoms. 
Typically, children present first with multiple, painful mouth ulcers in the anterior 
pharyngeal folds, uvula, tonsils and soft palate, though sometimes these lesions can be 
found on the buccal mucosa, tongue and lips as well. The children usually refuse to eat 
or drink because of the painful oral ulcers. Typical skin lesions may then develop on 
their palms and soles a day or two later 
HFMD and HA can be seen separately or together during outbreaks, although one 
clinical presentation usually predominates. Both HFMD and HA are caused by HEV-A, 
including Coxsackie A (serotypes 4, 5, 6, 7, 9, 10, 16) and EV-A71. HA are also caused by 
other serotypes of Coxsackie A, Coxsackie B, and Echovirus (Table 1.1). Co-circulation 
of these serotypes during epidemics of HFMD/HA may result in clinically 
indistinguishable mucocutaneous lesions. Aside from the possibility of progression to 
severe disease (see below) the most common clinical problem occurring with 
HFMD/HA patients is dehydration because of inadequate intake of fluid due to the 
painful mouth ulcers.  
1.2.3.1 Brainstem encephalitis  
Brainstem encephalitis associated with EV-A71 presents with specific clinical 
manifestations. These include myoclonic jerking, vomiting, ataxia, nystagmus and 
cranial nerve palsies. According to Lai (1997), “myoclonus’’ is a sudden, brief and 
involuntary muscular contraction that can occur unilaterally or bilaterally and may be 
symmetrical or asymmetrical, involving the head, neck, trunk, and limbs. Myoclonic 
jerks can occur when the central nervous system, especially the brainstem and 
forebrain, is damaged [102]. Myoclonic jerks have been reported variously in 22-68% 
of hospitalized HFMD patients, and in 86% of patients with brainstem encephalitis they 
are associated with severe disease and a higher incidence of neurological sequelae [74, 
103, 104]. Therefore, the occurrence of myoclonic jerk in HFMD patients is considered 
to be evidence of CNS involvement and one of the warning signs for progression to a 
more severe condition [83]. Other symptoms such as nystagmus, ataxia and tremor are 
said to occur in about 60% of HFMD cases with associated brainstem encephalitis, and 
Chapter 1 
21 
 
  
may indicate involvement of particular regions of the brainstem. Involvement of 
cranial nerve nuclei may results in the cranial nerve palsies that can be seen in 27% of 
the brainstem encephalitis [74]. Respiratory distress, including hyperventilation and/or 
irregular respiratory patterns such as Cheyne-Stokes breathing, occurs in about 22% 
and these disorders are associated with the severity of disease [74].  
1.2.3.2 Autonomic nervous system (ANS) dysregulation 
Dysregulation of the ANS pathways can progress to increasingly severe clinical 
symptoms, including non-cardiogenic pulmonary edema, which can rapidly result in 
cardiorespiratory failure and death.  
Since many of the signs are rather non-specific and can be present anyway among 
children with high fever, or may mimic the normal physiological responses in young 
children in whom both the peripheral and central nervous systems are developing, the 
frequency of ANS dysregulation in severe HFMD is not clear. However, the emergence 
of systemic hypertension (HTN) in HFMD patients is general acknowledged as clear 
evidence of ANS dysregulation. The proportion of children with hypertension among 
HFMD cases is also not clear however, since only severe cases are usually reported; 
more than 36% developed systemic hypertension in a study of 36 severe EV-A71 
infection cases from Taiwan [105], while 17 patients presented with hypertension in 22 
severe HFMD cases reported from China [106] 
Tachycardia is another feature of ANS dysfunction and may present at an earlier stage. 
In clinical practice, a heart rate (HR) persistently over 150 beats/min in the resting 
condition and adjusted for fever is considered as one indicator of ANS dysfunction [83]. 
Cardiovagal HR tests and assessment of heart rate variability (HRV) have been 
suggested as ways to diagnose and monitor autonomic dysfunction [107-109], but 
these tests are not yet practical options in most areas where severe HFMD is an issue. 
In genera HRV decreases in severe HFMD and may associate with CNS involvement and 
predict cardiopulmonary collapse [110]. 
Mottled skin reflects vasoconstriction, and was noted to occur in 7 patients among the 
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29 fatal cases described in the Sarawak outbreak [70]. Profuse sweating has also been 
reported in severe HFMD [111]. Other signs and symptoms of ANS dysregulation 
include refractory fever, i.e. core temperature > 40oC for at least 4 hours despite 
antipyretics, and hyperglycemia [112]. These signs may be warning signs of likely 
progression to severe disease [83]. Patients who present these features suggestive of 
hyper-activation of the sympathetic system could progress to heart failure after 2-5 
hours [111]. 
 
Picture 2: rapidly increasing blood pressure from 159/119 mmHg (Panel A) to 193/139 mmHg 
(Panel B) after about 8 minutes in a 2 year old Vietnamese child with HFMD managed on PICU 
during the 2011-2012 outbreak  
Tachypnea and irregular breathing are also considered as features of ANS 
dysregulation but they may also be related due to brainstem involvement. Some 
patients with these symptoms progress rapidly to more severe respiratory distress, 
including stridor, respiratory muscle retractions, Cheyne-Stokes breathing, etc. 
indicating laryngeal/respiratory muscle paralysis, and potentially development of 
pulmonary edema or cardiorespiratory failure. 
1.2.3.3 Pulmonary edema and cardiorespiratory failure. 
Patients with pulmonary edema usually develop respiratory distress, i.e. increased 
work of breathing with frothy pink secretions often requiring intubation and 
Panel A Panel B 
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ventilation. Typically, this occurs in patients with brainstem encephalitis patients who 
present initially with tachypnea, then deteriorate rapidly over a short period while 
under observation, developing increasingly severe respiratory breathing, tachycardia 
and hypertension. But sometimes, patients presenting with severe respiratory distress 
at admission and suffering from fulminant pulmonary edema may get even worse, 
going on to develop hypotensive shock with poor cardiac output. These patients with 
cardiorespiratory failure are hypotensive requiring inotropes and have poor peripheral 
perfusion, with evidence of decreased cardiac contractility on heart ultrasound and 
pulmonary congestion without cardiomegaly on chest X-ray.  
Some studies describe that the acute cardiorespiratory deterioration is characterized 
by tachycardia, tachypnea, increased respiratory effort, central fever, and poor 
perfusion [113-115]. Most of patients described were also hypertensive[67]. In a study 
to understand the mechanism underlying fulminant pulmonary edema, the mean 
arterial pressure (MAP) dramatically increased and fluctuated before the onset of 
pulmonary edema and then dropped subsequently to hypotensive levels before 
development of cardiorespiratory failure and death [114]. In that study the time from 
onset of respiratory distress to death was about 4 hours.    
 
 
 
 
 
 
 
Picture 3: Pulmonary edema in a 2yr boy diagnosed with enterovirus associated encephalitis: 
X-rays at admission and 6 hours later (unpublished, 2003)  
The proportion of patients developing pulmonary edema has varied from 24 to 72 % of 
fatal cases [70, 97]. In addition refractory shock or respiratory failure or a combination 
At admission  6 hours later  
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of these factors were thought to be responsible for more than 80% of deaths in one 
series, of whom 69% died of refractory shock [97].  
1.2.4 Pathogenesis and pathophysiology 
To date there is no good evidence to confirm that enteroviruses invade the lungs and 
heart directly as targets. Research has not revealed histological or virological evidence 
of direct myocardial invasion in patients with EV-A71 associated brainstem 
encephalitis/hypertension who had left ventricular dysfunction [111]. However, there 
is evidence that enteroviruses, especially EV-A71, can invade and spread within the 
CNS, including the brainstem. The impact of altered cytokine profiles on the 
cardiopulmonary system may also influence the severity of HFMD [116].  
1.2.4.1 Systemic inflammatory responses in HFMD 
System inflammatory responses to enteroviruses, particularly EV- A71, may produce a 
cytokine storm. This phenomenon is thought to play an important role in the 
pathogenesis of severe HFMD, including in development of pulmonary edema, 
myocarditis and encephalitis [117, 118]. EV-A71 related HFMD disease severity has 
been found to relate to altered levels of a number of different cytokines, including 
TNF∝, INFγ, IL6, and IL13, in both blood and CSF, with evidence that these 
concentrations correlate not only with the degree of brainstem and spinal ganglia 
involvement [119] but also with signs of enhanced vasomotor and cardiac sympathetic 
drive [120]. The levels of various pro-inflammatory cytokines were significantly higher 
in patients who manifested acute respiratory failure [116, 121, 122]. This increase in 
pro-inflammatory cytokines may lead to increased vascular permeability in the lung, 
altering the integrity of this barrier to fluid and protein flow into the lung alveolar and 
interstitial spaces, and thus contributing to the non-cardiogenic pulmonary edema 
[123]. Concentrations of many cytokines (interleukin (IL) 1b, IL 1b, IL-6, and IL-8)  and 
chemokines (IP-10, MCP-1, and G-CSF) are increased in the CSF in patients with 
encephalitis [122]. However, interestingly GM-CSF, MIP-1b, IL-2, IL-33, and IL-23, IL-3, 
IL-6, IL-12p40, and tumor necrosis factor (TNF)-a were also elevated in uncomplicated 
HFMD cases [122, 124]. Therefore, at this time the influence of cytokines and 
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chemokines on disease severity remains to be clearly elucidated. 
Host inflammatory responses are also considered to influence the thrombocytosis, 
neutrophilia and hyperglycaemia that can occur in severe HFMD patients, with these 
factors considered as risk factors for severe HFMD [125]. 
1.2.4.2 Central nervous system involvement – neurotropism and pathology 
Different enterovirus serotypes exhibit different neurotropic responses. A model using 
neonatal mice with CV-B3 infection showed that the virus was expressed in the choroid 
plexus and the subventricular area [126]. Moreover, CV-B also damaged the cortex and 
the hippocampus regions in another experiment in an animal model [127]. Echovirus 1 
may cause lesions in the motor cortices in infected animals resulting in paralysis of the 
hind limbs [128]. Meanwhile, EV-A71 attacks the spinal cord, cerebellum, medulla 
oblongata, pons, brain stem, midbrain, dentate nuclei, and cortex according both to 
clinical observational studies and an MR imaging study [74, 129, 130]. At autopsy 
deterioration of neurons was shown, with invasion of monocytes into the gray matter 
of the pons and spinal cord, and EV-A71 was isolated in brainstem tissue and CSF [70]. 
Brain CT and MRI have shown damage to the brainstem in encephalitis associated with 
EV [130-133]. In particular MRI showed damage to the pons in the midbrain and the 
dentate nucleus in the cerebellum. Damage was also seen in cervical spinal cord in 
some cases, although these lesions resolved on scans taken 2 weeks to 2 months later 
[132]. 
 
 
 
 
 
 
Picture 4: MRI showing brainstem involvement in a 5 month old infant presenting with 
neurological complications (unpublished data, 2004). 
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According to Plum and Posner (1982), patients with brainstem damage or herniation 
usually present abnormalities in respiratory pattern and pupil responses. Damage in 
the hippus leads to dilated and fixed pupils; damage to the 3rd cranial nerve causes 
asymmetrical dilated pupils; damage to the pons leads to pinpoint pupils; while lesions 
in the midbrain lead to mid-position fixed pupils. Hyperventilation, Kussmaul’s 
breathing, irregular breathing, Cheyne-Stoke’s or gasping respirations also indicate 
damage to the patient’s brainstem (Figure 1.8) [134]. 
 
 
 
 
 
 
 
 
 
Figure 1.8: Respiratory patterns and pupil abnormalities associated with brainstem 
damage [134]. 
1.2.4.3 ANS dysregulation 
The ANS is a visceral and largely involuntary motor/effector system including 
sympathetic and parasympathetic parts, each with a central and a peripheral 
component. However, the diverse functions of the peripheral ANS are integrated and 
regulated by the central ANS, the extensive circuitry of which ranges from the 
forebrain to the brainstem (Table 1.3) [135]. 
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Although the mechanisms underlying the ANS dysregulation are not yet understood 
for HFMD, there is evidence that inflammation occurs in the brainstem and spinal 
ganglia and  
Table 1.3: Central ANS and Function 
Anatomic Area  General Function Clinical Manifestations 
Insular and 
medial 
prefrontal 
cortices 
High-order autonomic control: input 
from gastric mechanoreceptors, 
arterial chemoreceptors, 
baroreceptors 
Cardiac arrhythmia 
Extended 
amygdala 
Autonomic expression of emotional 
states: integrates autonomic and 
motor responses 
Viscerosensory phenomena 
(e.g., unilateral hyperhidrosis) 
Vomiting (left temporal focus) 
Sexual arousal 
Hypothalamus Homeostasis: initiates and coordinates 
biological rhythms, 
Autonomic, neuroendocrine, and 
behavioral responses 
Hypothermia or hyperthermia 
Poor stress response 
(autonomic storm) 
Insomnia 
Midbrain Coordinates autonomic, pain-
controlling, and motor mechanisms 
for stress-related, aggressive, and 
Reproductive behaviors 
Hypertension or hypotension, 
arrhythmias Intractable 
vomiting and dysmotility 
Hypoventilation 
Urinary retention 
Pons Relays viscerosensory information to 
forebrain 
 
Nucleus of the 
tractus solitarius 
Relays viscerosensory information 
from vagus and glossopharyngeal 
nerves to other Central ANS regions 
 
Medulla Cardiovascular and respiratory control 
via premotor autonomic and 
respiratory neurons controlling input 
to spinal, respiratory, and 
preganglionic motor neurons 
Sleep-disordered breathing 
(e.g., apnea, alveolar 
hypoventilation 
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that this damage correlates with cytokine profiles [119]. Increased sympathetic activity 
results in tachycardia, increased peripheral vascular system resistance, severe systemic 
and pulmonary hypertension, and eventually pulmonary edema [64, 120]. 
1.2.4.4 Pulmonary edema and cardiorespiratory failure  
Pulmonary edema is often considered as the natural progression of ANS dysregulation 
resulting from excessive sympathetic hyperactivity in brainstem encephalitis. High 
plasma catecholamine concentrations were found in plasma from EV-A71 associated 
brainstem encephalitis/hypertension patients who had recently progressed to 
pulmonary edema [111]. Left ventricular failure in these patients could be related to 
catecholamine-associated cardiotoxic effects, which were found on histological 
examination of cardiac ventricular biopsies [64]. Clinical data describing HFMD patients 
who presented with hypertension before rapidly progressing to cardiorespiratory 
failure suggest that the excessive release of catecholamine could result in the 
hypertensive crisis that are similar to the emergency autonomic dysreflexia in spinal 
cord injury patients [105, 136, 137]. This may contribute to acute cardiorespiratory 
failure in the final stage of disease.   
Therefore, the combination of acute heart failure and increased vascular permeability 
in lung alveolar may enhance the possibility of pulmonary edema in severe HFMD as 
the result of the entire process of pathophysiology of severe HFMD (Figure 1. 9). 
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Figure 1.9: The postulated pathogenesis of enterovirus-71-associated acute pulmonary 
edema (modified from [64]) 
 
 
↑↑ 
? Viral entry via spinal neural route   
? Viral entry via blood–brain barrier  
Massive catecholamine 
release 
 
Catecholamine-associated 
cardiotoxic effects 
Increased pulmonary 
vascular permeability 
 
 
 
 
Strong systemic 
inflammatory 
response 
 
↑↑ SVR, ↑↑ SBP, 
↑↑ HR  
 
Virus entry into CNS 
Brainstem encephalitis 
Imbalance between 
sympathetic / para-
sympathetic activities 
Extensive damage to 
medulla oblongata  
Excessive sympathetic 
hyperactivity 
Sympathetic storm 
Cardiomyocyte 
apoptosis Cardiac damage 
Acute LV dysfunction 
Severe EV-A71 infection 
Virus entry into CNS  
 
Systemic viral 
sepsis 
 
Cytokine storm 
 
Acute pulmonary 
edema 
Major pathway 
Contributory pathway 
Very high 
Strong supporting evidence for role 
Hypothetical/unproven role, or evidence from 
EV-A71=enterovirus 71. CNS=central nervous system. SVR=systemic vascular resistance. SBP=systemic 
blood pressure. HR=heart rate. LV=left ventricular. 
Chapter 1 
30 
 
  
1.2.5 Laboratory diagnostics for enterovirus infection 
1.2.5.1 Reverse transcriptase polymerase chain reaction  
Detection of enteroviral nucleic acid in clinical specimens is the most widely used 
approach for diagnosis of HFMD. The method is sensitive, and suitable screening for 
high throughput of large numbers of samples. Overall, molecular methods are more 
sensitive than virus culture. In some studies the diagnostic yields by molecular assay 
and virus isolation were 66-86% [138, 139] and 26-34% [140-142], respectively.  
Generic real time reverse transcription polymerase chain reaction (RT-PCR) targeting 
the 5’UTR, a highly conserved region across enterovirus genomes, can be used to 
generically detect enterovirus RNA in test specimens. For detection or identification of 
specific enterovirus serotypes, RT-PCR assays targeting more variable genomic regions 
such as VP1 are often employed. Currently, several serotype specific assays have been 
developed for EV-A71, CV-A16 and other HFMD associated CV-As. Additionally, 
serotype determination can be achieved by utilizing generic primers to amplify 
complete or partial VP1 region, followed by sequencing of the PCR amplification 
obtained.  
1.2.5.2 Serology 
There are a number of serological methods for diagnosis of enteroviral infections. 
These methods can be used to detect viral antigen directly, e.g. immunosorbent 
assays, or alternatively to identify antibodies that react to the viral antigen, eg. 
haemagglutination inhibition tests, complement fixation tests and neutralization tests. 
However these test are rarely used now, as molecular methods are preferred. 
Microneutrolization tests are the most specific method to detect antibodies to 
enterovirus. However use of these tests is limited in routine practice because of poor 
sensitivity, and difficulties with standardization.   
Serotype specific immunoassays are commercial serological methods used to detect 
antibodies to a range of serotypes including CV-B serotypes 1-6, a few echoviruses, and 
one or two CV-A serotypes. Cross reactivity is a problem however; using IgM ELISA 
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methodology 67% of CV group B infections were positive in the early stage of disease, 
but the results were not specific and could also be found with other enteroviral 
serotypes [143, 144]. IgM antibodies can persist for up to 6 months and IgG antibodies 
persist for years after infection, so both acute and recovery phase samples are needed, 
demonstrating a four-fold increase in antibody titers to verify the diagnosis of acute 
infection. As a result serological methods are not generally applied for acute HFMD 
diagnosis, but can be used for epidemiological surveillance.  
1.2.5.3 Viral isolation  
HFMD associated enteroviruses can be cultured in a wide range of cell lines such as RD 
(human rhabdomyosarcoma), LLC-MK-2 (Rhesus monkey kidney), Vero (African green 
monkey kidney), or BHK-21 (Baby Hamster Kidney). After inoculation, the cell cultures 
are observed daily for cytopathic effects (CPE), which may occur 2-6 days or longer 
after infection. Sometimes several passages (i.e. re-inoculation of cultured material in 
fresh cell lines) are required to maximize the sensitivity. Viral isolates can be 
determined using serotype specific monoclonal antibody and/or specific PCR. [145].  
 
 
 
 
 
 
 
 
Cell culture findings from a vesicle fluid sample taken from a child with HFMD encephalitis. 
Panel A: control cells; panel B: infected cell lines (Vero cells) showing CPE. EV-A71 was then 
confirmed by specific PCR. (Pictures courtesy of Prof. D. Q. Ha, OUCRU)  
 
 
Panel A Panel B 
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Throat swabs, rectal swabs, vesicle swabs, urine, vesicle fluid and CSF can be used for 
virus isolation; vesicle and throat swabs provide the highest diagnostic yields with a 
recovery rate of around 49% and 48%, respectively [146]. Although difficult to collect, 
material obtained from vesicles should be sterile so the positive predictive value is 
higher than that of a throat swab, since enteroviruses can exist in the respiratory and 
gastrointestinal tracts as part of the normal flora.  
1.2.6 Clinical assessment and classification of HFMD  
Most HFMD cases will recover without specific treatment. However, a small proportion 
of patients progress to develop severe complications and may rapidly deteriorate to 
fulminant disease and death. Four disease stages are generally recognized – HFMD/HA, 
CNS involvement, ANS dysregulation, and cardiorespiratory failure. Based on the 
potential for progression through these 4 stages a WHO taskforce came together and 
delivered guidance for HFMD management in 2010 (Figure 1.10) [83]. According to 
these recommendations patients presenting with HFMD/HA should be assessed for the 
warnings signs described below:  
 High or refractory fever – thought to be associated with a robust immune response 
or development of ANS dyregulation 
 Vomiting, lethargy, agitation or irritability – may indicate onset of CNS involvement  
 More definitive neurological signs such as myoclonic jerks, truncal ataxia, 
nystagmus may also be seen as early signs of CNS involvement.  
 Mottled skin and dyspnea/tachypnea – may indicate ANS dysregulation.   
Based on these WHO guidelines, the Vietnamese Ministry of Health (MoH) released 
the following guide for classification and management of HFMD (Table 1.4). Briefly, 
Grade 1 represents classic HFMD without any complications. Patients with Grade 2 
disease show some evidence of central nervous system involvement, usually 
manifesting as myoclonus. This grade is further split into Grade 2a, in which there is a 
reported history of myoclonic jerks, and Grade 2b, in which medical or nursing staff 
observe the myoclonic jerks. In Grade 3 disease there is evidence of ANS dysregulation, 
while patients with Grade 4 disease have cardio-pulmonary failure [147] 
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oIVIG may be considered if not previously used   
oBlood culture (if septicemic shock cannot be   
Patients with ANS Dysregulation and any of the   
HFMD with Cardiopulmonary Failure Stage   
- From remote area/poor access to healthcare   
oInotropes: Milrinone,  Dobutamine,    
oJudicious intravenous fluid therapy   
(Dopamine or epinephrine is not   
oPulmonary edema/hemorrhage    
(Pediatric ICU)   
oCentral venous pressure   
oMechanical ventilation   
oArterial blood gases   
oHypotension/Shock   
     
oEchocardiography   
oEchocardiography   
oArterial blood gas   
oFull blood count   
recommended)    
oBlood glucose    
Special Consideration:  
Laboratory Test:    
oHeart failure   
oChest X-ray   
oVital signs   
   
excluded)   
- Anxious parents  
Monitoring   
Treatment:   
following:   
Criteria:    
Present    
   
oRespiratory abnormalities (tachypnea, labored    
∞Indications: Persistent and frequent myoclonus, persistent   
fluctuating oxygen saturation level, poor tissue perfusion,   
tachycardia, respiratory abnormalities, hypoxemia,   
HFMD with Autonomic Nervous System (ANS)    
Patients with CNS Involvement and any of the   
oJudicious intravenous  fluid therapy   
oResting Heart rate  150- 170/min   
Dysregulation Stage   
Warning Signs of CNS Involvement: (one or more of the following)  
(Pediatric ICU)   
oConsider early intubation ∞   
oCentral venous pressure   
Dyspnea/tachypnea   
“Wandering  eyes”    
oArterial blood gases   
oEchocardiography    
oEchocardiography   
oArterial blood gas   
oProfuse sweating   
Dobutamine     
oCSF examination    
oFull Blood Count   
Limb weakness   
Truncal ataxia   
oHypertension    
Milrinone    
Mottled skin   
oBlood glucose   
altered sensorium   
Laboratory Test:    
oChest X-ray    
oInotropes:    
breathing)   
oVital signs   
Treatment:    
Monitoring   
following:    
Criteria:   
oIVIG   
Fever  ≥ 39°C  or ≥ 48 hours     
   
* Patients with aseptic meningitis generally have a good   
plus acute flaccid paralysis; may be considered   
Agitation/irritability    
oMRI, if needed (CT scan is not recommended)   
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Figure 1. 10: Management algorithm of Hand, Foot and Mouth disease (WHO-2011) 
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Table 1.4: Vietnamese MoH HFMD Classification and Management Guidelines (March 
2012) * 
Classification Signs/symptoms Suggested Management 
Grade 1 Oral ulcers and/or vesicular rash on the hands, 
feet, and/or the buttocks 
OPD care, with advice sheet for family 
Careful observation for warning signs 
Grade 2a Grade 1 AND  
Myoclonic jerks observed by the family (not 
witnessed by medical staff) 
Legarthy, agitation/irritability  
Fever ≥ 39°C for ≥ 48 hours. Vomiting 
Hospitalization 
Oral phenobarbitone 
Vital Signs Monitoring: every 4-6 hours 
following standard protocols 
Grade 2b 
- Group 1 
Grade 1 AND  
Myoclonic jerks witnessed by medical staff or by 
the family (≥ 2 jerks/30 minutes or 1 jerk and 
stupor)  
Resting pulse rate > 130/min but <150/min 
(adjusted for fever*) 
Admit to HDU/PCIU  
IV Phenobarbitone 
Antipyretics 
Vital Signs Monitoring: every 1-3 hours for 
minimum 6 hours until stable 
Grade 2b 
- Group2 
Grade 1 AND witnessed myoclonic jerks 
accompanied by one of the following findings:  
Continuous limb tremor, limb weakness or 
paralysis, or drowsiness (provided no 
hypoglycemia) 
Resting pulse rate > 150 /min (adjusted for 
fever*) 
Fever ≥ 39.5oC (rectal) and unresponsive to 
antipyretics > 4 hours 
Give oxygen 
IV Phenobarbitone 
Antipyretics 
Start IVIG – 2g/kg in two divided doses 
Check: FBC, CRP, blood sugar, and consider 
lumbar puncture 
Vital Signs Monitoring: every 1-3 hours for > 
6hrs 
Grade 3 Serious complications in CNS or cardiopulmonary 
systems: 
Pulse >170 /min*   
Profuse sweating 
Stage 1 hypertension (SBP > 95th centile for age)  
Respiratory abnormalities: tachypnea,  
labored breathing 
Muscle hypertonia 
Coma (Glasgow coma score < 10) 
Oxygenation 
Consider need for ventilation  
IV Phenobarbitone and IVIG 
Milrinone if stage 2 hypertension (SBP > 99th 
centile for age + 5 mm Hg) 
Dobutamine if HR> 170 bpm 
Consider additional fever control measures  
Invasive blood pressure monitoring 
Check: FBC, CRP, blood sugar, and consider 
lumbar Puncture 
Vital signs monitoring: every 30-60 mins for ≥ 6 
hrs. 
Grade 4 Severe complications: 
Acute pulmonary edema 
Cardiac collapse 
SpO2 < 92% with cannula oxygen 6 litres/min) 
Respiratory arrest or gasping respiration 
Intubation and ventilation 
IV Phenobarbitone 
Dobutamine; Fluid challenge 
Antipyretics,  
Access CVC plus invasive BP monitoring 
Vital signs monitoring: every 15-30 mins for ≥ 6 
hrs. 
*: Old version classification  (Jun 2011): Grade 2b group 1: HR > 150 /min, Fever ≥ 39.5oC ;  Grade 2b group 2: did 
not  include HR and Fever  criteria; Grade  3:  Stage 2 hypertension (SBP > 99th centile for age + 5 mm Hg). Other 
criteria did not change. 
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1.2.7 Management 
Most HFMD infections are mild and self-limiting, and do not require specific treatment 
or hospitalization. However, patients who develop complications, particularly 
respiratory distress or cardiac failure should be closely observed in an intensive care 
unit (ICU) or high dependency unit (HDU), since respiratory support and hemodynamic 
stabilization are important in life support during the severe stage of disease [148]. 
WHO and Vietnamese MoH guidelines focus on early supportive care with careful 
observation to recognize disease progression as the cornerstone of case management 
(Table 1.4). These guidelines advocate use of oral or intravenous (IV) phenobarbital to 
treat myoclonic jerks and irritability. Warning signs are indications for transfer to HDU 
for close observation. Intravenous immunoglobulin (IVIG) is recommended for the 
treatment of Grade 3 and 4 disease, and Grade 2b if the clinician is particularly 
concerned - however there is no formal evidence to support its use, only some 
observational studies, indirect evidence and expert opinion [83, 149, 150]. Similarly 
milrinone, a phosphodiesterase-3 inhibitor, is recommended for the treatment of 
hypertension on the basis of limited evidence (see below) [117]. Respiratory support is 
indicated for severe respiratory distress or respiratory failure, and for patients with 
shock. Hemofiltration has been used in severe cases who do not improve with 
aggressive intensive care including ventilation, inotropes and heatstroke management 
[151]. Current Vietnamese MoH guidelines recommend that hemofiltration should be 
considered as a potential therapeutic option for patients with ANS dysregulation and 
severe refractory fever. This idea is based on the theoretical potential to remove 
cytokines from the blood [152-154] rather than in order to reduce the temperature 
directly by using cool replacement fluids [155]. 
1.2.7.1 Antiviral therapy  
As yet no specific antiviral agents for HFMD have been licensed by the FDA, although 
some antivirals have demonstrated effects against replication of enterovirus strains in 
vitro, in mice and in early phase clinical trials. Pleconaril is a broad spectrum 
antipicornaviral agent that binds to the hydrophobic pocket in the viral capsid, 
inducing conformational changes which lead to altered receptor binding and viral 
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uncoating [156]. At a concentration of ≤ 0.18 microM, pleconaril inhibited replication 
of 90% of the most common enteroviruses isolated in the Unite States in the 1970s 
and 1980s [157]. In a multicenter, double-blind placebo-controlled study of pleconaril 
in adult enterovirus meningitis, a modest benefit was demonstrated in reducing the 
severity and duration of symptoms in a subgroup of patients with more severe disease 
[158]. However, in a randomized placebo-controlled control trial in infants with 
enterovirus meningitis, there were no significant differences in the duration of 
hospitalization or symptoms between the two groups [159]. More recently however, in 
a randomized control trial involving 61 neonates with enteroviral sepsis, participants 
who received pleconaril were more likely to survive than the placebo recipients [160]. 
A number of other antiviral compounds, including vapendavir and pirodavir, have been 
assessed for their effect on enterviruses in vitro, but the results to date have not been 
very promising [161, 162]. 
1.2.7.2 Immunoglobulin 
There is no formal evidence of a significant effect in clinical practice, but IVIG was used 
for patients with agammaglobulinemia and enterovirus meningitis thirty years ago, 
with variable success [22, 163]. IVIG has also been used to treat viral myocarditis [58, 
149]. In the latter report 2 gm/kg IVIG was given to 21 children with acute myocarditis, 
with improved left ventricular function demonstrated compared to a historical control 
group that received standard treatment without IVIG.  
For severe HFMD there is also no formal evidence of a beneficial effect, although it is 
recommended by several bodies including WHO and the Vietnamese MoH for severe 
cases with neurological involvement. There is some indirect evidence to support this 
recommendation however. High-dose IVIG treatment activates regulatory T cells 
(Tregs) selectively and enhances their suppressive function in humans in vivo [164], 
and also results in down-regulation of IL-6 in vitro [165]. Plasma levels of various 
cytokines including IFN-gamma, IL-6, and IL-8 significantly decreased in HFMD patients 
with ANS dysregulation or pulmonary edema after administration of IVIG in one case 
series [166]. Moreover, using human plasma derived IVIG containing neutralizing 
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antibodies against EV-A71 protected against lethal EV-A71 challenge in a dose and 
time dependent manner in a suckling mouse model [167].  
1.2.7.3 Management of ANS dysregulation 
Management of ANS dysregulation focuses primarily on hemodynamic abnormalities, 
particularly hypertension. Milrinone, a phosphodiesterase-3 inhibitor, was used not 
only to control high blood pressure but also to support myocardial function in a group 
of 24 children with severe HFMD compared to historical controls in one study from 
Taiwan [117]. Milrinone also reduced mortality in patients who developed pulmonary 
edema associated with HFMD in a small open-label randomized clinical trial in Viet 
Nam [168]. It is now the recommended therapy for management of severe HFMD with 
ANS dysregulation, particularly hypertension, in Vietnam. Currently the MoH 
guidelines assign the threshold indication for use of milrinone at a systolic blood 
pressure (SBP) over the 99th centile for age plus 5 mm Hg, which approximates to the 
internationally accepted definition of Stage 2 hypertension in children [169]. 
Unfortunately however, clinical failures still happen despite high dose milrinone and a 
number of children go on to require haemofiltration and ventilatory support, the next 
steps recommended in the MOH guidelines [170].   
Considering alternative therapies, magnesium sulfate (MgSO4) had been widely used 
in controlling the ANS dysregulation seen in severe tetanus. MgSO4 was associated 
with significantly reduced requirements for drugs to control muscle spasms and 
cardiovascular instability in a randomized controlled comparison with placebo in adult 
patients with severe tetanus [171], and use of MgSO4 was associated with reduced 
circulating and urinary catecholamine concentrations [172, 173]. In vitro, it also has 
been shown to reduce catecholamine secretion from peripheral nerve endings and the 
adrenal medulla [174]. MgSO4 has been used in the treatment of eclampsia, severe 
asthma, pulmonary hypertension, and during anesthesia for spinal cord lesions, to 
manage ANS associated hypertensive crises [136, 137, 175, 176]. Intrapartum use of 
MgSO4 in women with preeclampsia was also associated with reduced cytokine levels 
in the women and their babies [177]. Similarly, use of magnesium in a small number of 
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patients with aneurysmal subarachnoid haemorrhage was associated with reduced 
serum levels of certain inflammatory cytokines [178].  
MgSO4 was first reported as a potential alternative treatment for severe HFMD cases 
who presented with hypertension in Hong Kong [179]. Based on this report, and given 
my experience in using MgSO4 in neonates with severe tetanus, in late 2011 I decided 
to try this as second line therapy in HFMD cases that did not show a good response to 
milrinone. In an initial 10 EV-A71 confirmed HFMD cases with ANS dysregulation that I 
managed at the Hospital for Tropical Diseases (HTD) over a 4 month period MgSO4 was 
added when hypertension remained poorly controlled despite high dose milrinone (up 
to 0.75 µg/kg/minute) in all cases the BP reduced within 30-60 minutes and remained 
stable subsequently on a continuous magnesium infusion for 48-72 hours [180]. No 
patient required hemofiltration, although 2 of 10 cases were ventilated because of 
respiratory distress. By comparison, during 2011 before MgSo4 was being used on the 
Paediatric Intensive Care Unit (PICU) at HTD, of the 35 cases treated with milrinone 
alone 9 required ventilation (9/35, 26%, unpublished data).  
1.2.8 Prevention 
Vaccination is the best way to protect individual children from infectious diseases and 
also limit wider dissemination of the disease. Several EV-A71 vaccines have been 
trialed recently but as yet none have been approved for deployment in public health 
programmes. 
A phase 1 study assessing a formalin-inactivated EV-A71 vaccine candidate showed 
production of cross-neutralizing antibodies against EV-A71 subgenotypes B1, B4, B5, 
and C4A in 60 healthy adults [181]. Two phase III trials have been conducted in 
children in China recently, involving slightly different EV-A71 vaccines [182, 183]. The 
safety profiles were acceptable, and in the two-year follow-up to the second trial there 
was 94.7% efficacy against EV7-A71 associated HFMD Thus these studies indicate that 
an approved EV-A71 vaccine may be available in near future.  
Currently however, no vaccines are approved. Prevention relies on simple and 
effective public health measures such as frequent hand washing to prevent 
transmission of enteroviruses. In hospital situations, other measures such as wearing 
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masks or protective clothing are not recommended, and isolation is only considered 
necessary in neonatal wards [18, 184].   
1.3 Knowledge gaps and objectives of this thesis 
Although HFMD was widespread in Vietnam in 2011/2012 and played a major role in 
childhood morbidity and mortality, there was little published information available 
describing the spectrum of severe disease, the pattern of autonomic dysregulation, 
or the clinical risk factors or predictors for poor outcome in these patients. At that 
time also, the recommended management strategies for severe disease were based 
primarily on expert opinion and one small study [83, 117, 168]. In our experience in 
HCMC milrinone, the recommended treatment for ANS dysregulation with 
hypertension was not always effective, and there were preliminary indications that 
MgSO4, a cheap, easily available and apparently safe drug, might be effective. 
However, there was no formal evidence to support use of MgSO4 in this way for 
severe HFMD cases.   
My overall aim in conducting this research programme was to fill in some of these 
knowledge gaps, with the following main objectives: 
a) To systematically describe the clinical features of all HFMD cases seen in PICU 
in one referral centre in Vietnam in 2011-2012, together with current 
management strategies and disease outcomes, and to investigate relationships 
with the enterovirus serotypes in circulation during this period.  
b) To investigate possible risk factors, identified during the first 24 hour in PICU, 
for subsequent progression to one of a number of well-defined severe 
outcomes.  
c) To evaluate the effect of MgSO4 on control of hypertension and other 
manifestations of autonomic dysfunction, in children with HFMD. 
d) To describe the safety profile of MgSO4 when used in children with severe 
HFMD and hypertension. 
e) To describe catecholamine levels as biomarkers of sympathetic activity in 
severe HFMD cases, and assess the impact of MgSO4 on these levels.  
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By addressing these aims, I hoped to provide clinicians with a detailed clinical picture 
of severe HFMD and the risk factors for disease progression, so they can respond 
effectively when major outbreaks happen. Secondly gaining knowledge about the 
efficacy and safety of MgSO4 in managing severe HFMD, would be useful whether the 
results were positive or not. Clearly if a positive effect could be demonstrated this 
would be of value for future management recommendations, but it is just as important 
to know if there is no benefit to use of MgSO4 before it becomes an established 
therapy.  
Chapter 2 
41 
 
Chapter 2 
MATERIALS AND METHODS 
In this chapter I will describe the general clinical, laboratory, and statistical methods 
used for the research presented in Chapters 3 – 5 of this thesis. Specific methods used 
for particular studies will be presented in the relevant chapters. 
2.1 Clinical studies  
All the clinical activities for the studies described here took place on the Pediatric 
Intensive care Unit (PICU) at the Hospital for Tropical Diseases (HTD) in Ho Chi Minh 
City. At HTD teenagers aged over 15 years are usually admitted to adult wards, so the 
studies described only involved children below 15 years of age. At the time of most of 
this work, HTD was admitting around 2,000 - 4,000 patients with suspected HFMD 
each year, most of whom were managed on the pediatric infection wards, but around 
15% were admitted to PICU because of severe disease. 
Initially I had planned to carry out the randomized control trial described in Chapter 4 
on two sites, HTD and Children’s Hospital 1 (CH1). At CH1 between 4,000-6,000 
children with the same severity of HFMD were seen each year and usually managed at 
the Infectious Disease Department. This is a very large department (90 beds) that 
includes a high dependency unit (HDU, 10 beds) where severe patients were managed 
except for very serious cases who needed highly specialized interventions such as 
hemofiltration, who were transferred to the main PICU at CH1. 
2.2 Ethics 
All studies were carried out in accordance with international standards for the ethical 
conduct of research involving human subjects. 
Ethical approval for the retrospective file review (Chapter 3) was obtained from the 
Scientific and Ethical Committee of HTD. Since the study was retrospective and 
anonymous, informed consent was not obtained from the parent/guardian of the 
individuals involved. All substantial amendments to the original approved documents, 
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including requests for further serotyping and sequencing to identify the serotype of 
enterovirus and subgenogroups of EV-A71, and also to collect the additional 
information on hemodynamic parameters (see Chapter 5) were also approved by the 
HTD Committee.  
The randomized controlled trial described in Chapter 4 was conducted in compliance 
with the current revision of the Declaration of Helsinki (Seoul 2008) and the terms of 
approval of all supervising Ethical Committees. The study protocol and its associated 
documents were reviewed and approved by the following committees: The Vietnam 
MoH’s Evaluation Committee on Ethics in Biomedical Research: The Scientific and 
Ethical Committee of HTD, The Science and Ethics Committee in Biomedical Research 
of CH1, and the Oxford Tropical Research Ethics Committee (OxTREC, University of 
Oxford). The study was managed by the OUCRU Clinical Trials Unit (CTU) in compliance 
with the ICH Guidelines of Good Clinical Practice, the Vietnamese MoH Guidelines of 
Good Clinical Practice and the relevant institutional and regulatory requirements. A 
parent/guardian gave written informed consent before enrolment for all participants 
enrolled in the RCT. Further details on this process are described in Chapter 4.  
2.3 Laboratory methods 
2.3.1 Standard laboratory tests  
Hematology: A full blood count was performed at least once, usually during the first 24 
hours after PICU admission, and then subsequently depending on the assessment of 
the attending doctors. Tests were performed in the routine hematology laboratory of 
HTD using the ADVIA 2010i haematology analyzer (Siemens Healthcare, Germany). 
Biochemistry: Blood sugar and CRP, using the routine HTD laboratories, were tested 
routinely at admission. CK-MB and Troponin I were measured in the routine labs 
whenever patients had signs or symptoms of cardiovascular compromise, using the 
Cobas C501 (Roche Diagnostics GmbH, Mannheim, Germany) and Archtect 4000SR 
(Abbott) analyzers. 
ELISA for catecholamine concentration: In the randomized trial, urine and plasma 
catecholamine concentrations were measured using the BI-CAT®Adrenaline and 
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Noradrenaline ELISA Assay Kit (EAGLE BIOSCIENCES, www.eaglebio.com), following the 
manufacturer’s instructions. The catecholamines were first extracted out of the 
sample, then derivatized for antibody recognition and to enhance their stability in the 
solid phase, and thereafter detected using antibodies specific for catecholamines. The 
amount of antibody bound to the solid phase catecholamine is inversely proportional 
to the catecholamine concentration of the sample. 
2.3.2 Real-time PCR for detection of enteroviruses 
Most, but not all, of the molecular biology diagnostics were performed in the OUCRU 
laboratory by staff from the Emerging Viral Infection research group, although some 
PCR testing was done in the routine HTD laboratory. Both labs use the same standard 
protocol that was developed and published by OUCRU laboratory [185].  
The process of specimen collection and storage: Diagnostic material from the throat, 
nose, vesicle fluid or other specimens was collected on appropriate swabs that were 
placed immediately in viral transport medium and brought to the laboratory. The 
material was divided into three aliquots and stored at -800C prior to analysis. 
Nucleic acid extraction: Viral RNA was extracted from 140 µl clinical specimens 
(throat, rectal or vesicle swabs, or CSF) together with 20 µl of Equine Arteritis Virus 
(EAV) functioning as an internal control, using QIAamp Viral RNA MINI Kits (Quiagen, 
Hilden, Germany). The process of extraction was performed following the instructions 
from the manufacturer. Viral RNA was then washed out in 50 µl elution buffer and 
stored at -80oC until used. 
Internally controlled one-step multiplex real-time RT-PCR: From Jan 2011 to August 
2011, Taqman Probes (enterovirus and EAV probes) supplied by Proligo® Reagents 
were used for detecting enteroviruses in the OUCRU molecular laboratory. After that 
period, one-step multiplex real-time RT-PCR was employed to simultaneously detect 
EVs and EV-A71 using the SuperScript III One-Step gRT-PCR System with Plantinum Taq 
DNA Polymerase (Invitrogen, Carlsbad, CA, USA) and was performed in a LightCycler 
480 II machine (Roche Diagnostics GmbH, Mannheim, Germany).  
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Primer and probe sequences that were adapted from previous studies of Scheltinga et 
al., 2005, Beld et al., 2004 and Khanh et al [186-188] were optimized and validated at 
the OUCRU laboratory (Table 2.1) [185].  
Table 2.1: Primer and probe sequences and concentrations used in one-step real-
time RT-PCR reaction 
 
Note: FAM = Carboxylfluorescein; Cy5 = Cyanine 5; Cyan500= Cyan 500 NHS ester; 
BHQ= black hole quencher; R= A or G; Y= T or C; V=A, C or G; D=A, G or T. 
5 µl of extracted viral RNA was mixed with 12.5 µl 2X RT-PCR Reaction Mix (Invitrogen), 
1 µl primers and probes of EAV, EVs and EV-A71 respectively (Table 2.1), 0.5µl of 
enzyme mix (Invitrogen). The real-time RT-PCR reaction was carried out in that mixed 
solution. One cycle of reverse transcription and polymerase activation were performed 
under thermocycling conditions that consisted of 60oC for 3 minutes, 53oC for 15 
Name Concentration 
(µM) 
Sequence (5’ – 3’) Note 
EAVF 
primer 
EAVR 
primer 
EAV-probe 
10 
10 
2.5 
CAT CTC TTG CTT TGC TCC TTA G 
AGC CGC ACC TTC ACA TTG 
FAM-5’-
CGCTGTCAGAACAACATTATTGCCCAC-
3’-BHQ1 
Internal control 
[188] 
ENT-F  
ENT-R 
ENTr-probe  
10 
10 
5 
5’-CCCTGAATGCGGCTAAT-3’ 
5’- ATTGTCACCATAAGCAGCC-3’ 
Cy5-ACCCAAAGTAGTCGGTTCCG -
BHQ3 
Enterovirus 
specific 
primers and 
probe [186]  
EV-A71-
634F 
EV-A71-
743R 
EV-A71-
probe 
10 
10 
1 
GGAGAACACAARCARGAGAAAGA 
ACYAAAGGGTACTTGGAYTTVGA 
Cyan500-
TGATGGGCACDTTCTCRGTGCG-BHQ1 
EV-A71 specific 
primers and 
probe [187]  
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minutes and 95oC for 2 minutes. The next step of 45 cycles of PCR amplification was 
done with conditions consisting of 95oC for 15 second, 53oC for 1 minute and 72oC for 
15 second. 
Principles for interpreting the results: The final result was identified as positive if a) 
positive controls showed Crossing point (Cp) values of 30+/-1; b) negative controls 
were negative, and c) the tested sample showed a positive result with Cp value equal 
to or less than 40. The final result was considered as negative if a) negative controls 
were negative; b) positive controls showed Cp values of 30+/-1; c) IC showed positive 
result with Cp value of between 30 and 33; and d) the tested sample was negative. A 
sample was considered as inconclusive if a) negative controls were positive; b) and/or 
the IC result was out of the expected range; and c) amplified signal was not observed 
for EVs/EV-A71. 
2.3.3 Nested PCR 
The remainder of the extracted RNA of samples that were EV-PCR positive but EV-A71 
PCR negative were stored at -800C. Later those stored specimens were used to identify 
the enterovirus serotypes using a nested PCR targeting the VP1 gene sequence (Figure 
2.1). Primer sequences were adjusted from W.A. Nix et al., 2006 [189] (Table 2.2).  
The first round of reverse transcription and amplification was performed by using 
SuperScript III One-step RT-PCR with five micro liters of the extracted viral RNA and a 
total reaction volume of 20 µl containing 10 µl of 2x reaction buffer (provided with the 
kit), 0.5 µl of SuperScriptIII RT/Platinum Taq High Fidelity mix (Invitrogen), 1 µl of first-
round primers mix Plantinum Taq High Fidelity and outer primers SO24 and SO22 
(Table 2.2). One cycle of reverse transcription under the thermocycling conditions of 
55oC for 3 minutes, 22oC for 10 minutes and 42oC for 30 minutes, followed by one cycle 
at 95oC for 1 minute and then 40 cycles of amplification consisting of 94oC for 30 
seconds, 42oC for 30 seconds and 60oC for 1 minute, and a final extension step at 72oC 
for 7 minutes. 
The second round amplification was done in a final reaction volume of 25 µl containing 
1 µl of the first round RT-PCR product, 23 µl mix of Platinum PCR Super (Invitrogen), 
and 0.5 µl of each of the AN89 and AN88 primers (Table 2.2). The thermocycling 
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conditions for the first cycle were 95oC for 1 minute, followed by 40 cycles at 94oC for 
20 seconds, 60oC for 30 seconds, and 72oC for 20 second, and final extension at 72oC 
for 7 minutes.  
Amplified products of the second round PCR were then separated on 1% agarose 
stained with Nancy-520, and observed under UV light. The expected size of the 
amplified product is between 350 – 400 base pair. 
2.3.4 Sequencing, sequence analysis and determination of EV serotype and EV-A71 
subgenogroups  
Primers AN232 and AN233 were used for identifying EV serotypes while EV-A71-VP1-
3F and EV-A71-VP1-703R were used for identifying the subgenogroups of EV-A71.  
Sequencing of VP1 PCR products of the expected size was performed in both directions 
using those primers and BigDye Terminator v3.1 Cycle Sequencing Kit (Applied 
Biosystems, Carlsbad, CA, USA) in an ABI 3130XL DNA sequencer (Applied Biosystems) 
(Table 2.2).   
5 µl of diluted purified PCR product, 4 µl of BigDye (Applied Biosystems), 2 µl of buffer, 
8 µl of molecular biological water, and 1 µl primer (AN232 or AN233) were mixed for 
the sequencing reaction. This reaction was performed at 95oC for 1 minute, followed 
by 30 cycles consisting of 94oC for 20 seconds and 60oC for 2 minutes. 
Obtained sequences were manually assembled and edited using Contig Express– a 
component of Vector NTI Suit 7 (Informax Inc., NY, USA). EV serotypes and EV-A71 
subgenogroups were determined by employing an online EV typing tool 
(http://www.rivm.nl/mpf/enterovirus/typingtool/) as described by Knoneman, A. et 
al., 2011. 
 
 
Chapter 2 
47 
 
Table 2.2: Primers sequences & concentrations of nested RT-PCR & sequencing 
reactions 
 
 
 
 
 
 
 
 
Name Sequence (5’3’) Note Working 
concentration 
(µM) 
SO224 
SO222 
AN32 
AN33 
AN34 
AN35 
GCIATGYTIGGIACICAYRT 
CICCIGGIGGIAYRWACAT 
GTYTGCCA 
GAYTGCCA 
CCRTCRTA 
RCTYTGCCA 
1st round 
RT-PCR 
10µM of each 
(Primer mix) 
AN89 
(forward) 
AN88 
(reverse) 
CCAGCACTGACAGCAGYNGARAYNGG 
TACTGGACCACCTGGNGGNAYRWACAT 
2nd round 
PCR 
10 
 
AN232 
AN233 
CCAGCACTGACAGCA 
TACTGGACCACCTGG 
Serotype 
sequencing 
10 
EV-A71-VP1-3F 
EV-A71-VP1-
703R 
AGAYAGGGTGGCRGATGT 
CTGAGAACGTGCCCATCA 
EV-A71 
Sequencing 
10 
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Figure 2.1: Algorithm for enterovirus serotyping and sequencing of genogroups of EV-A71 
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2.4 Data management 
2.4.1 Data entry, checking and cleaning 
Together with a team of experienced study doctors I checked the information in the 
paper CRFs used for the file review after the data had been extracted from the hospital 
notes and before sending them to the data entry team at CTU.  
The clinical and laboratory data of all studies were stored on an ICH-GCP compliant 
clinical data management platform called “CLIRES” that was developed at OUCRU. For 
the trial and cohort study, all data were single entered by study nurses, then checked 
again by the study coordinator and data entry team members, while for the descriptive 
datasets a double data entry method was used with inbuilt logical checks. All queries 
generated by the logical checks were referred back to me for cross-checking and 
correction based on the original source documents.  
2.4.2 Missing data  
A data assessment analysis was performed to check for duplicate records of the same 
patient and for missing data. Specific types of missing data were identified. Random 
missing data were accepted as truly missing and imputed if necessary for analyses 
using multivariable logistic regression (see Chapter 3). Non-random missing data were 
cross-checked with the hospital notes and the hospital’s electronic database, and the 
CLIRES system was updated with the new information.  
2.5 Statistical methods 
I used R studio software version 1.0.143 (https://download1.rstudio.org/RStudio-
1.0.143.dmg) to analyze the data and draw the figures in this thesis.   
Unless otherwise specified summary statistics are absolute count and percentage for 
categorical variables and median (interquartile range-IQR) for continuous data. 
However, for data involving small patient numbers median (range) is used. In the 
descriptive study, odds ratios (OR) and p-values for categorical variables were based 
on logistic regression models. The mean difference and p-value for continuous data 
were based on linear regression models. For variables with multiple categories, 
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ordered logistic regression was applied to calculate OR and significance tests. 
Multivariable logistic regression was used for prognostic factor analysis with stepwise 
backward model selection. Pearson correlation was used to evaluate relationships 
between continuous variables. 
In the MgSO4 trial, log-binomial regression, linear regression, and Cox regression were 
used for binary outcomes, continuous outcomes, and time-to-event outcomes, 
respectively. Measures of association are displayed as relative risk (RR), mean 
difference, and hazards ratio, depending on the type of outcome.  
P-values < 0.05 were considered statistically significant and 95 % confidence intervals 
(CI) were applied for all tests.  
Additional details on the specific statistical methods used will be described in the 
relevant chapters. 
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Chapter 3 
OVERVIEW OF SEVERE HFMD: CLINICAL FEATURES AND RISK FACTORS 
3.1 Introduction 
The clinical features of HFMD have been described in some research studies conducted 
during different outbreaks, but it is rare that the reports focus on severe cases or 
describe the evolution of the clinical features systematically over time [104, 190]. In 
2011, WHO included a clinical description in their HFMD guidelines [83], based largely 
on retrospective reports describing relatively small patient numbers and mostly 
focused on EV-A71 infection [74, 125, 191]. However, one prospective study described 
the clinical features and detailed virology in almost 800 children, of whom 277 had EV-
A71 infection [192]. Since 2011, this guideline has been adopted in many countries 
where HFMD has become a problem, including Vietnam. Some studies that focused on 
the severe end of the spectrum mostly came from China, and although these studies 
described the clinical features of severe cases in large patient populations, many were 
published in the Chinese language making them inaccessible to the general reader 
[193-195], or used alternative less specific classification systems for severe disease to 
the conventional WHO system [196, 197]. 
The 2011 outbreak of HFMD in Viet Nam continued to have a major impact on 
Vietnamese children during 2012, but mortality was reduced in comparison to 2011. 
Considering all reported cases throughout Vietnam the mortality rate was 170/113,113 
(0.15 %) in 2011 compared to 45/157,654 (0.03 %) in 2012 [198]. The Vietnamese MoH 
continued to revise the strategy for diagnosis and treatment of children with HFMD, 
issuing two revisions, the first in June 2011, the second in Mar 2012 with minor change 
(described in chapter 1), to the guidelines during this period, and this may have 
resulted in improved outcomes. However, alterations in the predominant serotypes 
circulating may also have occurred over time, potentially due to changing population 
immunity after a period of exposure to one serotype [199-201].  
Moreover, identification of risk factors that predict the likelihood of progression to 
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severe outcome is very important for clinicians, especially during outbreak situations. 
A number of different features, including age, sex, place of living, illness day at 
presentation, fever, heart rate, abnormal respiratory pattern, pleocytosis, and 
hyperglycaemia have been considered as risk factors/prognostic factors for severe 
disease (Table 3.1) [112, 194, 202-209], but in general these reports described 
associations between the factors with the outcome, rather than identifying features 
that occurred before the development of severe disease. In one prospective study 
peak temperature ≥ 38.5°C, history of lethargy, total duration of fever for more than 3 
days were predictors of neurological complications [209], but longitudinal relationships 
between these factors and outcome were not clearly defined.  
In this chapter I will systematically describe the spectrum of disease, management 
strategies and outcomes, for all patients admitted to PICU from January 2011 to 
December 2012 aiming to expand knowledge about HFMD in general and also 
investigate associations between enterovirus serotypes and clinical presentation. In 
addition I will present some analyses looking at risk prediction for subsequent 
deterioration, assessing the ability of features observed within the first 24 hours in 
PICU to predict severe outcome. These observations could be important for 
development of intervention strategies aiming to improve clinical management and 
achieve better outcomes in the future. 
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Table 3.1: Overview of studies assessing risk factors for severe HFMD from 2012 to 2016 [112, 194, 202-209] 
Reference Year Country Outcome definition Study design No of 
Patients 
No of severe 
cases 
Risk factors 
Factors 
Ooi M.H. et al 2009 Malaysia Neurological complications Prospective 
 
725 102 Peak temperature ≥ 38.5°C, History of lethargy, 
total duration of fever ≥ 3 only 
Kim S. J. et al 2013 Korea  Neurological complications Retrospective 168 88 Headache, neurologic signs 
Wang Q. et al 2014 China Any signs and symptoms of 
respiratory and circulatory 
disturbance involved the CNS 
Case- control 120 
 
 
60 ≥ 38.5°C, Rash type, Lethargy 
Li W. et al 2014 China  Brainstem encephalitis, 
and/or pulmonary edema 
Retrospective 1500 350 RR>26/min, Age<4 yrs, Glycemia>8.3 mmol/L, 
Lymphocyte>40%, and ALT>40 U/L 
Fang Y. et al 2014 China Neurological, respiratory, or 
circulatory complications or 
death. 
Meta-analysis * * Fever duration ≥3 days, ≥ 37.5 ° C, lethargy, 
hyperglycemia, vomiting, increased neutrophil 
count, EV-A71 infection, and young age 
Chew S. P.. et al 2015 Singa-
pore 
Death, encephalitis, 
meningitis, myocarditis, 
pulmonary edema or acute 
flaccid paralysis 
Case-control 72 24 Evidence of hypoperfusion, seizure, altered 
mentation, meningeal irritation, tachycardia, 
tachypnea, increased neutrophil count and EV-
A71 positivity 
Liu R.H. et al 2015 China Requirement of mechanical 
ventilation 
Retrospective 63 63 Poor peripheral circulation, pulmonary edema, 
white blood cell counts, blood lactate, glycemia 
Song C. et al 2015 China Cardiopulmonary collapse Retrospective 176 31 Vomiting, circulatory disturbance, EV-A71 
infection, dysfunction of respiratory rhythm 
and high level of brain natriuretic peptide 
Owatanapanich 
S. et al 
2016 Thailand Severe enterovirus infection Retrospective 156 25 Absence of oral lesions, seizures, and 
drowsiness/lethargy 
Long L. et al 2016 China Cardiopulmonary failure Retrospective 1,125 976 Young age, fever duration ≥3 days, coma, limb 
weakness, drowsiness and ANS involvement 
*: The number of patients included from the total of 19 studies varied depending on the factors assessed in the meta-analysi
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3.2 Materials and methods 
Clinical features: For this retrospective review of children admitted to PICU with a 
clinical diagnosis of HFMD from January  2011 to December  2012 I designed a CRF to 
collect data from the hospital files. File numbers were first identified from the 
hospital’s electronic database in which the final clinical diagnosis and the final overall 
severity grade were entered by nursing staff at the time of discharge. Files of all 
patients with a discharge diagnosis of HFMD Grade 2b and above from 2011-2012 
were retrieved from the medical records department. However, I was particularly 
interested in the evolution of signs and symptoms over the first 7 days of illness so 
patients who were admitted to PICU after day 7 of illness were not included in this 
analysis.  
I trained and supervised two study nurses and several experienced ICU ward doctors to 
systematically review the files and record the following information: demographic and 
epidemiological data; history and examination findings at PICU admission; a summary 
of all clinical events occurring each day with a particular focus on neurological, 
autonomic and cardiovascular manifestations; details on all interventions during the 
hospital stay; and information on important clinical outcomes. The CRF was structured 
to gather data from the daily morning ward round around 8 am, and include a 
summary of all events in the previous 24 hours. Data collection was helped by the fact 
that in response to the outbreak the Vietnamese MoH issued guidelines in 2011 
indicating that all important signs/symptoms should be documented in patients with 
HFMD, with a checklist provided for doctors and a nursing chart for nurses to record 
the essential information (Appendix, page 85) [147]. Such data were usually 
documented in the hospital files for the time period spent on PICU, but not always for 
the time prior to admission if managed on other wards, or later when the child had 
stabilized and was transferred out. Some vital signs, including blood pressure, were not 
always recorded, especially in young children if they were distressed. Information on 
the patient’s identity (hospital number) was included on the paper CRF for checking 
purposes, but the data were anonymized at the time of entry to the electronic 
database. 
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To gain a general perspective of HFMD at the hospital during the same time-period, I 
also collected basic information from the main HTD hospital database, for all children 
discharged with this diagnosis in 2011 and 2012. These data included the age, gender, 
date of admission, and final discharge classification, all in electronic format.   
Additional general information relating to ethics, data extraction and data 
management, etc. are described in Chapter 2. Definitions for clinical signs and 
symptoms, complications, disease severity measures/outcomes are shown in Appendix 
(page 86). 
Laboratory investigations: During the 2-year period that we focused on, there were 
some differences in the types of laboratory data available, because of gradual 
evolution of the Vietnamese HFMD management guidelines. In the early stages of the 
2011 outbreak, the MoH recommendation was to take throat, rectal, and vesicle swabs 
for laboratory confirmation of enterovirus infection by real-time PCR in all suspected 
HFMD patients admitted to PICU. Moreover, specific PCR for EV-A71 was only 
introduced in September 2011, when the laboratory developed the capacity to 
perform this analysis, but it was only done in cases in which the initial PCR for 
enterovirus proved to be positive. Later, specimens from cases that were positive with 
enterovirus but negative with EV-A71 were stored properly at – 80oC, so that when 
PCR for other enteroviruses had been developed it was possible to go back to the 
original samples and do further laboratory testing.  
Initially lumbar puncture was also recommended in patients who had signs and 
symptoms of CNS involvement, with CSF to be sent to the hospital laboratory for cell 
count, biochemical tests, culture and real-time PCR for enterovirus. In addition, WBC, 
blood sugar, and CRP were to be checked every day for the duration of the PICU stay. 
However subsequently these guidelines were rationalized due to the extremely heavy 
workload in 2011-2012 and after preliminary assessment had shown that lumbar 
puncture, daily WBC, biochemical tests, and real-time PCR in all samples did not help 
much for diagnosis or management. By 2012 the routine practice for all suspected 
HFMD cases on admission to PICU had become a) to send a throat swab for 
enterovirus PCR and b) to request an initial WBC and CRP. Lumbar puncture and repeat 
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hematology and biochemistry were left to the discretion of the treating clinicians, to 
be performed if they felt that any of these tests would be contributed to management.  
Details for the specific protocols for enterovirus diagnostics are presented in Chapter 2.  
Statistical methods: general statistical methodology is presented in Chapter 2. For the 
analysis to identify risk factors for progression to severe disease, the population of 
interest was defined as all cases admitted to PICU within the first 7 days of illness with 
clinically diagnosed HFMD of Grade 2b or above, provided they did not develop any of 
the predefined outcomes within the first 24 hours after admission. These outcomes 
included death or occurrence of severe complications that mandate specific therapy 
according to the Vietnamese M0H guidelines: hemodynamic instability requiring fluid 
resuscitation or inotropes; respiratory distress requiring ventilation; hypertension 
requiring milrinone; or high refractory fever requiring hemofiltration.  
Candidate predictors, all assessed within the first 24 hours in PICU, were chosen based 
on clinical experience and evidence from the published literature [112, 205, 206]. Signs 
or symptoms that occurred very infrequently, or that were closely related to each 
other or the outcomes of interest were not selected. The final list of variables chosen 
are described in the Appendix, page 90.  
Multivariable logistic regression was used for the analysis, with stepwise backward 
model selection. I carried out the regression once using the available dataset, and a 
second time after imputation for missing data. To do this I imputed missing values as 
“yes” if this was the dominant (>50%) response for that variable, and vice versa if the 
dominant response was “no”. P-values < 0.05 were considered significant and 95 % 
confidence intervals were applied for all tests. 
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3.3 Results 
From January 2011 to December 2012, 8736 patients who were admitted to HTD were 
given a final clinical diagnosis of HFMD at discharge, of whom 8711 children were 
under 15 years old. Among them, 1335  cases were either admitted directly to PICU, or 
transferred there from other pediatric departments because of concerns regarding 
potential CNS involvement or other severe manifestations related to the respiratory or 
cardiovascular systems. Within this group, 1289/8711 (15%) cases, including 971/8711 
(11.1%) Grade 2b, 296/8711 (3.4%) Grade 3, and 22/8711 (0.3%) Grade 4, were 
classified finally as presenting signs or symptoms of Grade 2b disease or above. The 
majority, 7422/8711 (85%) cases, presented mild disease only and were classified as 
Grade 1 (1837/8711, 21%)  or 2a (5585/8711, 64%). (Figure 3.1, Figure 3.2).  
Figure 3.1: Distribution of severity grades in HFMD patients admitted to HTD during 
2011-2012 
 
 
 
 
 
 
 
 
 
However, only 1272 of the cases admitted to PICU were admitted there during the first 
7 days of illness. In these patients, specimens were not available in 49 cases, leaving 
1223 patients for the main analysis. 1206 throat swabs, 60 rectal swabs, 49 CSFs, and 5 
vesicle fluid swabs were collected and had RT-PCR performed, although the schedule 
of tests performed differed according to the time during the study period (i.e. 
admission before or after September 2011).   
Treat & Follow-up at Ward Treat & Follow-up at PICU 
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Figure 3.2 : Flow diagram showing patient selection for clinical overview (blue boxes) 
& risk factor analysis (green boxes), and perfomance of diagnostic tests (pink boxes) 
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An enterovirus was identified in 68%, 75%, 8%, and 80% of those specimen groups, 
respectively. Overall, RT-PCR for enterovirus was positive in 842/1272 (66 %) cases. EV-
A71 was confirmed in 448/1272 cases (35%), while CV, including serotypes A2, A 4-6, 
A8-10, A 12, A 16, B4, were found in 167/1272 (13%) cases. In particular, CV-A6 and 
CV-A10 in CV group were dominant, identified in 73/167 (44%) and 35/167 (21%) 
cases. Echovirus, including serotypes 6, 9, and 33, were found in 56/1272 (4%) cases; 
data for these cases were grouped together with the data from children in whom the 
original group-specific RT-PCR was positive but no specific serotype was identified.  
In Figure 3.3 the distribution of HTD and PICU admissions by month is shown for the 2-
year period (Panel A). During the early part of 2011 overall numbers were low but from 
May to December there was a marked rise, followed again by a similar pattern in 2012. 
Figure 3.3: Seasonal distribution of HFMD cases in PICU and HTD in 2011-2012 (Panel 
A), and the enterovirus serotypes (Panel B) identified in the PICU population 
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This time period corresponds to the rainy season in Viet Nam. Interestingly the PICU 
admissions did rise correspondingly with the HTD peak in 2011, but then maintained at 
a relatively constant level per month during 2012 despite a large peak in HTD 
admissions from August to October 2012. Panel B shows the changing pattern of 
serotypes identified in the PICU patient group during the same time period. Prior to 
September 2011 very few cases had a specific serotype identified due to the limited 
diagnostics available at that time. After September 2011 EV-A71 was the predominant 
serotype for about 1 year, while CV and Echovirus were mainly found in 2012 
(126/176, 72% of all isolates) compared to 2011 (50/176, 28% of all isolates). From the 
epidemic profile it is possible that the large peak of patients in mid 2011 for whom the 
enterovirus PCR was positive, but no serotyping was done, may have had EV-A71 
infection 
3.3.1 Demographic information and clinical features within the first 24 hours of PICU 
admission 
The median (IQR) age of 8377 HFMD cases managed at HTD during the selected time 
period was 18 (12, 20) months; 7325/8377 (87 %) were 3 years old or younger, and 
5204/8711 (60%) were male. The median age in the PICU group, 18 (12, 27) months, 
was similar to the overall HTD patient group, 1103/1266 (87%) cases were aged 3 years 
or less and 781/1272 (61%) were male. (Note that in some children in both groups the 
age was only recorded in years rather than months, reducing the denominator 
slightly.) 
Data for the 1223 cases with a final Grade of 2b or above who were managed on PICU 
and had viral diagnostics performed are described in Table 3.2, presented according to 
the virology results. Since the CRF was structured to gather data from the daily 
morning ward round, and include a summary of all events in the previous 24 hours, the 
data represent events occurring within varying time intervals since each patient was 
admitted at a different time. Data was missing for less than 5% of children for most 
variables. All statistical comparisons presented are between the EV-A71 group and the 
CV group, using linear or logistic regression models as appropriate.   
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Table 3.2: Demographic information and clinical features occurring within the first 24 
hours, among 1223 children admitted to PICU with a clincial diagnosis of HFMD, 
presented according to viral serotype 
 EV-A71  
(N=448) 
CV  
(N=167) 
Estimated effect * 
(95%CI) 
 Other EV 
(N=227) 
NEG  
(N=381) 
Demographic information  
Sex (F)  168 (38) 63 (38) 1.01 (0.70, 1.45)  94 (41) 146 (38) 
Age (months)  21 (13, 30) 16 (10, 24) 5.23 (2.49, 7.97)
  18 (12, 27) 17 (11, 25) 
Weight (kg) 11 (10, 14) 11 (9, 13) 0.85 (0.08, 1.61)
&  11 (10, 13) 10 (9, 12) 
Urban address 232 (52) 103 (62) 0.67 (0.46, 0.96)&   138 (61) 234 (61) 
Year of presentation (2011) 180 (40) 49 (29) 1.62 (1.11, 2.39) &   175 (77) 211 (55) 
Illness day at PICU admission 3 (2, 4) 2 (2, 3) 0.80 (0.62, 0.98)
  3 (2, 4) 3 (2, 4) 
Previous HFMD infection  39 (9) 22 (13) 0.62 (0.36, 1.10))  19 (9) 58 (16) 
General signs and symptoms      
High fever (>400C)  58 (13) 20 (12) 1.08 (0.64, 1.90)  33 (15) 68 (18) 
Diarrhoea    7 (2) 2 (1) 1.29 (0.31, 8.69)  5 (2) 17 (4) 
Vomiting  10 (2) 5 (3) 0.72 (0.25, 2.36)  13 (6) 15 (4) 
Skin lesions and mouth ulcers 277 (63) 93 (58) 1.25 (0.86, 1.80)  123 (58) 126 (35) 
Skin lesions only 118 (27) 11 (7) 5.00 (2.73, 10.09)   58 (27) 82 (22) 
Mouth ulcers only 42 (9) 54 (33) 0.21 (0.13, 0.33)   27 (12) 110 (30) 
Target organ involvement      
Myoclonic jerks**  163 (37) 34 (21) 2.17 (1.43, 3.35)
   115 (52) 138 (37) 
Cerebellar signs**  11 (3) 5 (3) 0.80 (0.29, 2.58)  25 (11) 16 (4) 
Tachypnea for age**  99 (22) 7 (4) 6.45 (3.14, 15.59)   47 (22) 51 (14) 
Irregular breathing**  83 (19) 3 (2) 12.36 (4.54, 50.91)   24 (11) 22 (6) 
Tachycardia (HR>150 bpm)**  262 (59) 100 (60) 0.94 (0.66, 1.36)  135 (61) 212 (56) 
High SBP (mm Hg)** 96 (23) 17 (11) 2.35 (1.39, 4.21)&  31 (17) 48 (14) 
Skin ANS features ** 6 (1) 4 (2) 0.55 (0.15, 2.16)  8 (4) 15 (4) 
Missing data in less than 5% of all parameters presented, apart from blood pressure (6.5%), which could 
not be measured in some young children when distressed/crying. Percentages are calculated on the true 
denominator for each variable 
Summary statistic is absolute count (%) for categorical variables and median (IQR) for continuous data 
*: Estimated effect size: OR for categorical variables (based on logistic regression model) and mean 
difference (based on linear regression model) 
**: Details for all definitions are presented in the chapter appendix. ANS = autonomic nervous system 
: p< 0.001, &: p<0.05 
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General manifestations: Patients in the EV-A71 group were significantly older than in 
the CV group (median 21 vs. 16 months, p < 0.001), but this may be influenced by the 
untyped EV that were probably EV-A71 during the peak of the 2011 season. The 
median illness day when patients were generally admitted to hospital was Day 3, but 
significantly earlier (Day 2) in the CV group compared to the EV-A71 group. Parents 
may have worried more about the younger children, especially during the second year 
of the outbreak when there was a high degree of public anxiety. In total 58% of the 
cases came from urban areas; those with EV-A71 infection were equally distributed 
between urban and rural areas however, while the proportion of the CV cases living in 
urban areas was higher, (103/167, 62%) compared to EV-A71 group (232/448, 52%) 
with OR of 1.50 (1.04, 2.16), p=0.028).  
Almost all patients presented with fever, i.e. rectal temperature above 37.50C, but only 
179/1203 (15%) had a rectal temperature of 400C or more, with equal frequency in the 
serotype comparison. However, presentation with skin lesions only, i.e with 
rash/vesicles but without mouth ulcers, was clearly associated with EV-A71 infection 
(p< 0.001). In contrast, presentation with mouth ulcers only without skin lesions was 
strongly associated with CV infection (p< 0.001) (Table 3.2). Other general symptoms, 
such as vomiting and diarrhea, occurred in only a small number of patients overall, 
with similar frequency in the EV-A71 and CV groups. 
Central nervous system involvement: Myoclonic jerks were common, observed in 
450/1203 (37%) of children overall, but were more frequent in the EV-A71 group 
(163/448, 37%) than the CV group (34/167, 21%) (OR= 2.17 (1.43, 3.35), p < 0.001). 
Drowsiness and focal neurological signs were quite uncommon at this time. Lumbar 
puncture was only performed in 79 cases in total, most of them were done during the 
first 9 months of the outbreak in 2011, and in 49/79 (62%) showed typical features of 
viral meningitis with mild to moderate CSF pleocytosis but normal protein and sugar 
levels.   
Respiratory manifestations: Tachypnea for age was noted in 204/1195 (17%) cases 
during the first 24 hours, and was also significantly more common in the EV-A71 group 
(99/ 441, 22%) than in CV group (7/163, 4%) with OR of 6.45 (3.14, 15.59) p<0.001. 
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Irregular breathing was observed in 132/1190 (11%) cases in total, of which most were 
in the EV-A71 group, 83/441 (19%), compared to 3/163 (2%) cases in the CV group 
(OR=12.36 (4.54, 50.91), p<0,001). Severe respiratory pattern abnormalities such as 
labored breathing, stridor, or Cheyne-Stokes respirations were uncommon at this time, 
without a clear relationship to the serotype group.  
Cardiovascular manifestations: Tachycardia, defined as a heart rate over 150 
beats/min after adjustment for fever, was present in 709/1211 (59%) cases, in similar 
proportions of the EV-A71 and CV groups. However, high blood pressure (SBP over the 
Vietnamese MoH Stage 1 threshold) was noted in 192/1143 (17 %) of cases, with a 
strong relationship with EV-A71 infection, (103/314, 33%) compared to the CV group 
(18/94, 15%) with OR= 2.06 (1.19, 3.72), p=0.009.  
3.3.2 Evolution of clinical features over time, and development of complications  
3.3.2.1  Progress in PICU – all cases 
The patients were admitted to PICU on different days of illness, but in the majority, 
832/1223 (67%), this was either Day 2 or Day 3. The progress of the various signs and 
symptoms after admission is shown in Figure 3.4 according to illness day. For most 
variables data were missing in less than 5% of cases over the time course. Blood 
pressure and respiratory distress were not recorded specifically in the hospital files in 
the late stages if they had been normal in the early stage and the patients were 
clinically stable. I reviewed these missing data and accepted that the data should be 
considered as normal.  
Fever was noted in all cases seen on Day 1, and the proportion with fever gradually 
decreased over the first week. Skin lesions and mouth ulcer were also often noted on 
Day 1 and gradually disappeared in the following days. New skin or mouth lesions 
appeared after admission in only small numbers of patients, 48/1223 (4%) and 
21/1223 (2%) of patients, respectively.  
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Figure 3.4: Progress of signs and symptoms over the first 7 days of illness in 1223 
cases 
 
           * High SBP: SBP above Stage I of the Vietnamese MoH guidelines 
Numerator: Numbers represent the number of patients with that feature that day / 
Demoninator: the total number of patients with information for that day of illness
Clinical features 
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By contrast myoclonic jerks were only observed in 10/48 (20%) patients on Day 1, 
increasing to 30% on day 2, then decreasing over the followings days. Other 
neurological signs such as nystagmus or ataxia occurred rarely, but usually happened 
between Day 2 (16/447, 4 %) to Day 4 (19/1080, 2%).  
The earliest respiratory manifestation, i.e. tachypnea, occurred in a few cases on Day 1 
(2/43, 2%) and Day 2 (43/ 451, 10%), but the greatest frequency was seen on Day 3 
(105/873, 12%). Similarly, irregular breathing was highest on Day 3 (92/873, 11%) 
thereafter gradually reducing to Day 7 (5/1039, <1%). Severe respiratory distress, 
including laboured breathing, stridor, gasping respirations and apnea were rare, but 
occurred mostly on Day 3 (14/873, 2%). However, tachycardia occurred most 
commonly on Day 1 (25/48, 52%), then decreased progressively to Day 7 (33/1034, 
3%). Meanwhile, High SBP increased from 6/40, 15% of cases on Day 1 to peak at 
204/970, 21% of cases on Day 4, and was still present in 79/567 (14%) of cases on Day 
7.  
 
3.3.2.2  Clinical progress over time in the EV-A71 and CV groups  
The progression of selected clinical features over time in the EV-A71 and CV groups is 
presented in Figure 3.5. The lasagna plot shows the presence or absence of each 
feature in individual patients (one line per patient) during the period of observation.  
Visual inspection of these plots indicates that while fever was common in both groups 
during the early phase, it generally persisted for longer in the EV-A71 group. Skin 
lesions and mouth ulcers also persisted for longer in the EV-A71 group, although 
mouth ulcers were overall more common in the CV group during the first 3 days. 
Myoclonic jerks occurred more frequently and persisted for longer in the EV-A71 
group. Similarly, tachypnea, irregular breathing, and High SBP all occurred more 
frequently and persisted for longer in the EV-A71 group than the CV group, but the 
two groups showed similar patterns for tachycardia. 
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Figure 3.5: Lasagne plots showing the progress of signs and symptoms over the first 7 days of illness in the EV-A71 and CV groups 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*: Each patient is represented by a single line in the plot, with the presence or absence of each feature in that individual shown for each day under 
observation. 
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3.3.2.3  Overall outcomes and development of major complications (Table 3.3)  
A total of 553/1223 (45%) of the children developed signs of brainstem encephalitis 
during their time in PICU, significantly more frequently in the EV-A71 group (198/448, 
55%) than the CV group (42/167, 25%) with OR= 2.36 (1.60, 3.53), p<0.001. ANS 
dysregulation occurred in 211/1223 (17%) cases, and hypertension in 108/1223 (9%) 
cases, both strongly associated with EV-A71 infection (p< 0.001). Respiratory distress 
occurred in 182/1223 (15%) cases, and was also associated with EV-A71 infection. 
Clinical shock, pulmonary edema and cardiopulmonary failure occurred in 1 to 3% of 
the EV-A71 group, but did not occur at all in the CV group (Table 3.3). Focal 
neurological signs were rarely observed, recorded in only in 7/1223 (1%) cases across 
the groups. Neurological sequelae were noted at discharge in 9/1223 (1%) cases, but 
none of the children were followed up subsequently.  
Overall, 10 children died during the study period, between May 2011 and January 
2012. Details of the features noted within the first 24 hours on PICU in these cases, 
and a summary of complications that developed later, are presented in Table 3.4. The 
children ranged in age from 13 to 59 months, 50% were female, and disease 
progression was often rapid with four children dying within 24 hours of arrival. The 
remaining 6 children died 2-4 days later, in most cases with cardiopulmonary failure as 
the terminal event. EV-A71 was identified in 3 cases, in 2 of these cases with testing 
performed later on samples stored at the time of death. Five cases were positive with 
enterovirus species but did not have specific serotype identification performed, as this 
was not available at that time. Their samples were not also routinely stored for further 
serotyping later. 
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Table 3.3: Major complications and outcomes for 1223 PICU cases, presented 
according to viral serotype 
 EV-A71 
(N=448) 
CV 
 (N=167) 
OR  
(95% CI)* Other_EV 
(N=227) 
NEG 
(N=381) 
Major Complications       
Brainstem encephalitis  198 (55) 42 (25) 2.36 (1.60, 3.53) 137 (60) 176 (46) 
ANS dysregulation  110 (25) 12 (7) 4.20 (2.34, 8.25) 36 (16) 53 (14) 
Hypertension ** 72 (16) 4 (2) 7.80 (3.17, 25.93) 10 (4) 22 (6) 
Clinical shock  6 (1) 0 (0) # 3 (1) 3 (1) 
Respiratory distress  108 (24) 3 (2) 17.36 (6.42, 71.27) 38 (17) 33 (9) 
Pulmonary edema  4 (1) 0 (0) # 4 (2) 2 (1) 
Cardiopulmonary failure  14 (3) 0 (0) # 7 (3) 3 (1) 
Overall Outcomes      
Death  3 (1) 0 (0) # 5 (2) 2 (1) 
Neurological sequelae 3 (1) 0 (0) #  3 (1) 3 (1) 
Hospitalization duration 
(days) 
8.0 (7, 9) 7.0 (6, 9) -0.43 (-0.95, 0.09) 8 (7, 9) 8.0 (7, 10) 
Severe disease (Grade >=3) 162 (36) 7 (4) 0.08 (0.03, 0.16) 68 (30) 70 (18) 
Summary statistic is absolute count (%) for categorical variables and median (IQR) for continuous data 
*: Odds ratio and p-values are based on logistic regression model; : p< 0.001 
**: Systolic blood pressure above Stage 2 of the Vietnamese MoH guidelines.  
#: cannot be compared because there were no events in one group 
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Table 3.4: Clinical features observed within the first 24 hours on PICU, and later progression, in the 10 children who died 
No Date Sex Age 
(mths) 
PICU 
DOI 
 
Signs presenting during first 24 hrs in PICU  Complications Other notes Enterovirus 
serotypes 
Location 
of lesion 
T > 
40oC 
HR> 
150 
bpm 
Tachy-
pnea 
Irregular 
breathing 
Myoclonic 
Jerks 
BE  HTN Shock Respiratory 
Distress 
Pulmonary 
Edema 
 
1 May 11 F 37 Day 3 
Skin & 
Mouth 
(+) (+) (-) (-) (+)  (+) (-) (+) (+) (+) Died at D5 EV-A71 
2 Jun 11 F 19 Day 6 Skin (-) (+) (+) (+) (-)  (+) (+) (-) (+) (-) Died at D 10 Untyped EV 
3 Jun 11 M 59 Day 3 
Skin & 
Mouth 
(-) NA (+) (-) (-)  (-) (-) (+) (+) (-) 
Rapid progress < 
24hrs 
EV-A71 
4 Jun 11 F 44 Day 2 Skin (-) (-) (-) (-) (-)  (+) (+) (+) (+) (+) Died at D4 Untyped EV 
5 Jul 11 M 46 Day 2 
Skin & 
Mouth 
(+) (-) (+) (+) (+)  (+) (+) (+) (+) (+) Died at D5 NEG 
6 Jul 11 M 13 Day 3 Skin (+) (+) (+) (-) (+)  (+) (+) (-) (+) (+) Died at D6 Untyped EV 
7 Jul 11 F 21 Day 4 
Skin & 
Mouth 
(-) (-) (+) (+) (+)  (+) (+) (-) (+) (+) 
Rapid progress < 
24hrs 
Untyped EV 
8 Aug 11 M 21 Day 3 Skin (+) (+) (+) (+) (-)  (+) (-) (+) (+) (+) Died at D5 Untyped EV 
9 Oct 11 F 27 Day 4 
Skin & 
Mouth 
(+) (+) (+) NA (-)  (+) (-) (+) (+) (+) 
Mottled skin (+), 
rapid progress < 
24hrs 
EV-A71 
10 Jan 12 M 43 Day 3 
Skin & 
Mouth 
(-) (+) (+) (+) (-)  (+) (+) (+) (+) (+) 
Rapid progress < 
24hrs 
NEG 
Abbreviation: DOI: Day of illness at admission, BE: Brainstem encephalitis, HR: heart rate, HTN: hypertension
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3.3.3 Laboratory investigations in the 1223 cases   
Results for standard laboratory investigations were incomplete for many patients. A 
full blood count was performed in most patients (1136/1223, 93%) during the first 24 
hour in PICU, but other tests were performed according to clinical need rather than 
systematically.  
The median (IQR) maximum white blood count (WBC) was 14 (11, 18) x109/L, and this 
was higher in the CV group compared to the EV-A71 group within the first 24 hours 
(Figure 3.7, Table 3.5). There was a progressive decline in values obtained on later days 
of illness, and since the CV infected patients were admitted a little earlier (median 
illness Day 2) than the EV-A71 infected patients (median illness Day 3), the 
interpretation of these data remain unclear. Otherwise, the proportion of 
thrombocytosis (platelet count > 400.000/mm3) was higher in EV-A71 group compared 
to the CV group [197/448 (44%) vs. 53/166 (32%), p=0.009], but the actual differences 
were small.  
Figure 3.6: Boxplots showing white blood counts in the EV-A71 and CV groups, by 
illness day  
 
n= number of results available for that serotype each day 
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Table 3.5: Laboratory investigations in the first 24 hours in PICU 
Characteristics n 
EV-A71  
(N=448) 
n 
CV  
(N=167) 
Estimated effect   
(95% CI)* 
 n 
Other EV  
(N=227) 
n 
NEG 
 (N=381) 
WBC (x109/L) 421 13.3 (10.6, 16.8) 151 16.1 (12.9, 19.5)  -2.6 (-3.5, -1.6)   211 13.5 (11.2, 16.8) 353 12.4 (9.4, 16.0) 
Pleocytosis (>16 x109/L) 421 122 (29) 151 76 (50) 0.40 (0.27, 0.59)   211 63 (30) 211 87 (25) 
Platelet (x109/L) 422 370 (310, 442) 151 334 (284, 396) 38 (17, 60) 
 
 211 353 (296, 412) 353 329 (265, 401) 
Hyperglycemia (>150 mg/dl) 256 5 (2) 109 2 (2) 1.07 (0.23, 7.52)   126 5 (4) 194 7 (4) 
Serum Na (mmol/l) 126 134 (132, 136) 47 133 (130, 136) 1 (0, 2) &  113 136 (133, 138) 145 134 (132, 135) 
Hyponatremia (<130 mEq/l) 126 10 (8) 47 9 (19) 0.36 (0.14, 0.98) &  113 8 (7) 145 12 (8) 
CK-MB (UI/l) 33 32 (24, 42) 3 14 (14, 27) 19 (-13, 50)  19 35 (28, 60) 8 38 (28, 66) 
Abnormal CKMB (>60 UI/l) 33 5 (15) 3 0 (0) #  19 5 (26) 8 2 (25) 
Troponin (pg/ml) 35 15.0 (7.5, 28.5) 3 2.0 (2.0, 6.0)  0.30 ( -1.5, 2.1.)   22 0.0 (0.0, 12.0) 13 0.0 (0.0, 10.5) 
Abnormal Troponin I (> 75 pg/ml) 
 
35 2 (6) 3 0 (0) #   0 (0)  1 (8) 
Summary statistic is absolute count (%) for categorical variables and median (IQR) for continuous data 
*:Estimated effect: OR for categorical variables (based on logistic regression model) and mean difference (based on linear regression model); : p< 0.001,   &: p<0.05 
#: cannot be compared because there were no event in one group 
Hyperglycemia (>150 mg%, random test)
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3.3.4 Associations with EV-A71 subgenogroups 
From the 448 EV-A71 positive patients, there were 383 samples available for further 
testing to identify the subgenogroups circulating from September 2011 to December 
2012. However sequencing was unsuccessful in 85/383 (22%) of these cases, most 
likely because the viral load was low. Sequencing confirmed the presence of EV-A71 in 
the remaining samples. Genogroup C4 dominated overall, identified in 237/383 (62%) 
of the samples particularly during the latter part of 2011, gradually decreasing from 
April/May 2012 onwards (Figure 3.7). Meanwhile, genogroup B5 showed a clearly 
different pattern. It was found in 52/383 (14%) of cases, not at all in 2011, then with 
slowly increasing frequency during 2012 peaking in December of that year. Genogroup 
C5 was only identified in 9/383, (2%) of cases, circulating at low frequency in 2011 and 
disappearing from April 2012 onwards.  
Figure 3.7: Distribution of EV-A71 subgenogroups from Sep 2011 to Dec 2012  
 
 
Associations between EV-A71 genogroups and clinical features are presented in Table 
3.6. Myoclonic jerks were noted within the first 24 hours significantly more often in the 
C4 genogroup (108/235, 46%) than the B5 genogroup (14/52, 27%), with an OR of 2.31 
(1.21, 4.62), p=0.010. Other signs and symptoms were not notably different at this 
time, except that rare events like cerebellar signs and skin ANS features (such as 
mottling and profuse sweating) were only seen in patients infected with the C4 
genogroup.  
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Table 3.6: Clinical features during the first 24 hours in PICU, and overall 
complications associated with subgenotypes of EV-A71 (n=383) 
 
C4 
(N=237) 
B5 
(N=52) 
OR 
(95% CI)* 
C5 
(N=9) 
Undefined 
(N=85) 
Selected signs and symptoms at admission   
Myoclonic jerks 99 (42) 13 (25) 2.18 (1.13, 4.45)& 4 (44) 31 (36) 
Cerebellar signs 7 (3) 0 (0) # 0 (0) 2 (2) 
Tachypnea for age 56 (24) 11 (22) 1.12 (0.55, 2.42) 2 (22) 14 (16) 
Irregular breathing 47 (20) 9 (18) 1.14 (0.54, 2.66) 3 (33) 10 (12) 
Tachycardia (HR>150 bpm) 134 (57) 29 (56) 1.03 (0.56, 1.89) 6 (67) 53 (62) 
High SBP (mm Hg)** 56 (25) 13 (28) 0.87 (0.44, 1.81) 4 (50) 11 (13) 
Skin ANS features 4 (2) 0 (0) # 0 (0) 1 (1) 
Complications during the illness course    
Brainstem encephalitis 163 (69) 24 (46) 2.57 (1.40, 4.76) & 6 (67) 44 (52) 
Paralysis  3 (1) 0 (0) # 0 (0) 0 (0) 
ANS dysregulation 67 (28) 9 (17) 1.88 (0.91, 4.32) 3 (33) 11 (13) 
Hypertension*** 49 (21) 9 (17) 1.25 ((0.59, 2.88) 2 (22) 4 (5) 
Shock 4 (2) 0 (0) # 0 (0) 0 (0) 
Respiratory Distress 66 (28) 15 (29) 0.95 (0.50, 1.89) 3 (33) 8 (9) 
Pulmonary Edema 2 (1) 0 (0) # 0 (0) 0 (0) 
Cardiopulmonary failure  11 (5) 0 (0) # 1 (11) 0 (0) 
Summary statistic is absolute count (%) for categorical variables.   
*: Odds ratio and p-values are based on logistic regression model; &: p<0.05    
#: cannot be compared because there was no events in one group 
**: Systolic blood pressure above Stage 1 of the Vietnamese MoH guidelines. Missing blood pressure 
(5%), which could not be measured in some young children when distressed/crying. 
***: Systolic blood pressure above Stage 2 of the Vietnamese MoH guidelines 
 
Considering the whole time-course, brainstem encephalitis occurred significantly more 
often in the C4 genogroup (163/237, 69%) than in the B5 genogroup (24/52, 46%) with 
an OR of 2.57 (1.40, 4.76), p= 0.002, and major life-threatening complications including 
shock, pulmonary edema and cardiopulmonary failure were only seen in the C4 group. 
One child in the C4 genogroup died, but all other children in the groups selected for 
this analysis survived.    
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3.3.5 Risk factors for progression to severe disease  
During the first 24 hours in PICU, most patients had signs and symptoms of moderate 
severity, but in some cases there was already evidence of disease progression, with 
severe manifestation such as respiratory distress or high blood pressure present at this 
time (Table 3.2). Among the 1272 cases potentially eligible for analysis, 68 (5%) 
progressed to one of the pre-defined severe outcomes within the first 24 hours on 
PICU, and were therefore excluded. Subsequently 58/1272 (5%) and 22/1272 (2%) 
children progressed to a severe outcome, on days 2 and 3 in PICU respectively, with 
one further case progressing on day 4. Most of these children eventually made a full 
recovery, apart from the 10 deaths previously described.   
Excluding the cases that progressed quickly, there were 1204 cases that did not 
develop one of the severe outcomes during the first 24 hours, and these cases were 
selected for the multiple regression. Among them, 81/1204 (7%) cases did progress 
later, after more than 24 hours, while the remaining 1123 cases never progressed. 
From the original list, 9 clinical signs and symptoms or easily available laboratory 
parameters were selected as candidate predictors to assess in the multivariable 
analysis (Table 3.7). In the univariable regression, presence of skin lesions, tachypnea, 
and irregular breathing were strongly associated with disease progression and there 
was a borderline association for myoclonic jerks. Tachypnea for age and irregular 
breathing are closely related - I selected tachypnea for the multivariable regression as 
this is usually noted first, while irregular breathing is one factor that may prompt 
clinicians to consider ventilation (i.e. it is closer to one of the outcomes being assessed 
in the model). 
In the multivariable regression, the findings with and without imputation for missing 
values were very similar (Table 3.7). Presence of skin lesions (OR=3.53 (1.61, 9.32), 
p<0.001) and tachypnea for age (OR=2.23 (1.26, 3.82), p=0.007) were the only two 
candidate predictors independently associated with disease progression in the main 
analysis. On repeating the analysis including EV-A71 status (Table 3.8), I confirmed the 
previous finding of a strong association between EV-A71 infection and presence of skin 
lesions.In this analysis, EV-A71 status was the strongest predictor for disease 
progression (OR=2.61 (1.33, 5.34), p=0.005), but skin lesions were no longer included 
in the final model. 
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Table 3. 7: Multiviariable logistic regression to identify risk factors for progression to severe outcome  
 
 
Candidate predictors** 
Severe outcome* Logistic Regression 
 No (N=1123)  Yes (N=81) Univariable Multivariable Multivariable (imputation) 
n Summary 
statistic 
n 
Summary 
statistic 
OR 95% CI Pvalue OR 95% CI Pvalue OR 95% CI Pvalue 
Age (months) 1118 18 (12, 27) 81 17 (11, 25) 1.00 0.99, 1.02 0.581 1.01 0.99, 1.02 0.566 1.01 0.99, 1.02 0.412 
Sex (F) 1123 427 (38) 81 35 (43) 0.81 0.51, 1.28 0.357 0.89 0.54, 1.51 0.672 0.86 0.54, 1.38 0.539 
Illness day at PICU admission 1123 3 (2, 4) 81 3 (2, 3) 0.91 0.74, 1.11 0.354 0.92 0.72, 1.16 0.485 0.87 0.69, 1.08 0.203 
Skin lesions 1071 798 (75) 74 69 (91) 3.37 1.64, 8.15 <0.001 3.53 1.61, 9.32 <0.001 3.37 1.62, 8.20 <0.001 
High Fever (> 400C) 1108 157 (14) 75 16 (21) 1.64 0.89, 2.86 0.106 1.50 0.74, 2.86 0.250 1.56 0.84, 2.76 0.153 
Tachycardia (HR > 150 bpm) 1114 642 (58) 79 52 (66) 1.42 00.88, 2.32 0.236 1.27 0.75, 2.21 0.380 1.49 0.91, 2.49 0.115 
Myoclonic jerks 1105 385 (35) 79 36 (46) 1.56 0.98, 2.47 0.059 1.45 0.86, 2.41 0.159 1.49 0.93, 2.37 0.098 
Tachypnea for age 1101 165 (15) 76 24 (32) 3.22 1.86, 5.39 <0.001 2.23 1.26, 3.82 0.007 2.23 1.31, 3.68 0.004 
Pleocytosis (>16k/mm3) 1045 316 (30) 75 19 (25) 0.78 0.45, 1.32 0.363 0.86 0.47, 1.50 0.594 0.74 0.42, 1.26 0.269 
Urban address 1123 642 (57) 81 52 (64) 1.34 0.85, 2.17 0.213       
Mouth ulcers 1090 788 (72) 74 52 (70) 0.91 0.55, 1.55 0.709       
Skin ANS features 1103 31 (3) 76 2 (3) 0.93 0.15, 3.17 0.926       
Irregular breathing 1097 96 (9) 76 20 (26) 3.72 2.10, 6.38 <0.001       
Cerebellar signs 1104 54 (5) 78 3 (4) 0.77 0.10, 2.06 0.652       
Thrombocytosis (>400k/mm3) 1046 320 (31) 75 26 (35) 1.20 0.73, 1.95 0.465       
*: Severe outcome was defined as death, shock requiring inotropes or fluid resuscitation, severe respiratory distress requiring ventilation, hypertension requiring milrinone, or 
high refractory fever requiring hemofiltration. Patients with any of these outcomes within 24 hours of PICU admission were excluded.  
**: All predictors were assessed within the first 24 hours after PICU admissi
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Table 3.8: Multiviariable logistic regression to identify risk factors for progression to severe outcome, including EV-A71 status   
 
 
Candidate predictors 
 
Severe outcome Logistic Regression 
 
No 
(N=936) 
 
Yes 
(N=59) 
Univariable Multivariable Multivariable (imputation) 
n 
Summary 
statistic 
n 
Summary 
statistic 
OR 95% CI Pvalue OR 95% CI Pvalue OR 95% CI Pvalue 
Age (months) 932 18 (12, 27) 59 20 (11, 29) 1.01 (0.99, 1.03) 0.301 1.01 (0.99, 1.03) 0.489 1.01 (0.99, 1.03) 0.491 
Sex (F) 936 584 (62) 59 33 (56) 0.77 (0.45, 1.31) 0.325 0.91 (0.50, 1.69) 0.756 0.81 (0.47, 1.41) 0.457 
Illness day at PICU admission 936 3 (2, 4) 59 3 (2, 3) 0.97 (0.76, 1.22) 0.822 0.97 (0.72, 1.29) 0.858 0.9 (0.68, 1.17) 0.432 
Skin lesions 895 645 (72) 55 48 (87) 2.66 (1.27, 6.51) 0.008 1.84 (0.77, 5.10) 0.178 1.86 (0.84, 4.74) 0.132 
High fever (> 400C) 926 129 (14) 55 12 (22) 1.72 (0.85, 3.26) 0.126 1.43 (0.59, 3.09) 0.404 1.73 (0.83, 3.36) 0.136 
Tachycardia (HR > 150 bpm) 930 530 (57) 57 39 (68) 1.64 (0.94, 2.97) 0.085 1.32 (0.70, 2.58) 0.393 1.62 (0.90, 3.01) 0.107 
Myoclonic jerks 920 312 (34) 58 27 (47) 1.7 (0.99, 2.89) 0.054 1.52 (0.82, 2.78) 0.181 1.61 (0.92, 2.78) 0.093 
Tachypnea for age 916 129 (14) 55 17 (31) 2.73 (1.46, 4.91) 0.002 1.93 (0.96, 3.71) 0.066 2.06 (1.09, 3.75) 0.027 
Pleocytosis (>16k/mm3) 867 271 (31) 55 12 (22) 0.61 (0.31, 1.15) 0.129 0.71 (0.34, 1.39) 0.323 0.57 (0.28, 1.10) 0.094 
EV-A71 positive 936 370 (40) 59 40 (68) 3.22 (1.86, 5.76) <0.001 2.61 (1.33, 5.34) 0.005 2.56 (1.41, 4.80) 0.002 
Urban address 936 534 (57) 59 38 (64) 0.97 (0.53, 1.84) 0.915       
Mouth ulcers 911 664 (73) 54 39 (72) 1.36 (0.80, 2.40) 0.264       
Skin ANS features 923 21 (2) 55 1 (2) 0.8 (0.04, 3.91) 0.819       
Irregular breathing 915 79 (9) 55 13 (24) 3.28 (1.63, 6.21) 0.001       
Cerebellar signs 911 30 (3) 57 1 (2) 0.52 (0.03, 2.52) 0.487       
Thrombocytosis (>400k/mm3) 868 266 (31) 55 20 (36) 1.29 (0.72, 2.26) 0.38       
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Table 3.9: Multivariable logistic regression for severe outcome, focused on the groups with skin lesions only and mouth ulcers only 
Candidate predictors 
 
 
Severe outcome Logistic Regression 
 
No 
(N=1123) 
 
Yes 
(N=81) 
Univariable Multivariable 
n Summary statistic n Summary statistic OR 95% CI Pvalue OR 95% CI Pvalue 
Age (months) 1118 18 (12, 27) 81 17 (11, 25) 1.00 (0.99, 1.02) 0.58 1.01 (0.99, 1.02) 0.466 
Sex (F) 1123 427 (38) 81 35 (43) 0.81 (0.51, 1.28) 0.357 0.90 (0.54, 1.51) 0.672 
Illness day at PICU admission 1123 3 (2, 4) 81 3 (2, 3) 0.91 (0.74, 1.11) 0.354 0.93 (0.73, 1.16) 0.485 
Skin lesions only 1071 241 (22) 74 22 (29) 1.44 (0.84, 2.37) 0.180 1.10 (0.61, 1.93) 0.735 
Mouth ulcers only  1090 231 (21) 74 5 (7) 0.26 (0.09, 0.59) <0.001 0.32 (0.11, 0.77) 0.008 
High Fever (> 400C) 1108 157 (14) 75 16 (21) 1.64 (0.89, 2.86) 0.106 1.42 (0.70, 2.68) 0.322 
Tachycardia (HR > 150 bpm) 1114 642 (58) 79 52 (66) 1.42 (00.88, 2.32) 0.236 1.27 (0.74, 2.20) 0.386 
Myoclonic jerks 1105 385 (35) 79 36 (46) 1.56 (0.98, 2.47) 0.059 1.37 (0.82, 2.29) 0.226 
Tachypnea for age 1101 165 (15) 76 24 (32) 2.62 (1.55, 4.32) <0.001 2.26 (1.28, 3.88) 0.006 
Pleocytosis (>16k/mm3) 1045 316 (30) 75 19 (25) 0.78 (0.45, 1.32) 0.363 0.87 (0.48, 1.52) 0.644 
 Urban address 1123 642 (57) 81 52 (64) 1.34 (0.85, 2.17) 0.213   
Skin ANS features 1103 31 (3) 76 2 (3) 0.93 (0.15, 3.17) 0.926    
Irregular breathing 1097 96 (9) 76 20 (26) 3.72 (2.10, 6.38) <0.001    
Cerebellar signs 1104 54 (5) 78 3 (4) 0.77 (0.10, 2.06) 0.652    
Thrombocytosis (>400k/mm3) 1046 320 (31) 75 26 (35) 1.20 (0.73, 1.95) 0.465    
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Tachypnea for age persisted in the model with imputation for missing values, with OR 
of 2.06 (1.09, 3.75), p=0.027, but with borderline significance in the standard model 
(OR=1.93 (0.96, 3.71), p=0.066).   
In the light of this finding and given the previous analysis showing different 
relationships for skin lesions and mouth ulcers alone with enterovirus serotype, I also 
ran a post-hoc analysis focused on patients with either of these features separately. 
The presence of mouth ulcers without skin lesions was protective with OR=0.32 (0.11, 
0.77), p=0.008 (Table 3.9), but skin lesions alone did not come out in the multivariable 
analysis.  
 
3.4 Discussion 
In this chapter I presented a detailed description of the clinical features of 1272 HFMD 
cases that were managed on our PICU over a 2 year period during the recent major 
outbreak in Ho Chi Minh City. I assessed over 98% of all the children admitted with a 
clinical diagnosis of HFMD in the acute phase (<7 days of illness). A small number of 
children initially admitted for observation were not included in the review as the PICU 
clinician’s final assessment was of Grade 1 or 2a disease and they were soon 
discharged back to the pediatric wards. Although this was a retrospective file review, 
the data were quite comprehensive, generally with less than 5% missing information 
for all the variables assessed. In part this reflects the strict adherence to MoH 
guidelines for observation and management of HFMD cases that were drawn up during 
the early phase of the outbreak; with this good recordkeeping I feel that the data are 
representative of the progression of HFMD clinical features despite the inevitable 
limitations of a retrospective study. 
Young children under 3 years of age were affected primarily, with similar age ranges 
found among the patients with mild disease (HTD population) and those with more 
severe symptoms who were admitted to PICU. Both EV-A71 and CV-A16 were reported 
as circulating in southern Vietnam between 2005 and 2011 [89, 201], potentially 
providing a degree of immunity in the community, especially among the older age 
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groups [200], while younger children remained susceptible to infection with emerging 
serotypes [210]. Serotype identification was not done in the early stage of the 
outbreak in 2011 as the necessary serotype specific PCR was not available at that time 
and specimens were not routinely stored, but given the temporal evolution of the EV-
A71 related cases after September 2011 when the serotype specific PCR was 
introduced, it seems very likely that many of the cases during the summer months of 
2011 were also EV-A71 related. The subsequent transition from EV-A71 to CV 
circulation during 2012 may explain the changing ratio of severe HFMD cases 
compared to overall HFMD cases in HTD that we found between 2011 and 2012 
(Figure 3.3) [211].  
Typical neurological signs and symptoms previously observed in severe HFMD cases 
indicate involvement of the brainstem [82, 83]. In this study, the analysis of 
longitudinal data allows the progression of moderate and severe manifestation to be 
examined more clearly. Fever is commonly the first symptom, with skin lesions and 
mouth ulcer often occurring concurrently with fever in the early phase, sometimes 
persisting up to the 7th day of illness. Neurological signs, including myoclonic jerks and 
cerebellar signs were rare on the first day but did occur on the second and third days, a 
pattern consistent with theoretical ideas on enterovirus pathogenesis [64]. 
Subsequently other manifestations of CNS involvement, including tachypnea and 
irregular breathing or respiratory distress were mainly seen from day 3 of illness and 
lasted for around 3 days. Similarly cardiovascular abnormalities, other than tachycardia 
which was often present from day 1, commonly became apparent between days 3-5 of 
disease. Many other factors may contribute to tachycardia, including fever (although 
this was adjusted for), and distress due to mouth ulcers/skin lesions, inability to 
swallow etc. during the early phase. Development of hypertension from day 3 onwards 
may indicate viral spread to involve the medulla oblongata [134], but may also 
implicate an aggressive systemic inflammation response [64]. Brainstem involvement 
can result in an imbalance in the sympathetic/parasympathetic control mechanisms, 
potentially leading to a sympathetic storm, especially in association with EV-A71 [64]. 
EV-A71 has been considered as the primary cause of severe HFMD manifestations in 
the Asian epidemics over the last 10-20 years, with 10-30% of hospitalized cases 
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reported to progress to CNS complications, including meningitis, polio-like paralysis, 
and brainstem encephalitis [68]. In line with other reports [104, 207, 212], in this study 
I found the range of severe signs and symptoms to be more common in those with 
confirmed EV-A71 infection, compared to among the children infected with a variety of 
CV serotypes; myoclonic jerks, respiratory abnormalities, hypertension and other ANS 
signs were all more common and persisted for longer in the EV-A71 group. However, 
although most of the severe complications occurred in patients infected with EV-A71, 
problems also occurred in some children infected with CV, albeit with a lower 
frequency. Brainstem encephalitis (25%), hypertension (8%) and severe respiratory 
distress (2%) were all documented in the CV group, but none of these cases progressed 
to develop pulmonary edema or cardiopulmonary failure.  
The variety of clinical manifestation of HFMD observed in different studies likely 
depends on the neurotropic potential of the enterovirus serotype [213, 214], as well as 
on the host immune response [215, 216]. Within the EV-A71 serotype, there is also 
evidence to suggest that neurovirulence varies according to the specific genogroup 
involved [64, 217]. Genogroups C1 and C4 were reported to be circulating in Vietnam 
in 2005, later shifting to C5 in the latter half of 2005 and beyond [83, 89]. Detailed 
analysis of the circulating EV-A71 genogroups from the patients described here has 
shown that C4 dominated in 2011, with evidence of a shift to B5 in 2012. Associations 
between disease severity and EV-A71 genogroups have been difficult to clarify because 
of limited capacity to perform genogroup identification in many countries at risk of 
HFMD outbreaks, and also differences in study designs between countries or over 
time, thus limiting comparability of data. However group C2 in the outbreak in 
Western Australia [218], and B4 in the outbreak in Sarawak, Malaysia [192], were 
linked to severe neurological manifestations of HFMD. Although data collection in this 
study was retrospective, the data quality was generally good and outcome definitions 
were applied systematically to the whole dataset; comparative analysis showed that 
C4 was significantly more likely to cause brainstem encephalitis than B5, and that 
other severe complications also occurred either exclusively in the C4 group or more 
frequently in this group than the B5 group, indicating that genogroup C4 viruses are 
particularly neurotropic.  
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For the risk factor analysis I first carefully defined the severe outcomes of interest, and 
also made sure that any children in whom these events occurred within the first 24 
hours in PICU were excluded (68 children), so that the analysis focused on identifying 
factors that predicted events occurring later in the disease evolution, rather than 
associations that were temporally related but not actually predictive. For the 
candidate predictors I was also careful to exclude variables that were too closely 
related to the outcomes selected. A total of 81 children experienced one or more of 
the severe outcomes at least 24 hours after PICU admission, thus allowing inclusion of 
8-9 variables in the regression model. I selected candidate predictors occurring within 
the first 24 hours, either that have been previously published as showing an 
association with severe disease [112, 194, 202-209], or that were based on our clinical 
experience at HTD. However, although duration of fever for more than 3 days has been 
found to be associated with severe disease before, since I wished to look at factors 
present at admission and most cases were admitted on day 2 or 3 and progressed (if at 
all) within the next 48-72 hours this could not be included.  
A number of the candidate predictors that have previously been shown to be 
associated with severe disease, e.g. age, sex, high fever, myoclonic jerks, tachycardia, 
were not significant in the univariable analysis and did not come through in the 
multivariable analysis after controlling for other factors. Presence of skin lesions and 
tachypnea for age were the only two candidate predictors that were independently 
associated with subsequent deterioration, and both showed strong relationships with 
the outcome. Further analysis showed that the presence of skin lesions was related to 
EV-A71 status; this was not included in the original multivariable model as I was 
interested in readily available signs and symptoms or lab tests, and serotype specific 
PCR is unlikely to be available in most countries where major epidemics of severe 
HFMD occur. However, given the strong relationship with skin lesions this may be 
taken as a proxy for EV-A71 infection in this analysis. Presence of skin lesions is quite a 
broad category however, and it may be that in other epidemics when different 
serotypes prevail that also cause skin lesions but may be less neurotropic, that the 
relationship would not be maintained.  
On the other hand, presence of mouth ulcers alone, without skin lesions, was related 
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to CV infection, and in general the severe outcomes that I was interested in predicting 
did not occur in the CV group. In a meta-analysis of studies mostly conducted in 
mainland China [112], patients who presented with oral involvement were not at 
higher risk of severe disease, although in an evaluation of patients presenting with skin 
lesions with or without oral involvement in a case-control study in Singapore [205], 
oral lesions were associated with severe disease. In a post-hoc analysis I repeated the 
multivariable regression with presence of skin lesions and mouth lesions alone as 
candidate predictors, and found that presence of mouth ulcers without skin lesions 
had a strong protective effect, probably as a surrogate for CV infection. This may be of 
more use practically in outbreak situations, when deciding how to triage large numbers 
of children with potentially severe disease. 
Tachypnea and irregular breathing were both associated with severe outcome in the 
univariable regression, consistent with brainstem involvement. For the multivariable 
regression model I selected tachypnea for age rather than irregular breathing for the 
reasons mentioned earlier, and this was independently associated with disease 
progression in the main analysis. After inclusion of EV-A71 status, the association was 
borderline, confirming a strong interaction between EV-A71 and respiratory 
complications.  
The main limitation of this study was the fact that data collection was retrospective 
rather than prospective. However the practicality of collecting data prospectively 
during a major outbreak on this number of cases would be very daunting and would 
probably require a separate team of research staff so as not to compromise patient 
care. By making use of the MoH recommendations for monitoring and management of 
HFMD cases I was able to describe each patient’s condition within the first 24 hours, 
but for the risk factor analysis I could only include outcome events occurring after the 
first 24 hours. Had it been possible to collect data prospectively it would have been 
theoretically feasible to use a shorter time-window, such as 12 hours, and so more of 
the events within the first 24 hours could have been included, potentially reducing bias 
and allowing additional candidate parameters to be assessed in the model.  
Secondly by focusing the study on patients admitted to PICU this selected for children 
who already had some degree of compromise. However, the threshold for PICU 
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admission during this outbreak was relatively low due to heightened public anxiety, 
and I defined the outcomes for the risk factor analysis carefully, only including 
endpoints that were objective and likely to be accepted by all ICU clinicians as truly 
severe, rather than including more subjective features that could be open to 
interpretation. In consequence, the results from my analysis looking at longitudinal 
relationships between pre-defined factors and outcomes at least 24 hours later, 
differed from previously published studies, which did not clearly distinguish the 
timeline. Most other studies described associations with severe disease, often using 
less strict definitions for the endpoints. Of course in an outbreak situation the ability to 
triage before PICU admission would be a major advantage. But to look at risk 
prediction from an earlier stage in the illness course, assessments would have been 
needed on the whole suspected HFMD population in HTD, in order to identify factors 
that predicted the need for transfer to ICU. This is not practical for a detailed 
prospective study, but might be feasible if an electronic surveillance system could be 
set up, whereby a limited number of important features were recorded each day in the 
hospital patient database as part of routine clinical practice, ideally with the same 
system in operation at all the major hospitals across the region.  
 
3.5 Conclusions 
In summary, I have presented the clinical features of 1272 HFMD cases admitted to 
PICU during the 2011-2012 outbreak, in whom an enterovirus was identified using 
molecular methods in around 70% of cases, EV-A71 in 35%, various CVs in 13%, and 
echovirus/other serotypes in 18% of the cases. I described the characteristics on 
admission and the evolution of signs and symptoms over the first 7 days, comparing 
the findings between the EV-A71 and the CV groups. Neurological signs and symptoms 
occurred with greater frequency and persisted for longer in the EV-A71 group. Ten 
children died overall and severe complications occurred frequently, specifically signs 
consistent with brainstem encephalitis were found in 42% of children, commonly 
between days 3-5 of illness.  
Although all severe manifestations were significantly associated with EV-A71 infection, 
they also occurred in patients infected with other enterovirus serotypes, including CVs 
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and echovirus. Brainstem encephalitis was more likely to occur in patients infected 
with the EV-A71 C4 subgenogroup than other genogroups. During an outbreak changes 
in the pattern of dominant viruses that are in circulation may result in emergence of 
more or less severe phenotypes over time.  
 In the risk factor analysis presence of skin lesions and tachypnea for age within 24 
hours of PICU admission were the only two candidate predictors that were 
independently associated with subsequent deterioration to one of the pre-defined 
severe outcomes. Both these features showed an interaction with EV-A71 infection. 
Presentation with mouth ulcers alone, without skin lesions, was protective against the 
severe outcomes in the risk factor analysis, and was linked to CV infection. Patient who 
present with tachypnea or skin lesions should be closed observed to allow early 
recognition of progression to severe disease while patients with mouth ulcers only are 
unlikely to develop complications. 
The burden of emerging enterovirus infections affecting young children in the Asia-
Pacific region is considerable, with ongoing endemic transmission occurring in many 
countries, superimposed with major outbreaks every few years. The findings described 
here will be important in helping clinicians to assess and triage children with suspected 
HFMD, allowing appropriate follow-up and treatment to prevent severe complications 
of this common disease. 
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Appendix 1: Checklist for doctor and nurses to follow and manage suspected HFMD cases 
(Vietnamese MoH). Note that the frequency of observations depends on severity grade  
                                                  Date /time   
 
Signs/Symptoms 
     
History       
Vomiting      
Myoclonic jerks (times)      
Irrititability / Sleepiness      
Limb tremor / ataxia      
      
Examination       
Rash / Mouth ulcer      
Heart rate (bmp)      
Respiratory rate (time/minute)      
BP (mmHg) –  SBP/ DBP      
Temp (oC)      
Myoclonic Jerk (times)      
Neurological focus signs (describe):      
Limb tremor / ataxia      
Local sweating (where?)       
Convulsion (L: Local, G: general      
Mottled skin (Local)       
Cold skin  / CRT > 2 s      
Consciousness  (1-Alert, 2-Dowsiness, 3-Coma)      
GCS       
Respiratory rales (crackle, bronchi, wheeze)       
      
WBC (x109/L)      
Glycemia  (mg/dl)      
PCR (+: indication, EV, EV-A71, negative)      
Situation & Clinical stage       
Shock      
Respiratory distress      
Coma       
Pulmonary edema      
      
Clinical grade  (currently)      
Follow up and management      
Oxygen/ intubation      
Dobutamine( µg/kg/m)      
…………...........( µg /kg/m)      
Milrinone (µg /kg/m)      
Gamma-globulin (dose 1 or 2)      
Sedation: Phenobarbital (mg)      
Mannitol (volume-rate)      
Antibiotic:       
Arterial catheter      
CVP (cmH20)      
Follow up duration  (hour - minutes)      
Doctor /Nurse’s 
Signature 
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Appendix 2: Definitions for clinical signs and symptoms, complications and disease severity 
and outcomes 
Variables  Type  Value  Definition  
Demographic 
Age Cat  Months  
Urban/Rural  Binary   Urban: district in city or town in provinces  
Kindergarten Binary  Yes/no Studying in kindergarten  
Members in family 
infected with HFMD 
Binary  Yes/no  Any other member of family who was diagnosed with 
HFMD 
Illness day Cat  Days  The illness day of disease when admission  
Underlying disease  Binary  Yes/no  Chronic disease  
Previous HFMD 
infection 
Binary  Yes/no  Have been suffered from HFMD before current infection 
Signs and syndromes 
Fever  Binary  Yes/no  T0> 37.5,   
High Fever  Binary  Yes/no  T0 > 40 . 
Vesicle rash  Binary  Yes/no  Blister lesion examined by doctor 
Mouth ulcer  Binary  Yes/no  Eruption lesion in the mouth examined by doctor 
Cardiovascular system involvement 
Tachycardia  Binary  Yes/no  Any of heart rate > 150 bmp (after justify 10bmp per 1oC  
above 37oC 
High Systolic Blood 
Pressure 
Binary  Yes/no  Any of SBP is above MoH criteria (see in table 1.4, chapter 
1) 
Arrhythmia  Binary  Yes/no   Any event that recorded by doctors or presented in ECG 
recording 
Mottled skin  Binary  Yes/no  Abnormal skin that covered with whitish spots and darkish 
color areas that recorded by doctor 
Profuse Sweating  Binary  Yes/no  Local or general sweating that recorded by doctors of 
nurses in hospital files 
Skin ANS features  Binary  Yes/no  Clinical HFMD and cold sweating and/or mottled skin  
Respiratory distress 
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Tachypnea Binary  Yes/no  
Respiratory Rate: >6<12 mth: ≥ 50; >12<72 mth: ≥ 40; >72 
mth<12 yrs: ≥ 30; >12 yrs: ≥ 25 that assessed by clinical 
doctor  
Irregular breathing  Binary  Yes/no  Irregular pattern that recorded by doctors 
Stridor   Binary  Yes/no  Abnormal inspiration sound that recorded by doctors. 
Resp. retraction Binary  Yes/no  Labor breathing  
Wheezing  Binary  Yes/no   
Gasp breathing Binary  Yes/no   
Cheyne-Stoke Binary  Yes/no  Irregular breathing with short apnea period (<15s) 
Apnea breathing Binary  Yes/no  Apnea lasting over 15 seconds or gasp breathing recorded 
by doctor  
CNS involvement 
Drowsiness Binary  Yes/no  GCS <15 or stupor or legarthy manifestation that recorded 
by doctors 
Irritability Binary  Yes/no  Abnormal behavior that recorded by doctor or nurses 
Myoclonic jerks  Binary  Yes/no  A jerk recorded by doctor 
Cerebellar signs Binary  Yes/no  Presented any of the following signs: limb tremor, 
nystasmus, ataxia 
Limb weakness  Binary  Yes/no  Lack of strength of limbs recorded by doctor 
Cranial nerve paralysis Binary  Yes/no  Any cranial nerves paralysis recorded by doctor 
Laboratory 
Pleocytosis    Binary  Yes/No WBC > 16 x109/L 
Thrombocytosis  Binary  Yes/No Platelet > 400 x109/L 
Hyperglycemia  Binary  Yes/No Any blood sugar > 150 mg/dl  
Hyponatremia Binary  Yes/No Serum Na< 130 mmol/dl 
Complications    
Brainstem encephalitis Binary  Yes/no  Clinical HFMD and present of myoclonus and/or ataxia 
and/or nystagmus and/or oculomotor palsies, and/or 
bulbar palsy and/or brainstem abnormality in MRI and/or 
abnormal respiratory pattern (irregular breathing, labor 
breathing and severe respiratory breathing) 
Aseptic Meningitis  Binary  Yes/no  Clinical HFMD and cells/CSF >5 and bacterial culture (–ve)  
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Acute flaccid paralysis Binary  Yes/no  Flaccid muscle weakness and lack of reflexes 
Hypertension    SBP above Stage 2 of the Vietnamese MoH guidelines 
ANS dysregulation  Binary  Yes/No  
At least 2 of the following features: heart rate of 150-170 
beats/min, systolic blood pressure variability with absolute 
values higher than threshold in MoH guideline, profuse 
sweating, mottled skin, respiratory abnormalities, and 
hyperglycemia.  
 
Myocarditis  Binary  Yes/no Cardiac injury and clinical cardiac failure and inotrops using 
(dobutamin or dopamin) 
Shock  Binary  Yes/no  SBP < 70+ 2n and requirement of fluid resuscitation or 
vasopressor medicines 
Pulmonary edema Binary  Yes/no  Respiratory distress and tachycardia and tachypnea and/or 
rales and pink frothy secretion and bilateral pulmonary 
infiltrates without cardiomegaly in chest radiograph 
Respiratory distress  Binary  Yes/no Tachypnea for age and/or irregular breathing and/or stridor 
and/or apnea and/or gasp 
Cardiopulmonary 
failure 
Binary  Yes/no   Tachycardia (adjusted by fever) >150 bpm and respiratory 
distress and pulmonary edema and shock and/or 
pulmonary congestion on chest radiography and reduced 
cardiac contractility on echocardiography 
Management 
IVIG  Binary Yes/No Patient received any dose of IVIG 
MgSO4 Binary Yes/No Patient were commenced MgSO4 for hypertension 
treatment Nircardipine Binary Yes/No Patient were commenced Nircardipine for hypertension 
treatment 
Oxygenation Binary Yes/No Patient received oxygen because of respiratory distress 
Ventilation Binary Yes/No Both non-invasive and invasive ventilation  
Inotropes  Binary Yes/No Patient were commenced dobutamine or dopamine 
Fluid resuscitation Binary Yes/No Patient were commenced a bolus of fluid challenge or fluid 
resuscitation because of shock  
Hemofiltration  Binary Yes/No Patient were performed the CVVH   
Outcome 
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Death Binary Yes/No Both death or discharge because of worst condition 
Neurological sequelae Binary Yes/No Any neurological sequelae still exist at discharge 
Duration of 
Hospitalization 
Cat Days Time from HTD admission to discharge 
Severe grade  Binary Yes/No Clinical HFMD and grade 2b at discharge 
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Appendix 3: Description of pre-defined candidate predictor present during the first 24 hours in PICU 
and definitions for severe outcome 
Prognosis factors 
Factors Type  Value  Definition  
Age Cat  Months  
Sex Binary  M/F  
Weight  Cat  Kg  
Urban/Rural  Binary  Yes/no See above  
Illness day Cat  Days  See above  
High fever  Binary  Yes/no  See above 
Skin lesion  Binary  Yes/no  See above 
Mouth ulcer  Binary  Yes/no  See above 
Tachycardia  Binary  Yes/no  See above 
Skin ANS features  Binary  Yes/No  See above 
Tachypnea Binary  Yes/no  See above 
Irregular breathing  Binary  Yes/no  See above 
Myoclonic jerks  Binary  Yes/no  See above 
Cerebellar signs  Binary  Yes/no  See above 
Pleocytosis    Binary  Yes/No See above 
Thrombocytosis Binary  Yes/No See above 
Hyperglycemia   Yes/No See above 
Severe outcome  Binary Yes/No Death or presenting severe condition that defined as either 
a) hemodynamic unstable that required fluid resuscitation 
or inotropes or b) severe respiratory distress that required 
ventilation support, or c) severe high blood pressure that 
required milrinone, or d) high refractory fever requiring 
hemofiltration,   
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Chapter 4 
THE MAGNESIUM SULFATE TRIAL 
4.1 Background 
Neurological manifestations of enterovirus infections include a range of problems such 
as aseptic meningitis and acute flaccid paralysis, but the issue of particular concern in 
severe HFMD is brainstem encephalitis. ANS dysregulation may occur, potentially with 
rapid progression to cardiopulmonary failure [64]. Although the mechanisms 
underlying the ANS dysregulation have not been clearly defined there is evidence that 
inflammation occurs in the medulla oblongata and cervical spinal cord, causing 
increased sympathetic activity and resulting in severe systemic and pulmonary 
hypertension, and eventually pulmonary oedema [64]. The clinical features indicating 
ANS dysregulation include high persistent fever, profuse sweating, mottled skin, 
tachycardia, tachypnoea, hypertension and hyperglycaemia [83]. One potential 
mechanism could be related to high catecholamine levels [64, 111]. Alternatively, in a 
number of animal studies of neurogenic hypertension, associations have been 
demonstrated between inflammatory cytokine levels and enhanced vasomotor and 
cardiac sympathetic drive [120].  
Management of ANS dysregulation presents particular challenges. In one report from 
Taiwan, use of the phosphodiesterase-3 inhibitor, milrinone, was said to control 
hypertension and support myocardial function in a group of 24 children with severe 
HFMD compared to historical controls [117]. In addition, milrinone has also been 
shown to decrease mortality in HFMD patients with pulmonary edema in a small open-
label randomized clinical trial in Viet Nam [168]. This has now become the 
recommended therapy for severe HFMD with ANS dysregulation in Vietnam, with MoH 
Guidelines setting down indications for when milrinone should be commenced in 
suspected HFMD cases. Currently the MoH Guidelines define the intervention level for 
use of milrinone at a systolic pressure exceeding the 99th centile for age plus 5 mm Hg, 
which approximates to the internationally accepted definition of Stage 2 hypertension 
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in children (Appendices, page 198) [169]. However, clinical failures still occur despite 
high dose IV milrinone, and a number of children go on to require haemofiltration and 
ventilatory support, the next steps recommended in the MoH guidelines [170]. 
Secondly, there is very little clinical or safety data available with respect to milrinone 
use in children, apart from a few small studies following cardiac surgery. Adverse 
effects reported in adults include ectopic activity and potentially life-threatening 
ventricular arrhythmias [219]. Reports in children suggest that milrinone use is an 
independent risk factor for clinically significant tachyarrhythmias after congenital heart 
surgery, and may be associated with development of acute renal failure [220].  
In 2011, during the first year of the major HFMD epidemic in Vietnam there were a 
significant number of milrinone treatment failures. As described in the introduction, 
MgSO4 is a drug in regular use on our PICU for children with ANS dysregulation in 
association with neonatal tetanus. Our experience of using this drug for neonatal 
tetanus has been very positive, so therefore I considered the possibility of using it as 
second line therapy for the severe HFMD cases. Formal safety data relating to use of 
MgSO4 in paediatrics are limited, but from its use in children with severe asthma, and 
in a small number of neonates with uncontrolled pulmonary hypertension, adverse 
effects appear to be infrequent [176, 221, 222]. From the December of 2011 to the 
December of 2012, I used MgSO4 for a total of 18 severe HFMD patients that failed on 
milrinone, and only 2 of these cases required ventilation (2/18, 11%), in both cases 
because of respiratory distress, and there were no other serious adverse events (SAEs). 
By comparison, during 2011 before MgSO4 was being used, of the 46 cases treated 
with milrinone alone, 13 required ventilation (13/46, 28%). 
In summary, although HFMD had become one of the major contributors to childhood 
morbidity and mortality in Vietnam, in 2011 management strategies relied on 
guidelines that were based on expert opinion and only two small clinical studies [83, 
117, 150, 168]. The efficacy of milrinone, an expensive drug with a significant toxicity 
profile, for management of ANS dysregulation was unclear, and MgSO4, an alternative 
therapeutic agent that is cheap, safe and easily available appeared to be effective as 
second line therapy in severe cases. I hypothesized that intervention with MgSO4 
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early, when ANS dysregulation first becomes apparent, might control cardiovascular 
instability more effectively and prevent progression to severe disease. Therefore I 
developed a protocol for a randomized controlled intervention trial comparing MgSO4 
with placebo in children with HFMD, autonomic instability and systemic hypertension. 
In collaboration with Professor Wills I was able to obtain a grant to support this trial 
from the Thrasher Research Fund, and also to obtain the necessary ethical permissions 
from the Vietnamese MoH and other regulatory bodies. Recruitment commenced in 
June 2014. However over the next two years the number of HFMD cases admitted to 
HTD declined dramatically and by the end of 2016 the trial had to be stopped on the 
grounds of futility.  
In this chapter I will present information on the study design, execution, and findings 
from the trial. Additional information, including all definitions, standard operating 
procedures (SOPs) etc., is provided in Appendices. The trial was registered with 
ClinicalTrials.gov (NCT01940250, Registered 22 August 2013), and the full protocol has 
been published [223].  
4.2 Materials and methods 
4.2.1 Study design 
This was a randomized, double-blind, placebo-controlled trial of IV MgSO4 versus 
placebo in Vietnamese children with HFMD and signs of ANS dysregulation with 
systemic hypertension. Two study sites in Ho Chi Minh City were planned: the PICU at 
HTD as a single site initially; and the High Dependency Unit (HDU) on the Infectious 
Diseases Ward at CH1 to join later once all study procedures were running smoothly.  
The study protocol and its associated documents were reviewed and approved by the 
ethical committees of HTD and CH1, the Oxford University Tropical Research Ethics 
Committee, and the Ethical Committee of the Vietnamese MoH.  
All patients aged 6 months to 15 years with a clinical diagnosis of HFMD requiring 
PICU/HDU admission at these sites were eligible for enrolment into the study if they 
developed systemic hypertension and at least one other clinical sign of ANS 
dysregulation. Potential participants must also fulfil the indication of invasive BP 
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monitoring on clinical grounds. Trained study physicians assessed potential patients for 
the following inclusion and exclusion criteria, which are defined in more detail on page 
202 of the Appendices. 
4.2.2 Inclusion and exclusion criteria  
The following criteria were applied: a) the SBP, measured via an indwelling catheter, 
exceeds the internationally recognized definition for Stage 1 hypertension in children 
(Appendices, page 198) [224]; b) the child has at least one other criterion for ANS 
dysregulation (Appendices, page 205), such as tachypnea for age, irregular or labored 
breathing but with oxygen saturation above 92% in air and a normal arterial blood gas, 
resting HR sustained above 150 beats/minute, mottled skin, profuse sweating, 
refractory fever, or hyperglycemia; and c) no contraindications to study inclusion are 
present, including a past history of hypertension, chronic renal, cardiac or pulmonary 
disease, or any neurological disorder; features indicating a current hypertensive 
emergency (see below); treatment with milrinone or any other inotropic agent has 
already commenced; respiratory distress is present with oxygen saturation below 92% 
in air or an arterial pCO2 over 45 mmHg; atrioventricular block or any arrhythmia 
(other than sinus tachycardia) is present on an ECG rhythm strip, or the QT interval is 
prolonged; or reduced urine output or increased creatinine levels indicating renal 
compromise. If the patient fulfilled these criteria and a parent or guardian gave written 
informed consent (see below), then the child was enrolled in the study. 
Specific definitions for hypertension were as follows:  
 For children aged 1 year and over, at least 3 consecutive SBP recordings above 
the 95th centile for age, gender and length (USA guidelines for defining Stage 1 
hypertension in children [224], measured invasively over a period of 20 minutes 
provided the child is not distressed or crying.  
 For children aged 6 months to 1 year, systolic BP > 100 mm Hg measured 
invasively on at least 3 occasions over a period for 20 minutes provided the 
child is not distressed or crying 
The Vietnamese MoH guidelines specify that milrinone should be given to children 
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with HFMD and ANS dysregulation when the SBP is sustained at a level exceeding the 
99th percentile for age plus 5 mmHg (i.e. Stage 2 hypertension) with the intention that 
treatment should commence within 1 to 2 hours [28]. Enrollment to the study was 
specifically designed to be early, when hypertension was first identified (at Stage 1), so 
that in the event of treatment failure, the MoH treatment guidelines could be applied. 
This stipulation was at the request of MoH, but it was agreed at the MoH’s Institutional 
Review Board review that patients presenting with Stage 2 hypertension could also be 
enrolled provided all procedures were carried out rapidly and that if the SBP did not 
improve within 30 minutes of commencing the randomized study drug, milrinone 
would be added. Thus all patients with Stage 2 hypertension should be on milrinone 
within 1 hour of presentation unless the SBP had fallen to Stage 1 levels within this 
time frame. 
4.2.3 Study endpoints 
The primary endpoint was a composite endpoint indicating disease progression within 
72 hours. It was defined as occurrence of any of the following within 72 hours of 
commencing the study drug infusion: a) specific BP criteria necessitating addition of 
milrinone as detailed below; b) need for mechanical ventilation; c) development of 
shock; and d) death.  
The specific criteria for adding milrinone were: 
 Hypertensive emergency – a severe symptomatic elevation in BP (> 30% 
compared to baseline BP) WITH evidence of acute target organ damage (e.g. 
brain, kidneys, eyes)  
 SBP fails to decrease by 25% over the first 8 hours despite maximum MgSO4 
maintenance infusion  
 For children aged 1 year and over: 
– SBP increases to > 99th percentile plus between 5 -15 mm Hg 
consistently for 30 minutes  
– SBP increases to > 99th percentile plus 15 mm Hg consistently for 15 
minutes 
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– SBP increases to ≥ 40 mm Hg over baseline for 15 minutes, if this value 
is lower than either of the first two cut-offs. The baseline SBP is defined 
as the lowest value measured at any time after admission to hospital 
before enrolment in the study. 
 For children aged 6 months to 1 years: 
– SBP increases to ≥110 mm Hg up to 120 mmHg consistently for 30 
minutes  
 SBP increases to ≥ 120 mm Hg consistently for 15 minutes  
Secondary endpoints were originally planned to include comparison of the primary 
endpoint parameters singly, but finally the sample size was too small to allow this. 
Other secondary endpoints included the time to requirement for milrinone, and the 
Area Under The Curve (AUC) for HR, SBP, MAP above the Stage 1 hypertension level 
during the first 72 hours. In addition the duration of hospitalization, and 
neurodevelopmental status assessed 6 months after discharge using locally adapted 
and validated Bayley Scales of Infant and Toddler Development, Third Edition (Bayley-
III) [225] were compared between the study arms.  
Safety endpoints included the number of adverse events (AEs) and SAEs that occurred 
in the two treatment arms.  
Exploratory endpoints: Comparisons of sequential daily plasma and urine 
catecholamine levels between the study arms. In addition, we also investigated 
correlations between catecholamine levels and clinical information including HR, SBP, 
and MAP during hospitalization. 
4.2.4 Sample size calculation  
During 2011 approximately one third of patients with Grade 3 HFMD managed at HTD 
(48/140, 34%) and CH1 (48/148, 32%) required milrinone for ANS dysregulation with 
hypertension, and in 9/48 (19%) of the HTD cases and 10/48 (21%) of the CH1 cases 
milrinone alone failed to control the hypertension. Following introduction of new 
Vietnam MoH management guidelines to commence intra-arterial BP monitoring early 
(at the first sign of autonomic disturbance), among 16 children managed in this way at 
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HTD over a 2 month period, 12/16 patients developed Stage 1 hypertension, and 7 of 
these 12 cases developed Stage 2 hypertension and were treated with milrinone. 
Based on this observation (i.e. that 7/12 children with Stage 1 hypertension 
progressed), we estimated a progression rate of 50% in the control arm for the sample 
size calculation for this study. 
With respect to the hypothesized treatment effect there was little direct information 
for the actual scenario we planned to investigate, i.e. the influence of MgSO4 
commenced at Stage 1 hypertension on subsequent control of BP and progression to 
severe disease. In the case series described earlier, when MgSO4 was added to the 
treatment regimen of patients with poorly controlled hypertension despite high dose 
milrinone, in all cases the BP reduced within 30-60 minutes and thereafter remained 
stable on a continuous MgSO4 infusion. In the tetanus study mentioned previously (in 
which the study drug was given to patients with severe tetanus requiring a 
tracheostomy [171]) requirement for additional therapy to treat ANS dysregulation 
was reduced from 14/97 (14%) in the placebo group to 3/97 (3%) in the MgSO4 group, 
although the need for assisted ventilation was similar in the two groups. Thus indirect 
evidence suggested that the effect size of the proposed intervention could be large; 
we therefore estimated that use of MgSO4 could reduce the risk of progression by at 
>50%.   
Based on 1:1 randomization, an anticipated relative reduction in the risk of progression 
of 50% (from 50% in the control arm to 25% in MgSO4 recipients), 90% power and a 
two-sided 5% significance level, 85 patients per treatment group would be required. To 
allow for some violations of our assumptions and losses to follow-up, we planned to 
recruit 190 patients (95 patients per treatment arm) into the study. 
4.2.5 Randomization and blinding 
Randomization was carried out in a 1:1 ratio, with the intention to stratify according to 
the hospital where recruitment took place. A randomization list using block 
randomization with blocks of variable size was prepared using a computer program 
and maintained confidentially from study staff by the Clinical Trials Pharmacist. A 
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chronological log of all enrolled patients was maintained, with the next available 
sequential study code assigned to each patient as they enrolled. The assigned patient 
number corresponded to a coded, sealed, package containing 50 ampoules of MgSO4 
or visually matched placebo.  
4.2.6 Intervention 
Following written informed consent a loading dose of 50mg/kg of either MgSO4 or 
visually matched placebo was commenced by continuous infusion into a peripheral IV 
line over 20 minutes, followed by a maintenance infusion for 72 hours according to 
response, aiming for Mg levels  2-3 normal level in the treatment arm.  
Patients were randomly assigned to one of the two treatment arms, and followed the 
same dosing schedule: 
 Group 1:  MgSO4 15% solution in sterile water in 10ml vials (Fresenius 
Kabi) diluted to 10% solution by mixing with 5 ml Nacl 0.9% 
 Group 2:  Sterile water in 10 ml vials (Fresenius Krabi) diluted to 15ml by 
mixing with 5 ml Nacl 0.9% .  
 Schedule:  Loading dose: 50mg/kg over 20 minutes (0.5ml/kg) 
 Maintainance: 30–50 mg/kg/hr (0.3 ml/kg/hr to 0.5 ml/kg/hr) for 72 hrs 
MgSO4 and placebo were available in 10 ml visually matched ampoules supplied by 
Fresenius Kabi. Kits containing sufficient ampoules for each patient were prepared 
centrally by an unblinded study pharmacist to be distributed to the sites as required. 
All drugs were stored in accordance with the manufacturers' recommendations in a 
secure area, and all movements of study medication were recorded, with individual 
subject and overall drug accountability records kept by the study staff.  
All staff involved in clinical care were blind to the treatment allocation. To maintain 
blinding Mg/Ca levels were monitored and adjusted by independent doctors from 
another clinical facility as detailed in the section on dose adjustment below.  
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4.2.7 Dose adjustment 
After the initial loading dose the study infusion dose was increased in 0.1 ml/kg/hr 
stages (10mg/kg/hr) every 15 minutes to a maximum dose of 0.5 ml/kg/hr (50 
mg/kg/hr), with the following caveats: 
 If the SBP decreased to < 90th percentile for age, gender and length the dose 
should be reduced by 1 stage every 15 minutes 
 If the SBP increased to the levels described below for treatment failure, action 
should be taken as indicated 
 If the plasma Mg level was > 2.5 mmol/l or < 1.8 mmol/l a 25% increase or 
decrease in the infusion rate should be implemented as appropriate. To 
maintain blinding, plasma Mg/Ca values were sent to an independent doctor 
each morning who reviewed the results, followed a defined protocol and SOPs 
to decide on any changes, and then informed the PICU staff promptly of any 
dose adjustments to be made to the study drug infusion but did not report the 
actual lab values to the staff. Similar (sham) dose adjustments were made for 
the placebo infusions, according to a randomized list available only to the 
Mg/Ca monitoring doctor. 
4.2.8 Recruitment of participants  
Phase 1 (HTD only): Study staff working on PICU at HTD identified the 
parents/guardians of potentially eligible patients as soon as possible after admission. If 
the initial screening criteria were met, the staff provided the patient information sheet 
(PIS) to the family and discussed the study. Subsequently if a child developed 
autonomic disturbance with hypertension the study staff talked again to the family and 
requested consent, then followed the full pathway for inclusion/exclusion criteria, and 
if appropriate, proceeded to enrolment and randomization. Screening, enrolment, and 
obtaining informed consent were performed rapidly at this time, in order not to delay 
the commencement of necessary treatment.  
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In case worry over the child’s illness had affected the parents/guardians ability to 
make an informed decision on study participation, a study doctor reviewed the PIS 
with the family at least once more 12-36 hours after enrolment.  
Phase 2 (HTD and CH1): Initially it was planned that after enrolment of the first 30 
patients the independent Data and Safety Monitoring (DSMB) would review all data, 
and unless specific safety concerns were identified recruitment would be expanded to 
include CHI. However actually no patients were recruited at CH1 before the trial 
closed. 
4.2.9 Clinical assessments and laboratory measurements  
Patients were examined daily by trained HDU/PICU study doctors. A record of all 
significant events in the previous 24 hours plus detailed physical examination findings 
(in particular the nervous system, respiratory and cardiovascular systems) was 
recorded each morning in the CRF. Vital signs, including HR, BP, respiratory rate, SpO2 
were monitored at least hourly and recorded in a special nursing chart. A standard ECG 
recording was performed at the bedside by a trained nurse once daily, and also if any 
abnormality was noted on the monitor by study staff (eg. premature beats, atrial or 
ventricular arrhythmias). Urine output was monitored continuously using specific 
collecting bags and calculated every 4 hours. 
All data were subsequently entered into an electronic database. Personal information 
was recorded on the CRF for the purpose of consent, and to enable follow-up of 
treatment outcomes, but access to identifying information was restricted to site-
specific study staff and the clinical care team. Thus, only anonymised data was entered 
into the password-protected database. A system of double data entry was used to 
minimize data entry errors, as well as a data query and validation system to check all 
anomalies. 
The following laboratory tests were performed on site in the standard hospital 
laboratories or at the OUCRU research laboratory. 
 Blood glucose and arterial blood gases measured at least once daily or more 
frequently according to the clinical situation 
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 Plasma Mg and Ca concentrations measured at baseline and approximately 12 
hours after the start of the study infusion, then once daily for the remaining 72 
hours.  
 Plasma electrolytes, creatinine, CK-MB and Troponin I measured at baseline and 
once daily thereafter. 
 Plasma catecholamine (adrenaline and noradrenaline) concentrations measured at 
baseline and then once daily for 72 hours. Urine catecholamines measured every 
24 hrs on an aliquot taken from the total urine collection since the previous day 
(BI-CAT ELISA Assay kit, Eagle Biosciences Inc.). (Urine was collected at the bedside 
into large bottles containing a small volume of 6M HCL, then aliquotted and frozen 
promptly, as described on page 222 of the Appendices)  
 A nasal/throat swab and a rectal swab obtained at enrolment for enterovirus PCR, 
and serotype specific PCR if appropriate. 
4.2.10 AEs and SAEs 
Conventional definitions were applied for AEs and SAEs. All events were recorded on 
the patient CRF using specific forms, and were reported to the relevant authorities 
following specified protocols. In addition, for analysis of the safety endpoints the 
intensity of clinical and laboratory AEs was recorded on a five-point scale adapted from 
the NCI guidelines (CTCAE version 4.03)[226] to ensure that the cutoffs used were 
appropriate to the age of the children participating in the study (Appendices, page 
212).  
If any of the following occurred the study treatment was to be stopped immediately 
and rescue treatment given as appropriate (Appendices, page 228). 
 Serious cardiac arrhythmia (eg atrio-ventricular block, prolonged QT interval) 
 Hypotension: SBP < 70 + (2 X age) mmHg for 15 minutes or more 
 Urine output < 1ml/kg/hr for 4 hours or more  
 Cardiac arrest or any other emergency situation where the treating physician feels 
there is a contra-indication to the study drug.  
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Formal SOPs were written for all these scenarios, with detailed instructions for rescue 
treatment and for unblinding if necessary. In addition, if a patient developed 
respiratory distress (as defined in the Appendices, page 230) an urgent plasma Mg 
level was performed, with action to be taken following the relevant SOP.  
The Clinical Trials Pharmacist maintained the unblinded randomization list with details 
of the contents of each individual treatment package. In the event of an AE where 
knowledge of the identity of the study treatment could contribute to the treating 
physician’s ability to care for the patient, emergency unblinding could be authorized by 
any clinician involved in the patient’s care, following the specified SOP and after 
discussion with me.  
An independent DSMB was set up consisting of four Vietnamese and international 
experts with the necessary knowledge of paediatrics, clinical trials and statistics. The 
DSMB reviewed the protocol and agreed to a data review schedule and reporting 
requirements before the study commenced, with particular reference to SAE 
reporting. The Board reviewed the data after the first 5, and then the first 20 patients, 
and subsequently the members were consulted several times about the low 
recruitment rate and agreed to the final decision to terminate the study.  
4.2.11 Follow up 
All patients were assessed daily for the duration of the hospital stay. At discharge a full 
neurological and neurodevelopmental assessment was performed. However patients 
who had not recovered from the effects of sedation by the time of discharge but were 
otherwise considered fit to go home, were asked to attend one to two weeks later for 
formal review and neurological assessment. All patients were also asked to return at 6 
months post-enrolment for a clinical and neurodevelopmental assessment. If any 
further follow-up was felt necessary after this, study participants were referred back to 
the standard hospital out-patient clinic system. 
Neurodevelopmental assessments done at discharge (or 1-2 weeks later) and at 6 
months used the Bayley-III and Movement ABC-2 tools – for children 36 months and 
under the Bayley-III was used, while for children aged 48 months and above the 
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Movement ABC-2 tool was used for the assessments. Children aged between 37 and 
47 months at enrolment had both assessments done at both visits. The Bayley-III tool 
was recently translated and adapted for use in a Vietnamese population [225]. Data 
were collected on several hundred healthy Vietnamese children covering the 
appropriate age range, providing a suitable control population for comparison with the 
results from the severe HFMD cases.  
5.2.10 Statistical analysis  
The primary analysis population was defined as all randomized patients who 
commenced the loading dose infusion of study drug, with intention-to-treat analysis 
being done according to the randomized treatment arm. The per-protocol analysis that 
was intially planned was not performed due to the small size of the final study 
population. Similarly, the analysis that was initally planned in the subgroup of patients 
with confirmed EV-A71 infection was not conducted. 
A formal data analysis plan was written before unblinding the data. As a general 
principle log-binomial regression, linear regression, and Cox regression were used 
respectively for binary endoints, continuous outcomes, and time-to-event endpoints, 
with the results diplayed as relative risk, mean difference, and hazard ratios, as 
appropriate. Log transformation was carried out if necessary for continuous outcomes 
with skewed distributions.  
The primary endpoint of disease progression was compared between the two 
treatment arms based on univariate log-binomial regression, both unadjusted and 
after adjustment for age and day of illness at enrolment as covariates.  
Among the secondary endpoints the time from commencement of study drug to 
addition of milrinone was analysed using univariate Cox regression with and without 
adjustment for baseline SBP and day of illness at study entry. Between-group 
comparisons of the AUCs for the various cardiovascular parameters assessed – HR, SBP 
and MAP above the Stage 1 level for each individual – were based on univariate linear 
regression and also linear regression with adjustment for the baseline value of the 
variable of interest. Length of hospital stay after study enrolment was also based on 
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univariate linear regression. For comparisons of the Bayley-III results, Z-scores for each 
domain were calculated by comparing the patient’s score with the mean and standard 
deviation of the score for the same domain derived from a population of healthy 
children matched by age group (within 3 month age bands). These data came from a 
study of 250 healthy Vietnamese children from Ho Chi Minh City who were assessed 
using the Bayley-III in 2014-2015 [225]. Linear regression was used to calculate mean 
differences with and without adjusting for age, sex and maternal education level.  
For the exploratory endpoints, plasma and urine catecholamine levels were compared 
between the treatment groups using linear mixed effects models, which modelled the 
mean time trend of the catecholamine levels as a linear function of the time from 
commencing the study drug adjusted for treatment allocation and including a random 
intercept. Correlations between each cardiovascular parameter (HR, SBP, and MAP) 
and each plasma or urine catecholamine level were assessed using Pearson 
correlations between residuals derived from linear regression models of these 
longitudinal measurements adjusted for treatment allocation and hours from drug 
administration. As cardiovascular parameters were measured more frequently than 
catecholamine levels, the residuals at all time-points for cardiovascular parameters 
were used, whereas for the catecholamine measurements, only the residuals at time-
points which were closest to the time-points of the cardiovascular parameter 
measurements were used in the correlation analysis. Significance levels for these 
correlations were calculated using their Fisher transformation. Standard errors of 
these transformed correlations were derived using a cluster bootstrap technique, 
which resamples patients rather than samples, to take into account multiple 
measurements per patient.  
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4.3 Results 
From June 2014 to September 2016, 329 HFMD cases with Grade 2b or above were 
admitted to the PICU at HTD. Among the 59 cases classified as Grade 3, 54 children 
developed hypertension and underwent full screening for potential inclusion in the 
study: 16 cases presented hypertension alone; 6 cases developed rapidly progressive 
hypertension that required milrinone immediately; 6 cases met various other exclusion 
criteria such as hypercapnia (1 case), abnormal ECG (1 case), failure to place arterial 
catheter (1 case); and 3 families declined consent for the study. Thus 26 children were 
screened and written consent was given by a parent or guardian, and these children 
were successfully enrolled in the study (Figure 4.1).  
Following two reviews by the DSMB, after 5 and 20 cases had enrolled, the screening 
and enrolment process was extended to the CH1 site in October 2015. However by this 
time the HFMD numbers in the city were already declining. From that time onwards, 
94 cases were screened at CHI, 40 of whom progressed to Grade 3 disease, 19 with 
hypertension. Unfortunately none of these children were successfully enrolled in the 
study however for the reasons indicated in Figure 4.1.  
By the Spring of 2016 it was clear that the overall numbers of cases across Vietnam 
were much lower than previously. We considered trying to open a third site to boost 
recruitment numbers but felt that it would be very unlikely that we could achieve the 
required sample size within an acceptable time-frame even if many sites were opened. 
Thus, after consultation with the DSMB, recruitment was closed in October 2016, at 
which point a total of 26 cases were included in the study.  
Note that after unblinding the Mg/Ca database kept by the independent doctors it 
became apparent that non-consecutive randomization had occurred for the last 
patient enrolled. This patient had been given ID Number 28 instead of 26, but all other 
processes were followed appropriately. The analysis was carried out according to the 
randomization code actually allotted.  
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Figure 4. 1: Patient recruitment and allocation algorithm 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
* For the last subject there was an error in the randomization process. Non-consecutive randomization occurred 
with 2 study numbers omitted inadvertently, such that the participant was allocated the treatment package for 
Participant 28 instead of Participant 26. All other procedures were followed correctly. 
 
No losses to follow-up 
 
2 discontinued intervention: 
-1 resp distress after 69 hrs 
-1 emergency HTN after 6.5 hrs 
No losses to follow-up 
 
1 discontinued intervention: 
-resp distress after 27.5 hrs   
 
40 excluded during 
screening and consent 
process: 
-9 HTN only 
-7 emergency HTN  
-3 failed to assess IBP 
-21 abnormal 
breathing only, no 
HTN 
 
 
 
Overall enrolment  
26 patients 
All 12 participants analysed  
12 randomly assigned to 
and received Placebo 
 
Grade 2b & 3 
329 patients 
 14* randomly assigned to 
and received MgSO4 
 
All 14 participants analysed  
26 patients 
Grade 3 
59 patients 
Grade 2b & 3 
94 patients 
HTD 
June 2014- Sep 2016 
CH 1 
Oct 2015 –Sep 2016 
Grade 3 
40 patients 
0 patients 
33 excluded during 
screening and consent 
process: 
-16 HTN only 
-6 emergency HTN 
-1 hypercapnia 
-1 abnormal ECG 
-1 failure to access IBP 
-3 refused consent 
-5 irregular breathing only, 
no HTN 
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All children received the designated study drug according to the randomization code, 
and 23/26 cases completed the full 72 hour infusion as per the protocol. In one case 
emergency hypertension developed on Day 1, prompting the attending clinician to 
unblind the randomization; the child was in the placebo group and subsequently the 
doctor added open label MgSO4 to the regime, following which the BP settled without 
additional therapy. Two other cases experienced SAEs (respiratory distress) requiring 
ventilation, and the treatment code was unblinded for safety reasons. One child was in 
the placebo group and the Mg/Ca levels were within the normal range. The other child 
was in the active intervention arm, and in this case the plasma Mg level at the time of 
unblinding was 2.3mmol/l with a Ca level of 1.9mmol/l. The study drug was stopped, 
milrinone was added to control the BP, and the child was ventilated. He recovered fully 
and was discharged home on day 14.  
There were no protocol violations, and a total 11 protocol deviations, but all were 
minor. 
4.3.1 Summary of baseline features at study enrolment  
The baseline characteristics at randomization were similar between the MgSO4 and 
placebo groups (Table 4.1). All participants were admitted and enrolled into the study 
at a median of illness day 3. The median (range) age in the MgSO4 group was slightly 
greater than in the placebo group [24.4 (8.5, 72.7) vs. 21.1 (7.3, 57.1)] months, but the 
difference was small; 9/14 (64%) cases in the MgSO4 group were female compared to 
6/12 (50%) cases in the placebo group. Weight and length were similar between the 
two study groups.  
Clinical features were also quite similar in terms of fever, skin and mouth lesions, and 
also general cardiovascular and respiratory parameters. Skin ANS features rarely 
occurred, with no children noted to have profuse sweating and only 3 cases with 
mottled skin. The median HR, SBP and diastolic blood pressure (DBP) were marginally 
higher in the placebo group than in the MgSO4 group, but when considered in the light 
of the internationally accepted staging of hypertension the proportion with Stage 2  
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Table 4.1: Baseline demographic information and clinical features 
 
All patients 
(N=26) 
Placebo 
(N=12) 
MgSO4 
(N=14) 
Illness day at enrolment  3.0 (1.0, 6.0) 
 
3.5 (1.0, 6.0) 3.0 (2.0, 5.0) 
Age (months) 23.1 (7.3, 72.7) 
 
21.1 (7.3, 57.1) 
 
24.4 (8.5, 72.7) 
 Sex (female) 15 (58) 6 (50) 9 (64) 
Length (cm) 86 (66, 108) 
) 
86 (66, 108) 
)) 
85 (66, 107) 
) Weight (kg) 10.7 (6.6, 20.0) 
) 
 
11.0 (6.8, 19.3) 
 
 
10.7 (6.6, 20.0) 
) 
 
Temperature (0C) 38.5 (37.5, 40.0) 
) 
38.5 (38.0, 39.5) 
) 
38.5 (37.5, 40) 
) Mouth ulcers present 21 (81) 10 (83) 11 (79) 
Skin lesions present  20 (77) 9 (75) 11 (79) 
Mottled skin 3 (12) 2 (17) 1 (7) 
Abnormal CRT (> 2s) 1 (4) 1 (8) 0 (0) 
Liver palpable  8 (31) 5 (42) 3 (21) 
HR (beats/min) 150 (122, 170) 
) 
153 (122, 170) 
) 
150 (130, 170) 
) Tachycardia* 8 (31) 2 (17) 6 (43) 
SBP (mmHg) 113 (101, 134) 
) 
116 (105, 129) 
) 
113 (101, 134) 
) Stage of hypertension    
- Stage1 15 (58) 4 (33) 11 (79) 
- Stage2 11 (42) 8 (67) 3 (21) 
DBP (mmHg) 61 (47, 73) 
) 
61 (52, 73) 
) 
59 (47, 73) 
) SpO2 (%) 99 (94, 100) 
) 
99 (96, 100) 
) 
99 (94, 100) 
Respiratory rate (/min) 37 (23, 70) 39 (24, 70) 36 (23, 55) 
Irregular breathing  12 (46) 7 (58) 5 (36) 
Respiratory retraction 4 (15) 1 (8) 3 (21) 
Irritable 5 (19) 4 (33) 1 (7) 
Witnessed myoclonic 
jerks 
2 (8) 2 (17) 0 (0) 
Limb tremor / ataxia 1 (4) 1 (8) 0 (0) 
Nystagmus 1 (4) 1 (8) 0 (0) 
 
Summary statistic is absolute count (%) for categorical variables and median (range) for continuous data 
CRT: Capillary Refill Time; SBP: Systolic blood pressure, DBP: Diastolic blood pressure 
*: Heart rate sustained >150 beats/min, adjusted down by 10 for each 1 degree of fever above 37.0 oC 
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hypertension was considerably higher in the placebo group (8/12, 67%) than in the 
MgSO4 group (3/14, 21%). The median respiratory rate and proportion with irregular 
breathing were also marginally higher in the placebo group than in the MgSO4 group, 
but the proportion with respiratory retractions was lower. The SpO2 in air was much 
the same in both groups. 
There were no cases in either group with altered consciousness, assessed in term of 
the modified Glasgow Coma Score for young children, but 4/12 (33%) of the 
participants in the placebo group were considered to be irritable at enrolment as 
compared to 1/14 (7%) in the MgSO4 group. Other neurological manifestations 
including ataxia and nystagmus were rare, only occurring in one patient each (different 
cases) in the placebo group. Witnessed myoclonic jerks were rather infrequent but this 
likely reflects the fact that all patients with severe HFMD were routinely sedated on 
admission. 
The baseline laboratory results are shown in Table 4.2. Median (range) plasma Mg 
levels were quite similar at baseline in the MgSO4 group [0.88 (0.78, 0.98)] mmol/l] 
compared to the placebo group [0.85 (0.70, 0.99)] mmol/l. However 5 cases in the 
placebo group had values below the local normal range (0.8-1.0 mmol/l) while only 1 
case in the MgSO4 group had a low level. There were no values in either study arm 
that were above the normal range at baseline.  
Some abnormalities were noted in various baseline tests but these were well 
distributed between the groups. Thus hyponatremia was quite common, and also mild 
to moderate leukocytosis. One child in the MgSO4 group had a very low Hb at 
enrolment, 6.4 g/dL, with a blood picture consistent with iron deficiency. Serum iron 
and ferritin were very low and the child commenced oral iron supplements which were 
continued at discharge. The anemia was considered to be of nutritional origin.  
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Table 4.2: Baseline laboratory investigations  
 All patients (N=26) Placebo (N=12) MgSO4 (N=14) 
Arterial blood gases 
 - pH 7.42 (7.36, 7.59) 7.44 (7.40, 7.59) 7.41 (7.36, 7.48) 
 - pO2 (mmHg) 107 (75, 161) 104 (75, 144) 123 (80, 161) 
 - pCO2 (mmHg) 31.8 (18.6, 40.1) 29.8 (18.6, 35.7) 33.3 (29.4, 40.1) 
 - HCO3 (mmol/l) 21.3 (17.8, 25.5) 20.8 (17.8, 23.2) 22.1 (19.2, 25.5) 
Hb (g/dl) 11.8 (6.4, 15.2) 11.8 (8.8, 15.2) 11.8 (6.4, 14.3) 
WBC (x109/L)* 12.2 (4.6, 26.5) 
 
10.2 (4.6, 15.5) 
 
13.6 (5.5, 26.5) 
 NEU (x109/L) 5.9 (2.1, 15.1) 
 
5.6 (2.1, 10.6) 
 
6.6 (2.4, 15.1) 
 LYM (x109/L) 3.2 (1.0, 11.2) 
 
3.1 (1.6, 5.5) 
 
4.3 (1.0, 11.2) 
 PLT (x109/L) 340 (172, 641) 
 
289 (196, 462) 
 
384 (172, 641) 
 CRP (mg/l) 1 (0, 167) 2(0, 167) 1 (0, 45) 
CK-MB (UI/l)** 24.9 (10.4, 64.8) 23.4 (10.4, 64.8) 25.45 (13.8, 48.1) 
Troponin I (pg/ml) 5.3 (0.0, 27.0) 5.25 (0.0, 20.3) 5.35 (0.0, 27.0) 
Mg (mmol/l)*** 0.87 (0.70, 0.99) 
 
0.85 (0.70, 0.99) 
 
0.88 (0.78, 0.98) 
 
 
Ca (mmol/l) *** 2.28 (1.69, 2.52) 
 
 
2.28 (1.69, 2.52) 
 
2.31 (1.95, 2.42) 
 
Na (mmol/l) 131 (125, 136) 131 (126, 134) 131 (125, 136) 
K (mmol/l) 3.88 (3.10, 4.59) 4.01 (3.10, 4.59) 3.67 (3.42, 4.34) 
Creatinine (mol/l) 26.5 (17.0, 52.0) 26.0 (17.0, 52.0) 26.5 (18.0, 42.2) 
Glycemia (mmol/l) 5.7 (4.0, 8.1) 5.4 (4.0, 7.6) 5.7 (5.0, 8.1) 
 
Summary statistic is median (range) for all variables 
*: FBCs performed within the 24 hours prior to enrolment were not repeated at study enrollment.  
**: CK-MB was not done in one case because the reagent was out of stock on that day 
***: Blood for Mg/Ca levels was taken 15-45 minutes after commencing the drug in three cases in the 
MgSO4 group 
Viral diagnostic results between the two treatment arms 
Results of the viral diagnostic testing showed 18/26 (70%) of cases to be positive for an 
enterovirus (Table 4.3). Among these cases, EV-A71 was dominant with 9/14 (64%) 
confirmed cases in the MgSO4 group and 4/12 (33%) in the placebo group. Other 
enterovirus serotypes, including CV-A16, CV-A10 and EV-C, were also identified but 
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only in small numbers. In total in 5/12 (42%) in the placebo group and 3/14 (21%) in 
the MgSO4 group the enterovirus PCR was negative.  
Table 4.3: Enterovirus serotypes identified among patients in the two treatment arms 
Enterovirus serotype All patients (N=26) Placebo (N=12) MgSO4 (N=14) 
EV-A71 13 (50) 4 (33) 9 (64) 
CV-A16 3 (12) 1 (8) 2 (14) 
CV-A10 1 (4) 1 (8) 0 (0.00) 
EV-C 1 (4) 1 (8) 0 (0.00) 
Negative  8 (30) 5 (42) 3 (21) 
 
Summary statistic is absolute count (%) for all variables 
EV-A71: enterovirus A71, CV-A16 and CV-A10: Coxsackievirus A16 and A 10, EV-C: enterovirus group C 
4.3.2 Relationships between Mg and Ca levels in the two treatment arms. 
All patients had samples checked at baseline (Day 0) and between 8-10 am every 
morning for 3 days. In addition study participants admitted in the afternoon had a 
sample taken between 8-10pm on the first day (referred to as mid-point values), 
primarily to ensure high levels with potential toxicity were not being missed until the 
next morning. Since patients were enrolled at different times of the day, the interval 
between the baseline and the mid-point value was variable, but intervals between 
subsequent daily samples were all approximately 24 hours. For the final sample on the 
morning of Day 3, most individuals had already completed the 72-hour study schedule 
and stopped the study drug by this time; thus only 3 cases had notably increased levels 
at this time (Figure 4.2).  
As expected in the MgSO4 group, the level of Mg increased in plasma during the 
period of the infusion and then returned to normal after stopping the drug. While in 
the placebo group the Mg/Ca levels remained stable for the duration of the study. A 
clear relationship was observed between the serum Mg and Ca levels as shown in 
Figure 4.2. The median Ca level in the MgSO4 group decreased from around 2.28 
mmol/l at baseline to a minimum of 1.85 mmol/l on Day 1 then increased again to 2.13 
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mmol/l on Day 3. A Ca level of 1.8 mmol/l had been designated as the level at which 
the independent doctor would recommend giving a bolus of Calcium; however in no 
patient in the MgSO4 arm was this needed.  
From the safety perspective, the Mg level did not exceed 3 mmol/l (the stopping 
criterion in the SOP) in any child, with the maximum recorded value begin 2.72 mmol/l. 
A total of 7/130 (5%) measurements taken in the MgSO4 group were in the 2.5-3 
mmol/l range, resulting in the independent monitoring doctor recommending to the 
attending clinician a dose reduction in 6 cases. In the 7th case the independent doctor 
did not act on a value of 2.52 mmol/l obtained at the mid-point of Day 1 and only 
marginally above the value of 2.5 mmol/l specified in the SOP for dose reduction; the 
subsequent measurement in the same patient the following morning was 2.29 mmol/l 
without any change to the infusion rate.  
An error occurred when two mid-point patient samples were sent to the laboratory at 
the same time and the technician mixed the samples up. Based on an apparent result 
of 0.86 mmol/l instead of 2.24 mmol/l, the independent doctor recommended that the 
clinical doctor increase the study drug infusion but this was not done since the infusion 
was already at the maximum permitted rate, i.e 0.5 ml/kg/hr. The next level was 2.53 
mmol/l, following which the infusion rate was appropriately reduced on the advice of 
the independent doctor. Conversely, the “wrong” level in the other (placebo) case (i.e. 
2.24 mmol) was within the safe range, and so no change was recommended. In none 
of these cases did any AEs occur.  
A total of 22/130 (17%) of the plasma values in the MgSO4 group were below the 
estimated lower limit for a therapeutic effect in this study (1.8 mmol/l) at some point 
during the 72 hours; 3 measurements at the mid-point of Day 0, 1 on Day 1, 6 on Day 
2, and 12 on Day 3. The early low values responded to an increase in the infusion rate, 
while many of the late low values were because the patients had stopped the drug 
infusion (one unblinded following an SAE, and another 6 who had already completed 
their 72 hour infusion by the morning of Day 3). 
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Figure 4.2: Boxplots showing the Magnesium and Calcium levels in the two treatment arms. 
 
D0 = baseline values, Mid-point = values measured 8-16 hrs after commencing the study drug. Other values (D1, D2, D3) were measured at 8-10 am on the relevant study 
day. The number or study participants with values at each time point are indicated along the bottom of the graph. 
Note: Mg/Ca results were excluded for the following reasons. A) One placebo case was unblinded and commenced open label MgSO4. B) Two mid-point samples from 
different children were mixed up in the biochemistry lab. C) Three children in the MgSO4 arm did not have their baseline samples taken until 15-45 minutes after 
commencing the study drug infusion. 
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4.3.3 Comparison of the primary and secondary endpoints between the two 
treatment arms. 
Effect of MgSO4 on the composite primary outcome (Table 4.4).  
No patient died or developed shock in either study arm. A total of 6/12 (50%) cases 
required addition of milrinone in the placebo group compared to 6/14 (43%) cases in 
the MgSO4 group, while 2 cases in total required ventilation, one child in each group. 
These two children also required milrinone. Thus the analysis of the composite 
endpoint (including these four parameters), showed that the proportion who 
experienced the primary endpoint was very slightly higher in the placebo group (6/12, 
50%) than in MgSO4 group (6/14, 43%), but there was no significant difference 
between the two groups with a relative risk (95%CI) of 0.86 (0.37, 1.96), p=0.715. 
When adjusting for age and illness day the result was very similar, with a relative risk 
(95%CI) of 0.96 (0.43, 2.16), p=0.923.  
Effect of MgSO4 on hemodynamic parameters and duration of stay (Table 4.4)    
Evaluation of the AUCs for the various cardiovascular parameters assessed – HR, SBP 
and MAP above the Stage 1 level for each individual patient – showed each AUC to be 
slightly lower in the MgSO4 group compared to the placebo group, but there were no 
statistically significant differences using linear regression (p= 0.168, 0.562 and 0.468 
respectively). Repeat analysis including adjustment for the respective baseline values 
for these parameters also showed no differences.  
The duration of hospital stay did not differ between the treatment arms. 
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Table 4.4: Comparison of primary and secondary endpoints between the two treatment arms 
Characteristic 
Placebo  
(N=12) 
MgSO4  
(N=14) 
Estimated effect & p-value 
Estimated effect 
after adjustment* 
p-value 
Primary endpoint # 6 (50) 6 (43) 0.86 (0.37, 1.96)  0.96 (0.43, 2.16) 0.923 
Required milrinone 6 (50) 6 (43)     
Required ventilation 1 (8) 1 (7)     
Elapsed time to start of milrinone (hours) 45.8 (0.6, 72.0) 72.0 (1.2, 72.0)     
Duration of hospitalization (days from enrolment)  0.12 (-1.55, 1.79) 0.889   
- 4 3 (25) 3 (21)     
- 5 4 (33) 5 (36)     
- 6 3 (25) 5 (36)     
- 9 2 (17) 0 (0)     
- 14 0 (0) 1 (7)     
AUC of HR (beats/min x hr) 9558 (8940, 10334) 9018 (8625, 9560) -456 (-1103, 191) 0.168 -529 (-1237, 180) 0.144 
AUC of SBP above stage 1 HTN (mmHg x hr) 305 (190, 469) 253 (105, 458) -83 (-364, 198) 0.562 -53.82 (-327, 219) 0.699 
AUC of MAP above stage 1 HTN (mmHg x hr) 162 (53, 282) 144 (94, 212) -89 (-277, 99) 0.468 -52.90 (-242, 137) 0.584 
 
Summary statistic is absolute count (%) for categorical variables and median (range) for continuous data 
#: composite outcome including death, shock, requirement for milrinone and ventilation. 
&: Relative risk, mean difference based on the Log-binomial regression, linear regression for binary outcome, continuous outcome, respectively. 
*: Primary endpoint was adjusted for age and illness day; AUCs of HR, SBP and MAP were adjusted for their respective values at baseline.
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Comparison of elapsed time from baseline to addition of milrinone (Table 4.5, Figure 
4.3) 
Overall 12 patients (6 in each group) required addition of milrinone because the study 
drug failed to control hypertension, in line with the predefined criteria. The median 
time from commencing the study drug to addition of milrinone was longer in the 
MgSO4 group compared to the placebo group, with a median (IQR) of NA (2.25, NA) 
hours vs. 45.75 (1.62, NA) hours respectively (NA-Not available). Using Cox regression 
the difference was not statistically significant, with a hazard ratio (95% CI) of 0.80 (0.26, 
2.47); p=0.694 (Table 4.5). In the Kaplan-Meier analysis, there was no significant 
difference in the milrinone-free trajectories between the treatment groups (logrank 
test, p=0.702) (Figure 4.3).   
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Table 4.5: Comparison of the time elapsed from baseline to commencement of milrinone between the two study arms, using Cox regression 
analysis with and without adjustment for baseline SBP and illness day.  
 Placebo 
(n=12) 
MgSO4 
(n=14) 
Before adjusting  Adjusted* 
Comparison p-value**  Comparison p-value** 
 events/n (risk [%]) events/n (risk [%]) HR (95%CI); p-value   HR (95%CI); p-value  
Milrinone use 6/12 (50) 6/14 (43) 0.80 (0.26, 2.47); p=0.694 0.564  0.80 (0.25, 2.55); p=0.706 0.486 
Time to addition of milrinone (hours)      
-Median (IQR) 45.75 (1.62, NA) NA (2.25, NA)      
 
Summary statistic is absolute count (%) for categorical variables and median (IQR) for continuous data; HR =Hazard Ratio 
The upper IQR of time to milrinone addition (i.e. the time at which 75% patients received milrinone) in the placebo group was unidentified as only 50% of patients in this 
group received milrinone. 
The median and upper IQR of time to milrinone addition (i.e. the time at which 50% & 75% patients received milrinone) in the MgSO4 group were unidentified as only 43% 
of patients in this group received milrinone. 
*: Adjusted for SBP at baseline and illness day  
**: test for proportional hazards 
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Figure 4.3: Kaplan-Meier curve showing the time in hours from baseline to addition 
of milrinone in the two study arms.  
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4.3.4 Comparison of neurological and neurodevelopmental assessments at discharge 
and 6 months later between the two treatment arms 
All study participants had recovered sufficiently to be discharged home by Day 14 after 
enrolment. The duration of hospital stay did not differ between the treatment arms. At 
discharge 3 children had clinically apparent neurological problems, while the remaining 
23 patients had no detectable neurological abnormalities on examination.   
A 72 month old child (MgSO4 treatment arm) who had required high dose milrinone 
for 5 days and developed respiratory distress needing ventilation for 6 days, also 
complicated by a secondary pneumonia, had generalized weakness involving all four 
limbs when discharged. At an interim assessment 3 months later he had recovered 
completely. A 14 month old girl (placebo group) had severe hypertension requiring 
nicardipine after failing on high dose milrinone, developed respiratory distress and was 
ventilated for 3 days, and also experienced profound hyponatraemia with a Na level of 
118 mmol/l on study day 3 that improved gradually to 135 mmol/l by study day 6. At 
discharge she had 9th and 11th cranial nerve palsies, which were still present but 
improved by 3 months, but had resolved by the formal 6-month visit. The third child, 
also in the placebo group, was aged 29 months; he did not have a particularly 
complicated clinical course and did not require milrinone, but at discharge he 
presented generalized weakness of all four limbs. He was reviewed one month later 
and had made a full recovery by that time.  
For children aged 36 months or younger at enrolment, neurodevelopmental 
assessments were performed by trained examiners using the Vietnam adapted Bayley-
III tool. No children were within the age bracket 36-48 months, while 2 children (one in 
each group) were older than 48 months and were tested using the Movement ABC-2 
tool. For these two children, aged 57 and 73 months, the findings were abnormal in 
one case at discharge and totally normal at 6-month assessment, but no specific data 
will be presented here.  
Among the remaining 24 cases, one child was of ethnic Chinese origin and was too 
young to understand instructions from the Vietnamese examiner, one 14 month old 
child would not cooperate at the first assessment two weeks after discharge but did 
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complete the assessment after 6 months, while another child did complete the early 
assessment but would not cooperate with the 6-month assessment. Therefore, the 
data presented here refer to assessments on 22 children.  
Z-scores, normalised to the control population of healthy Vietnamese children 
previously assessed by Dr Sabanathan [225] were compared between the two 
treatment arms (Table 4.6). Minor differences were observed in all five domains at 
discharge, but the only area in which a significant difference was demonstrated was in 
the domain relating to expressive communication, where the Z-scores were slightly 
higher in the MgSO4 group compared to the placebo group, p=0.022 in the unadjusted 
analysis, and p=0.031 after adjustment for potential confounders including sex, age 
and maternal education level.   
All 26 children attended the 6-month follow up visit, and neurological examination was 
normal in all cases. For the neurodevelopmental assessments at 6 months the Z-scores 
for the 5 domains were consistently higher than those at discharge, but there were no 
differences between the treatment arms at this time. In-hospital sedation may have 
contributed to the slightly lower Z-scores at discharge, but by 6 months the 
neurodevelopmental status of children in both groups was comparable with that of 
their peers who had not experienced severe HFMD. On this analysis of a small number 
of cases, no adverse effects of MgSO4 were demonstrated after 6 months. 
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Table 4.6: Comparison of Bayley-III neurodevelopmental assessments at discharge and 6 months later between the two treatment arms 
 n # 
Placebo  
(N=12) 
n 
MgSO4  
 (N=14) 
Unadjusted mean 
difference  
p-value 
Adjusted mean 
difference* 
p-value 
At discharge 
CS 9 0.1 (-1.3, 1.2) 13 -0.3 (-2.3, 2.5) -0.32(-1.30, 0.65) 0.474 -0.42 (-1.56, 0.72) 0.365 
RC 9 -0.6 (-1.5, 1.1) 13 -0.0 (-1.3, 1.2) 0.39 (-0.31, 1.10) 0.229 0.38 (-0.45, 1.20) 0.265 
EC 9 -0.3 (-2.1, 1.3) 13 0.3 (-1.2, 1.5) 0.98 (0.10, 1.87) 0.022 0.90 (-0.08, 1.88) 0.031 
FM 9 -0.1 (-0.9, 1.0) 13 -0.4 (-1.2, 2.3) 0.11 (-0.76, 0.98) 0.785 -0.06 (-0.97, 0.86) 0.876 
GM 9 -0.1 (-1.2, 0.7) 13 0.3 (-2.0, 1.5) 0.26 (-0.61, 1.13) 0.521 0.33 (-0.66, 1.32) 0.409 
Six months after discharge 
CS 10 2.5 (0.1, 5.5) 12 1.4 (-1.3, 4.1) -0.73 (-2.11, 0.65) 0.254 -0.28 (-1.38, 0.83) 0.532 
RC 10 1.1 (-5.3, 8.8) 12 1.5 (-0.6, 5.2) 0.26 (-2.12, 2.63) 0.813 0.61 (-1.40, 2.61) 0.455 
EC 10 1.2 (-1.0, 3.0) 12 1.6 (-1.0, 5.1) 0.18 (-1.13, 1.49) 0.765 0.61 (-0.65, 1.86) 0.238 
FM 10 2.6 (0.2, 5.5) 12 1.9 (-0.6, 3.5) -0.92 (-2.18, 0.34) 0.876 -0.79 (-2.12, 0.54) 0.150 
GM 10 1.9 (0.0, 4.0) 12 2.2 (0.4, 3.8) 0.07 (-0.91, 1.05) 0.876 0.37 (-0.59, 1.33) 0.341 
Summary statistic is the median (range) of Z-scores 
#: 2 children older than 48 months were assessed by Movement ABC-2 tool; 1 child could not be assessed as the mother tongue was Chinese, 1 child would 
not cooperate with the test at discharge and 1 child (a different case) at the 6 month visit. 
*: Mean differences of Z-scores were adjusted for sex, age, and maternal education level 
CS= Cognitive Scale; RC: Receptive Communication; EC= Expressive Communication; FM= Fine Motor; GM= Gross Motor
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4.3.5 AEs and SAEs in the two treatment arms  
AEs are presented in Table 4.7, including both the total number of AEs in each group, 
and also the total number of patients with any AE. A total of 21 events occurred in 10 
patients in the placebo group (83%) compared to 22 events in 10 children in the 
MgSO4 group (71%). Fever related AEs were the most common in both groups, 
followed by reduced urine output to less than 1 ml/kg/hr for consecutive 4 hours, but 
all these cases resolved with observation and/or standard supportive care only. 
Depressed tendon reflexes were also relatively common, but in all cases the children 
were receiving parenteral sedation in accordance with MoH guidelines.  
Respiratory events (irregular breathing, retractions, stridor) occurred in 2 patients in 
the placebo group and 3 in the MgSO4 group. Among these cases, 2 developed severe 
respiratory distress requiring ventilation and were classified as Grade 4 SAEs (one 
patient in each group). An additional patient in the MgSO4 group required increased 
oxygen but in the end did not need respiratory support and this was finally classified as 
a Grade 3 SAE. In the placebo group the only other SAE reported (Grade 3) was in the 
patient who required ventilation for severe respiratory distress; this child had impaired 
consciousness with a GCS reduced to 9 the day before she was ventilated. 
In accordance with the relevant SOPs Mg/Ca levels were checked in response to the 
various clinical scenarios. There were no cases in which the AEs or SAEs were 
associated with levels of Mg that exceeded 3 mmol/l, the generally accepted threshold 
at which respiratory or neurological events may occur.  
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Table 4.7: Clinical AEs and SAEs in the two groups 
 Placebo (n=12) MgSO4 (n=14) 
Any AE* 21 / 10 (83) 22 / 10 (71) 
     Fever 6  7  
     Diminished deep tendon reflexes 2 3 
     Coma / lethargy / irritability 2  1 
     Respiratory problems 3 4  
     Reduced urine output (<1ml/kg/hr for 4 hrs) 4  5  
     Other** 4  2 
Any SAE (Grades 3 and 4)*  3 / 2 (17) 3 / 3 (21) 
     Respiratory distress 2 3  
     Coma 1  0  
*: Numbers are total events / events grouped by patient (% of patients in the group with any event) 
**: Placebo group: 2 case each of red skin, diarrhoea, measles  
**: MgSO4 group: 1 case of vomiting, myoclonic jerk  
 
Definitions for the various laboratory abnormalities, adapted from the US CTCAE 
guidelines are described in the Appendices (page 212). Table 4.8 presents all 
laboratory AEs that occurred after enrolment, with those classified as Grade 3 or 4 also 
listed separately. Equivalent numbers of AEs and SAEs occurred in the two treatment 
arms. A total of 32 AEs occurred in 12 (100%) of the placebo group compared to 29 AEs 
in 12 (86%) of the MgSO4 group. The most common AEs, observed at similar rates in 
both groups, were respiratory alkalosis and hyponatremia. Many children were 
tachypnoeic thus explaining the respiratory alkalosis; in a number of them the 
abnormalities fulfilled the CTCAE criteria for an SAE, but in all cases the patients clinical 
condition improved without intervention. Sodium levels were commonly below 130 
mmol/l, with values this low noted in 5/12 (42%) patients in the placebo group and 
7/14 (50%) cases in the MgSO4 group. None of these patients were receiving IV fluids 
other than for drug delivery. However in one child the sodium fell to 118 mmol/l on 
study day 3, by which time the child was receiving IV fluid (Ringer Lactate) at 5 
ml/kg/hour while being ventilated.  
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Minor creatinine abnormalities were noted occasionally (Grade 1 only) and no serious 
renal problems were encountered in either treatment group. Abnormal cardiac 
enzymes (CK-MB and Troponin I) also occurred with similar frequency in both groups, 
and in some cases the Troponin I values qualified as Grade 3 SAEs. However none of 
the patients had clinical evidence of cardiac involvement and all the ECGs were within 
normal limits including the daily evaluation of the QT interval.  
Table 4.8: Laboratory AEs and SAEs in the two treatment arms (new after enrolment) 
 Placebo (n=12) MgSO4  (n=14) 
All AEs*  32 / 12 (100) 29 / 12 (86) 
   Respiratory Acidosis 0  2  
   Respiratory Alkalosis 8  4 
   Abnormal CK-MB 5  6  
   Abnormal Creatinine 2  1  
   Abnormal Hb 0  1  
   Hyperkalemia 2  0  
   Hypokalemia 4  2  
   Hyponatremia 7  8  
   Abnormal Troponin I 4  5  
SAEs (Grade 3-4)* 14 / 8 (67) 17 / 9 (64) 
   Respiratory Acidosis  0  1  
   Respiratory Alkalosis 3  4  
   Abnormal CK-MB 1  0  
   Hypokalemia 1  1  
   Hyponatremia 5  7  
   Abnormal Troponin I 4  4 
 
*: Numbers are total events / events grouped by patient (% of patients in the group with any event) 
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4.3.6 Effects of MgSO4 on catecholamine levels (Table 4.9 and Figure 4.4)  
Plasma catecholamine levels, specifically adrenaline and noradrenaline, were 
measured on specimens collected at enrolment and then subsequently every morning 
between 8-10am for the next 3 days. The catecholamine levels in plasma and urine 
were generally elevated or at the upper end of the of the expected normal ranges for 
children (Figure 4.4). 
Although at enrolment median plasma levels of adrenaline were lower in the MgSO4 
group than in in the placebo group, median (range) 92.5 (20.0, 370.0) vs. 137.5 (0.0, 
590.0) pg/ml in the two groups respectively, over the next few days as the levels were 
falling in both groups, relationships between the two study arms varied. Using a linear 
mixed effects regression model that accounted for the evolution of the responses in 
the two groups, no significant difference was found in the overall profiles between the 
study arms (p=0.609). Also the regression analysis did not show a statistically 
significant reduction over time in the adrenaline concentrations (p=0.284). A similar 
pattern was seen in the plasma noradrenaline levels – i.e. an apparent reduction over 
time that was variable on the individual day measurements between the two study 
arms, but no significant findings overall either for the comparison between the study 
arms or for the evolution over time (p=0.997 and p=0.466, respectively).   
No urine was obtained at baseline, but all urine was collected from that time onwards 
until 8am the following morning, with ongoing 24-hour collections thereafter for the 
72-hour study period. Similar to the plasma findings, urine levels of adrenaline and 
noradrenaline were slightly lower in the MgSO4 group than in the placebo group 
during the first 24-hour period (Day1) but relationships between the two study arms 
were variable subsequently. Using linear mixed effect regression models, no significant 
differences were detected between the study arms. However with respect to the 
evolution of urine catecholamine concentrations over time, both adrenaline and 
noradrenaline were confirmed to show a progressive decline (p= 0.032 and p=0.013, 
respectively).  
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Table 4.9: Comparison of catecholamine levels in plasma and urine between the two study arms, by fixed effect regression adjusting for the 
time and day of assessment  
      Comparison by linear mixed effects regression 
  Placebo (N=12)  MgSO4 (N=14)  Covariates Mean difference (95%CI) p-value 
Plasma Adrenaline (pg/ml)* 
Baseline 12 137.5 (0.0, 590.0) 
 
10 92.5 (20.0, 370.0) 
 
 (Intercept)  
 
1.602 (1.028, 2.176) 
 
0.000 
 Day 1 10 52.0 (0.0, 227.0) 
 
13 58.0 (0.0, 586.0) 
 
 MgSO4 0.189 (-0.524,0.902) 
 (-0.299, 0.393) 
0.609 
 Day 2 11 23.0 (0.0, 394.0) 
 
13 34.5 (11.0, 117.0) 
) 
 Time  -0.006 (-0.017, 0.006) 
 (-0.130,  -0.001) 
0.284 
 Day 3 2 202.5 (39.0, 366.0) 
 
3 11.0 (10.0, 53.0) 
 
    
Plasma Noradrenaline (pg/ml)* 
Baseline 12 520.5 (155.0, 1372.0) 
 
10 334.5 (135.0, 1195.0) 
 
 (Intercept)  
 
2.615 (2.450, 2.780) 
 
0.000 
 Day 1 10 330.0 (111.0, 1213.0) 
 
11 459.0 (159.0, 2166.0) 
) 
 MgSO4 0.000 (-0.213,0.213) 
 (-0.177, 0.215) 
0.997 
 Day 2 11 223.0 (65.0, 1250.0) 
 
12 359.0 (130.0, 1152.0) 
 
 Time -0.001 (-0.214, 0.212) 
 (-0.066, -0.003) 
0.466 
 Day 3 2 1042.5 (479.0, 1606.0) 
 
3 348.0 (305.0, 396.0) 
 
    
Urine Adrenaline (g/kg/24hr) 
Day 1 10 0.326 (0.019, 1.315) 
 
11 0.297 (0.000, 2.261) 
 
 (Intercept) 
 
-0.336 (-0.743, 0.072) 
 ( 
0.113 
 Day 2 12 0.210 (0.083, 4.257) 
 
14 0.237 (0.000, 2.173) 
 
 MgSO4 -0.130 (-0.545,0.286) 
 (-0.1972, 0.089) 
0.545 
 Day 3 12 0.196 (0.000, 1.857) 
 
14 0.121 (0.003, 0.415) 
 
 Time -0.007 (-0.012, -0.001) 
 (-0.094, -0.023, 
0.032 
 Day 4 2 0.866 (0.073, 1.658) 
 
3 0.133 (0.090, 0.344) 
 
    
Urine Noradrenaline (g/kg/24hr) 
Day 1 10 1.439 (0.247, 7.503) 11 1.384 (0.043, 4.355)  (Intercept)  
 
0.273 (-0.011, 0.557) 
 ( 
0.065 
 Day 2 12 1.059 (0.317, 7.963) 14 1.114 (0.089, 4.368)  MgSO4 -0.082 (-0.376,0.212) 
 (-0.125, 0.067) 
0.589 
Day 3 12 0.815 (0.053, 7.091) 14 0.828 (0.019, 2.152)  Time  -0.005 (-0.008, -0.001)  
 (-0.060,  -0.017) 
0.013 
 Day 4 2 2.250 (0.638, 3.863) 3 0.682 (0.483, 0.743)     
Note: Assay sensitivity for a) plasma adrenaline: 5 pg/ml, b) plasma noradrenaline: 16 pg/ml, c) urine adrenaline: 0.08 ng/ml, d) urine noradrenaline 0.24 ng/ml 
Summary statistic is median (range) for all parameters. Significant p-values shown in red bold face type.  
* Missing data in 8 samples due to initial test failure and insufficient plasma to repeat the test. 
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Figure 4.4: Boxplots showing the evolution of plasma and urine catecholamine levels 
over time in the two study arms. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Dotted blue lines represent the upper limit of normal in children for the respective 
measurements. 
Since the distribution of the catecholamine levels was skewed the data were log-transformed. 
Since levels of some samples were below the assay sensitivity level, 0.001 was added to each 
result to avoid a final result of infinity when taking the log10 value of 0. 
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4.3.7 Correlations between catecholamine levels and hemodynamic parameters  
HR, SBP and MAP values correlated to varying degrees with plasma adrenaline and 
noradrenaline concentrations, but none of the relationships were strong (Table 4. 10). 
The relationship between increasing HR with higher plasma adrenaline levels [rho 
(95%CI) of 0.33 (0.17, 0.48), p<0.001],] was slightly stronger than for the other 
parameters, SBP and MAP. Relationships between plasma noradrenaline and the three 
cardiovascular parameters were rather similar, all with adjusted correlation 
coefficients around 0.3.  
Relationships between urine catecholamine levels and the different cardiovascular 
parameters were less convincing.  
Table 4.10: Relationships between catecholamine levels and HR, SBP, and MAP 
adjusted for treatment arm and timing of sample 
 rho 
 
(95% CI)* p-value 
Plasma Adrenaline (pg/ml)*    
     HR (beats/min) 0.33 
 
(0.17, 0.48) 
 
<0.001 
     SBP (mmHg)  0.23 
 
(0.08, 0.38) 
 
0.003 
     MAP (mmHg) 0.20 
 
(0.01, 0.38) 
 
0.040 
Plasma Noradrenaline (pg/ml)*    
    HR (beats/min) 0.32 
 
 
(0.14, 0.48) 
 
<0.001 
 
 
    SBP (mmHg)  0.32 
 
(0.09, 0.52) 
) 
0.008 
     MAP (mmHg) 0.30 
 
(0.08, 0.49) 
 
0.007 
 Urine Adrenaline (g/kg/24hr)    
    HR (beat/min) -0.08 
 
(-0.39, 0.25) 
 
0.644 
     SBP (mmHg)  0.13 
 
(-0.20, 0.44) 
 
0.445 
     MAP (mmHg) 0.21 
 
(-0.23, 0.57) 
) 
0.351 
 Urine Noradrenaline (g/kg/24hr)    
    HR (beats/min) 0.18 
 
(-0.11, 0.44) 
 
0.230 
     SBP (mmHg)  0.20 
 
(-0.12, 0.48) 
 
0.216 
     MAP (mmHg) 0.20 
 
(-0.14, 0.50) 
 
0.251 
 rho = Pearson's correlation coefficient, adjusted for treatment arm and time of sample from 
study enrolment  
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4.4 Discussion 
Therapeutic options for severe HFMD remain limited [83, 117, 168], despite the rapidly 
increasing burden of disease in the Southeast Asian region over the last two decades, 
and the life-threatening nature of the clinical syndromes seen in a small proportion of 
cases [97, 192, 227-229]. ANS dyregulation is one of the key features of severe disease, 
indicating brainstem involvement, and early recognition of the associated 
hypertension is thought to be essential to successful management. However, there is a 
lack of good evidence on how to control hypertension in severe HFMD.  
During the recent major epidemic in southern Vietnam, at a time when we were seeing 
large numbers of severe cases, I developed the protocol for this trial investigating the 
efficacy of MgSO4 in severe HFMD [98]. Use of a novel treatment in severe patients 
who have failed on conventional treatment is accepted as reasonable by most 
clinicians faced with difficult decision-making in such circumstances. However 
conducting a randomized blinded trial in severely ill children requires a cautious 
approach with a strong focus on safety, in order to convince ICU staff that it is ethical 
to allow their patients to be enrolled. Although there was some safety data on use of 
therapeutic effect of MgSO4 in young children in other diseases [176, 230, 231], this 
would be the first use in a blinded trial in severe HFMD. In the early stages of the 
discussion about the trial with MoH, there was a feeling among some members of the 
Vietnamese Guidelines Committee that MgSO4 should be introduced directly into the 
guidelines on the strength of the evidence from the preliminary pilot series data. 
Eventually I was able to persuade MoH that a formal RCT investigating intervention 
with MgSO4 at a less serious stage of the illness with safety as the priority was 
acceptable ethically, and that it was also necessary and important to demonstrate 
clearly whether the observed effect was real. Then the trial was designed very carefully 
to ensure there would be no treatment delay for the children and that all possible 
safety mechanisms were incorporated in the protocol. All these activities took over a 
year to complete so that the study did not actually start until mid-2014, by which time 
the epidemic in the region was waning and the number of severe cases was declining. 
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This may have been partly due to changes in the HFMD epidemiology across the 
region, with a reduction in the number of cases with EV-A71 infection.  
The trial started first at one study site, the PICU at HTD, so that I could personally 
ensure that all the SOPs and study procedures worked well, and that seriously ill 
children with the potential to deteriorate rapidly, could be rapidly enrolled without 
compromising their rights. We also had an independent DSMB who reviewed all the 
data after the first 5 cases had enrolled, and again after 20 cases had enrolled. In 
addition MoH conducted an audit during the early phase of the trial and reviewed all 
AEs and SAEs. Inevitably with a trial of this complexity not all eligible participants were 
enrolled. At HTD, where I was personally on site most of the time, we were able to 
recruit 26 patients before the disappearance of HFMD locally. However, when the trial 
opened at CH1, which is a much bigger and busier hospital seeing more than double 
the caseload of HTD, it became clear that the rapid recruitment protocols were not 
working. In 10 of the cases screened at this site the main reasons for failure to recruit 
were worsening hypertension with failure to access an arterial line, both probably 
related to staff workload. After making efforts to improve recruitment at this site, we 
considered opening a third site in the Mekong Delta but by this time it was apparent 
that the sample size of 190 patients could not be achieved before the disease 
disappeared.  
For the 26 cases enrolled at HTD compliance with all aspects of the study protocols 
was very good, with only a small number of minor protocol deviations and very good 
data quality overall. Also all 26 children attended the follow-up visit after 6 months, 
although two did not cooperate with the neurodevelopmental testing. After the 
decision to stop the trial was taken, together with the OUCRU statisticians I wrote a 
formal analysis plan taking into account the very small number enrolled compared to 
the initial sample size calculation (which itself was based on a large postulated effect 
size). The primary analysis was by intention-to treat according to the randomized arm. 
We decided however, that because of the very low rate of non-compliance a per-
protocol analysis was not necessary, and that the various planned analyses by 
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individual outcome and/or by enterovirus serotype should be dropped due to the 
small numbers.  
Baseline information was quite similar between two treatment arms, with only minor 
differences apparent in most of the characteristics assessed. However there was a 
clear difference in the proportion enrolled with Stage 2 hypertension, a feature 
associated with more severe disease, with 8/12 (67%) enrolled at this stage in the 
placebo group versus 3/14 (21%) in the MgSO4 group. Median systolic and diastolic 
pressures were also marginally higher in the placebo group but these values were not 
age-adjusted. Conversely, EV-A71, the serotype that has generally been associated 
with more severe outcomes [112, 208], predominated in the MgSO4 group. However, 
the number of cases with negative enterovirus PCR was greater (5/12, 42%) in the 
placebo group compared to 3/14 (21%) in the MgSO4 group; although these may be 
true negatives, a number of factors including sample quality, transport, and processing 
may have affected the sensitivity of the PCR. Overall, these differences between the 
treatment arms are likely to be random and related to the small number of 
participants recruited [232], but of course there is the potential for an effect on the 
outcomes of interest.  
Although the initial sample size was based on efficacy measures, the trial was set up 
with as strong emphasis on safety. Because of the small number of patients enrolled 
and concerns about random error in small trials [232], we did not do formal statistical 
comparison of the AE and SAE rates between the treatment groups. However, the 
numbers and types of both clinical and laboratory events were similar in the two 
groups. One particular concern about potential side effects of MgSO4 is development 
of respiratory muscle weakness when plasma levels exceed 3 mmol/l [233]. In this trial, 
to be cautious I chose an upper limit of 2.5 mmol/l as the safety level at which the 
independent should recommend titrating the infusion rate downward. However a 
higher level of 4 mmol/l was used in the tetanus trial performed here some years ago 
[171], but the patients were all adults who had tracheostomies, meaning that the 
doctors would be able to respond rapidly to deteriorating respiratory status. Levels 
   Chapter 4 
132 
  
  
from 3.5 to 5.5 mmol/l were targeted in a trial assessing the efficacy and safety of 
MgSO4 in severe persistent pulmonary hypertension in neonates [176], but all these 
cases were already ventilated. 
Severe HFMD can cause significant neurological sequelae in survivors, but it is also 
important to investigate possible negative effects on the long-term development of 
children treated with MgSO4 during the severe acute phase. A small number of study 
participants did have clinically detectable neurological abnormalities at discharge that 
persisted for a few months, but all appeared to have recovered fully by 6 months. To 
be more detailed we performed neurodevelopmental assessments after 6 months 
using the Vietnam adapted Bayley-III scale. In the initial testing carried out at or soon 
after discharge there were minor differences in the expressive language domain of the 
tool, but there were no differences between the MgSO4 and placebo groups at 6 
months. Sedation may have affected the ability of some children to perform the tests 
around discharge, but a random effect due to the small number of study participants 
and multiple statistical analyses is also possible.  
No long-term detrimental neurodevelopmental effects were reported in the small 
study of neonates treated with MgSO4 for persistent pulmonary hypertension 
previously mentioned [176], with normal developmental assessments documented in 
these 11 infants after 6 and 12 months. However, a neuroprotective effect in neonates 
was noted, in a large meta-analysis assessing the safety and efficacy of MgSO4 given to 
women at high risk of pre-term labour; a reduction in the rate of moderate to severe 
cerebral palsy was found in the babies of mothers who received MgSO4 compared to 
those who did not, in this meta-analysis involving almost 20,000 preterm infants, 
although mortality was similar between the groups [231], In contrast, no improvement 
in clinical outcome after one month, based on death or a modified Rankin Score of 4-5, 
was found among 1204 adults enrolled in a randomized placebo-controlled trial 
assessing use of MgSO4 for aneurysmal sub-arachnoid haemorrhage [234]. In our trial 
the numbers were too small to assess the efficacy of MgSO4 on neurodevelopmental 
outcomes after severe HFMD, but from the safety perspective the results are 
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reassuring. To evaluate neuroprotective efficacy, a much larger study population 
would be needed, as was originally intended.   
Altogether, reports of AEs in children associated with use of MgSO4 have not been 
common up to now, for example in the Cochrane meta-analysis of the effect of MgSO4 
in acute asthma in children, the long-term follow up of children in the Magpie trial (a 
randomized placebo-controlled trial of MgSO4 in around 7,000 women with pre-
eclampsia), or the neuroprotection meta-analysis for preterm neonates described 
above [221, 231, 235]. However many of the authors concluded that the data on AEs 
was not sufficient to make firm conclusions about whether MgSO4 is safe or not, 
especially in children with asthma. Of note, increased toxicity was observed in the 
mothers in the meta-analysis of MgSO4 use in women at high risk of preterm labor, 
but with considerable heterogeneity between individual studies; respiratory 
depression did occur in the mothers although there were no significant differences in 
terms of AEs in their infants [231]. Therefore the potential for side effects with MgSO4 
remains a concern both in clinical practice, and for future clinical research studies. 
With respect to efficacy, although we observed minor differences in the findings for a 
number of parameters generally favouring the MgSO4 group, there were no significant 
differences in any of the primary and secondary outcomes evaluated. However, given 
the small number of patients enrolled and the low event rate, no real conclusions can 
be drawn. The initial pilot data had suggested an effect in patients with Stage 2 
hypertension who were already on milrinone, and it is possible that among the less 
severe cases enrolled in the RCT, that any potential beneficial effect was diluted. 
Baseline severity was generally similar in the treatment arms although a smaller 
proportion of the MgSO4 group had Stage 2 hypertension at enrollment. Also it may be 
that the dose we used in this RCT was not effective. We chose a cautious approach 
given that we anticipated enrollment of large numbers of children in a short space of 
time, who were breathing spontaneously. Higher dosage might put them at risk of 
respiratory depression, potentially requiring intubation and ventilation, which might 
increase the risk of a bad outcome for the individual child and would seriously stretch 
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the resources of our PICU. Aiming for a higher plasma Mg level as was done in the 
tetanus trial might have proved more effective in controlling hypertension [171]. 
Finally the domination of EV-A71 as the etiological agent causing infection had 
changed by the time we were able to commence recruitment, and there is general 
recognition that other enterovirus serotypes are less likely to cause very severe 
disease.  
Catecholamine levels (both adrenaline and noradrenaline) in urine decreased 
significantly during the course of the study, but without a clear change in 
corresponding plasma catecholamine levels. No differences were seen in either plasma 
or urine measurements between the treatment arms, but given the small numbers in 
each group this was to be expected. Studies in pregnant and non-pregnant rabbits 
have shown that MgSO4 reduces plasma adrenaline levels in parallel with reducing 
MAP [236]. In adults with tetanus, those treated with MgSO4 had significantly less ANS 
dysregulation, required less cardiovascular stabilizing drugs and had lower urinary 
excretion of adrenaline but higher excretion of noradrenaline [172]. In a case series of 
17 individuals with phaechromocytoma, use of MgSO4 during induction of anaesthesia 
resulted in satisfactory control of cardiovascular parameters in 15 cases, although four 
patients also received nitroprusside. Catecholamine release was studied in 5 of the 
patients and indicated that MgSO4 use was associated with reduced catecholamine 
concentrations [237]. Lastly, catecholamine storm is thought to be the mechanism 
underlying the Irukandji syndrome (caused by envenomation by Carukia barnesi, a kind 
of jellyfish) for which MgSO4 is often used as rescue treatment in Australia. However in 
a systematic review carried out in 2017 the authors found no clear evidence to support 
treatment with MgSO4 and concluded that additional research is needed to confirm or 
refute the current practice [238]. An association between catecholamine levels, 
particularly adrenaline levels, and cardiovascular parameters is thus supported by 
several lines of evidence, but considerable debate continues around the question of 
whether intervention with MgSO4 influences either hypertension related to ANS 
dysregulation or the associated catecholamine pathway derangements.  
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4.5 Conclusion 
This was the first randomized controlled trial of a novel treatment for hypertension 
secondary to ANS dysregulation ever carried out in young children with severe HFMD. 
It was started in the later stages of a major HFMD epidemic across the region, at a time 
when there was heightened public awareness and anxiety about this disease, resulting 
in huge pressure on healthcare services.  
The trial was designed and executed very carefully, with a major emphasis on safety 
for the participants, and it is likely that this did slow down recruitment. Obviously, the 
low rate of recruitment, with only 26 patient enrolled before the disease disappeared, 
adversely affected the power to ascertain efficacy, but we learned a great deal about 
how to develop and manage such a trial in difficult circumstances and generated 
valuable safety data. It seems likely that further epidemics of HFMD will continue to 
occur at intervals across the Asian region, and that at some point in the future 
clinicians will again face the difficulty of managing young children with severe disease 
with brainstem involvement and ANS dysregulation.  
Although we found no evidence of benefit in this trial involving a very small number of 
children, it is clear that these data are not sufficient to address the important question 
originally posed, and that a much larger trial is still needed to properly evaluate 
whether MgSO4 has a role in controlling the BP in severe HFMD. The experience 
gained from this trial, both the general experience of conducting a complex trial in 
difficult circumstances, and the more particular information regarding the positive 
safety profile of MgSO4 used in this way plus the information generated on dosing in 
relation to plasma Mg/Ca levels, should prove invaluable if and when the next 
epidemic occurs. A well-designed protocol is already available, together with detailed 
SOPs to guide implementation, hopefully allowing all the necessary steps to set up a 
new RCT to take place rapidly, ideally within the first 6 months of the emergence of 
another epidemic in the region. 
  
  Chapter 5 
136 
  
  
Chapter 5 
MgSO4 IN SEVERE HFMD: THE RETROSPECTIVE COHORT ANALYSIS 
5.1 Introduction 
As described previously, the phosphodiesterase-3 inhibitor, milrinone, is currently 
recommended in the Vietnamese MoH guidelines for management of HFMD patients 
with brainstem encephalitis who develop ANS dysregulation and Stage 2 hypertension. 
However, in practice a number of children continue to deteriorate despite maximum 
dose milrinone. Through close observation of severe HFMD cases and extrapolation 
from my experience with neonatal tetanus cases I postulated that MgSO4 might be 
beneficial in these severe cases, and therefore began giving this treatment empirically 
to those for whom milrinone failed to control blood pressure from the end of 
2011/early2012. Initial results of using MgSO4 as second line therapy in this way 
appeared promising and this approach was increasingly adopted for severe cases 
during 2012. During 2013 I developed the protocol for the randomized controlled trial 
described in Chapter 4 and recruitment commenced in June 2014. Unfortunately 
however by then the numbers of HFMD cases being seen in Ho Chi Minh City and 
generally across the region had started to decrease, and by the end of 2015 severe 
case numbers were very small (Figure 5.1). By September 2016 there were so few 
cases being enrolled that the trial was stopped. As can be seen almost all cases 
admitted from November 2015 onwards at the two hospital sites had Grade 2 disease 
and did not progress to Grade 3 disease.  
In the RCT the criteria for enrolment and randomization to receive either MgSO4 or 
placebo in a double-blind manner were deliberately set at the lower level of 
hypertension (Stage 1) so as to allow for the existing MoH guidelines to be applied if 
the SBP reached the Stage 2 hypertension level. However, during the stage of protocol 
development and study set up I continued to use MgSo4 as second line therapy for 
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severe cases with Stage 2 hypertension who were already on high dose milrinone. In 
addition, after commencing the RCT there were several severe cases 
Figure 5.1: Total HFMD admissions, and screening/enrolment numbers for the 
MgSO4 RCT, at the two HCMC study sites from Nov 2015 to Oct 2016, with a 
breakdown by discharge severity Grade. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
that did not fit the study enrolment criteria or where the family declined to participate, 
for whom MgSO4 was also given a second line therapy. Apart from the basic difference 
in clinical severity between the trial population (Stage 1 hypertension without 
milrinone) and the open-label MgSO4 recipients (Stage 2 hypertension already on high 
dose milrinone) the same general approach to treatment was in operation by the same 
core group of PICU clinicians throughout this period.  
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Since the trial was stopped early and the results were inconclusive I decided to review 
the information available for all HFMD cases managed on PICU between 2011 and 
2015 who were treated with MgSO4 outside the trial.  I also identified a group of 
patients of similar severity who had not been treated with MgSO4 during this period, 
in order to compare a variety of endpoints with the MgSO4 group. In this chapter I will 
present the methodology and findings from this retrospective analysis.  
5.2 Materials and methods 
5.2.1 Study design 
This was a retrospective observational cohort study to assess the response to open-
label intravenous MgSO4 used in Vietnamese children with Grade 3 HFMD and signs of 
ANS dysregulation with Stage 2 hypertension. I wished to compare responses in 
patients who fulfilled these criteria and received MgSO4 (the exposed group), with 
similar cases who achieved the same basic severity level but for whom MgSO4 was not 
used (the control group), particularly during the transition period when this treatment 
was considered novel. 
5.2.2 MgSO4 regimen 
The regimen used in the exposed patient group was basically similar to that used in the 
trial – with a loading dose of 50mg/kg MgSO4 diluted to 10% in sterile water and given 
by continuous infusion into a peripheral intravenous line over 20 minutes, followed by 
a maintenance infusion of 30-50 mg/kg/hr according to response. This dosing schedule 
was selected because the clinicians on PICU were familiar with it from their 
management of neonatal tetanus cases. It is also similar to the regimen recommended 
at the Royal Children’s Hospital in Melbourne for treatment of severe exacerbations of 
asthma [239]. 
As this was a novel treatment being given to very sick children, there was a strong 
emphasis on safety monitoring. Plasma Mg/Ca levels were measured routinely after 6 
and 12 hours and then daily if stable, with the clinicians aiming to raise plasma Mg 
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levels to around twice normal (1.8mmol/l). By the time the RCT described in Chapter 4 
started the staff were comfortable that clinical signs of toxicity were unlikely at this 
level, and they were therefore happy to increase the infusion rate to the higher range 
of 50mg/kg in most cases, aiming not to exceed the upper limit of 2.5 mmol/l for 
plasma Mg rather than to achieve the lower limit of 1.8 mmol/l.  
5.2.3 Standard clinical and laboratory protocols in operation 2011-2015 
The Vietnamese MoH guidelines specify patient care protocols for a variety of 
conditions. Based on the WHO 2010 HFMD guidelines and local VN guidelines from 
mid-2011, HFMD patients graded as 2b or above should be managed in an 
environment with the capacity to carry out detailed clinical observations every 1 to 3 
hours, increasing to every 30-60 minutes in the event of deterioration. Detailed 
guidelines also exist for most treatment strategies, including specific indications for 
drug therapy (IVIG, milrinone etc.) as well as practical interventions such as ventilation 
and hemofiltration (see Appendices, page 210). 
In addition the guidelines recommend a schedule for laboratory investigations in 
severe HFMD patients. Blood glucose, FBC and CRP should be measured routinely in all 
HFMD cases admitted to HDU/PICU, with other tests left to the discretion of the 
treating clinician. Collection and storage of diagnostic swabs for enterovirus PCR 
became mandatory for all HDU/ICU cases during 2011.  
5.2.4 Identification of study subjects  
The HTD main database records basic information on all patients admitted to the 
hospital, including information on all medications prescribed. From this database I 
extracted the hospital file numbers of all patients who had received milrinone over a 5-
year period from January 2011 to December 2015. I then requested these files and 
checked each record to confirm that the patients had been admitted to PICU with a 
clinical diagnosis of HFMD, and that they had not been enrolled in the MgSO4 RCT.  
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I then reviewed the selected hospital files and determined which patients did not 
respond to milrinone according to the following criteria, and also the date/time when 
they reached this severity level.  
 SBP persisting above Stage 2 hypertension (VN MoH guidelines) for at least 60 
minutes after commencing maximum dose milrinone, i.e. 0.7 µg/kg/minute  
 SBP increasing rapidly (by more than 10 mm Hg above the MoH threshold) after 
reaching a dose of at least 0.6 µg/kg/minute milrinone, or within 30 minutes of 
moving up to 0.7 µg/kg/minute 
I also checked that the patients a) had not received fluid resuscitation or inotropes 
such as dopamine, adrenaline or noradrenaline during this time-period or previously 
during the hospital admission, and b) had not needed any other supportive therapy 
such as ventilation or haemofiltration during this time-period or previously. 
I selected all cases who fulfilled these criteria for detailed file review and data 
extraction. For the MgSO4 group the date/time of starting the drug was taken as T=0, 
while for the control subjects T=0 was the time when they would have been eligible to 
start MgSO4 according to the above criteria.  
5.2.5 Data collection and data management 
I developed a specific case report form (CRF) for this study focused on documenting all 
available information on cardiovascular parameters in these patients. The CRF 
included baseline information from T=0 and then hourly nursing observations for a 
minimum of 24 hours from that time, then with reduced frequency for up to 72 hours 
or until recordings in the hospital files stopped. In addition data for up to 6 hours prior 
to T-0 were extracted from the files, provided the patient was in PICU during this 
period.  
After training using the study specific CRF, research nurses who were familiar with 
extracting data from hospital files collected the data. I crosschecked and corrected the 
paper CRFs based on the hospital files, together with several PICU colleagues, and the 
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study nurses then entered the information into an electronic database. After 
completing single data entry, the electronic data were checked to identify outliers or 
implausible values and traced back against the clinical files and/or the hospital’s 
electronic clinical and laboratory databases.  
These children were also included in the main clinical observational study described in 
Chapter 3.  That database included once daily assessments during the PICU stay, with 
information on clinical signs, particularly neurological features and cardiovascular and 
respiratory manifestations, collected from the routine daily ward round 
documentation.  Information on ANS manifestations such as mottled skin, sweating 
etc. was not systematically recorded in the hospital files during this period, but any 
information noted in the files was collected. 
5.2.6 Statistical analysis  
Patients who received MgSO4 for hypertension were considered as the exposed 
patients, while those who did not receive MgSO4 but may have received alternative 
second line therapy, were considered as unexposed and formed the control group. 
Major events: My intention was to examine a composite endpoint comprising 
progression to any major clinical event within the first 72 hours after T=0; the 
endpoints were shock, need for inotropic support, respiratory compromise requiring 
ventilation, or death. Comparison between the groups was based on logistic regression 
with the non randomized treatment assignment as the only covariate. However, there 
were no deaths and very few major events in either patient group. I also assessed the 
duration of milrinone therapy and of hospitalization after T=0, using linear regression. 
Ten deaths did occur within the specified time period, 9 of them during 2011 and one 
in January 2012 (Table 3.4, Chapter 3). Among these patients, 6 had hypertension but 
deterioration was generally rapid, progressing to pulmonary edema and/or shock 
before they reached the maximum dose of milrinone. Thus none of the 10 patients 
fulfilled the selection criteria for inclusion in this analysis.   
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Comparison of hemodynamic parameters between treatment groups: I also wanted 
to compare the magnitude and time course of hemodynamic stabilization over the 24 
hours after T=0 in the two groups to see if blood pressure was more effectively 
controlled in the MgSO4 group. For this analysis I focused on the SBP and the mean 
arterial pressure (MAP) calculated in a standard way as follows: [SBP+2(DBP)]/3. 
Examination of the MgSO4 group data showed that the actual time of starting MgSO4 
in this group was quite variable in relation to the apparent T=0 as defined in the 
selection criteria described earlier. A number of factors may have influenced this 
clinical decision-making including the age of the patient, the rapidity of the 
deterioration in blood pressure, and the experience of the clinician involved. For this 
detailed analysis of hemodynamic parameters and so as to allow for the intrinsic 
variability in the initiation time in the MgS04 group, I decided to develop a prediction 
model for MgSO4 initiation after consultation with experienced statisticians at OUCRU. 
This model was then used subsequently as an imputation model to create multiple 
imputed datasets that defined multiple presumptive time points for when MgSO4 
might have been initiated in the control group.  
This prediction/imputation model is a logistic regression model based on three factors: 
a) the difference between the current SBP and the age-dependent cut-off for Stage 2 
hypertension; b) the difference between the current SBP and the previous SBP value; 
and c) the current dose of milrinone. For control patients, at each time-point when the 
SBP was measured and was larger than the age-dependent cut-off, a probability of 
initiating MgSO4 was estimated from the imputation model. For each patient, the 
imputed time of MgSO4 initiation was the first instance when MgSO4 would be used, 
based on random assignment using a Bernoulli distribution where the probability of 
success is the probability of initiating MgSO4 estimated from the imputation model. A 
patient was considered as not receiving MgSO4 if it was not initiated at all time-points 
based on these probability models. This procedure was repeated 20 times for each 
patient to create 20 imputed datasets. 
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Although MgSO4 was initiated at Stage 2 hypertension in the exposed group after 
failure with milrinone, this is a rather high BP level and Stage 1 hypertension is more 
relevant as a clinical threshold for concern and potential intervention. Therefore I 
examined the area under the curve (AUC) for all SBP and the MAP values above the 
appropriate age-dependent Stage 1 hypertension threshold during the first 24 hours in 
the two groups, comparing values after actual T=0 in the exposed MgSO4 group and 
presumptive time points for initiating MgSO4 in 20 imputation datasets in the control 
group.  
Relationships between Mg/Ca levels and hemodynamic parameters: Associations 
between sequential Mg/Ca levels and SBP and MAP were explored using scatterplots 
and Pearson correlation coefficients.  
5.3 Results 
From January 2011 to December 2015, 165 children with severe HFMD were admitted 
to the PICU at HTD and treated with milrinone, and therefore were potentially eligible 
for inclusion in this analysis (Figure 5.2). In this group, 103/165 (63%) required high 
dose milrinone for control of hypertension, and in 47/103 cases the blood pressure 
remained high or continued to increase despite being on the maximum dose of the 
drug. Within this group however, one case had already commenced nicardipine before 
the addition of milrinone, and in another case MgSO4 was added due to severe asthma 
rather than for hypertension; these cases were not included in the analysis. A total of 
45 cases were selected, 33 in the group exposed to MgSO4 and 12 in the unexposed 
(control) group. One child in the control group developed respiratory distress and was 
ventilated, but subsequently the blood pressure remained poorly controlled and 
magnesium was added at this time. All blood pressure measurements after addition of 
MgSO4 were censored from this point onwards.  
In all 33 children in the exposed group the MgSO4 infusion was continued for at least 
24 hours. By 48 hours the infusion had been stopped in 8 cases, and by 72 hours it had 
been stopped in 18 cases. Among the patients in the control group alternative therapy 
for hypertension was added only in the one case described above, who was ventilated 
  Chapter 5 
144 
  
  
7 hours after reaching maximum dose milrinone, and then 1 hour later MgSO4 was 
added for poorly controlled hypertension.    
 
Figure 5.2: Flow chart describing selection of patients for inclusion in the analysis  
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milrinone 
10 cases 
2013-2014-2015 
47 patients 
 
Without  
MgSO4 
4  cases 
Unexposed MgSO4 group 
12 cases 
 
2011 
48 patients 
2012 
70 patients 
*: 1 case was eventually treated with MgSO4 but only some time later, after being ventilated 
**: 1 case had received nicardipine before adding MgSO4 and 1 case received MgSO4 because of 
severe asthma manifestation 
With MgSO4 
16 cases 
 
High dose milrinone 
20 cases  
Enrolled into the  Mg 
study (in 2014-2015) 
10 patients 
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5.3.1 Baseline clinical and laboratory information for the two groups  
Most patients (8/12, 67%) in the control group were hospitalized during 2011, the first year of 
the major outbreak, with hospital admission for the remaining 4 children distributed 
intermittently through 2012. MgSO4 was first given at the end of 2011 and by mid-2012 had 
become an accepted therapeutic intervention. From then onwards almost all HFMD cases who 
did not respond to milrinone were treated with MgSO4 (Figure 5.3).   
Baseline demographic, clinical and laboratory information comparing the subjects in the 
exposed and control groups are shown in Table 5.1. For most continuous parameters the data 
presented are the worst values documented within the 24 hour period prior to T=0, except for 
the illness day and the blood pressure values, which correspond to T=0.   
 
Figure 5.3: Temporal distribution of hospital admissions between 2011 and 2015, for 
patients in the two groups  
  
Note: MgSO4 exposed patients are shown in red, and control patients in blue. 
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Table 5.1: Clinical and laboratory features in the MgSO4 exposed and control groups, 
assessed within the 24 hours before the actual/potential time to start MgSO4 (T=0) 
 n 
MgSO4  
(N=33) 
n 
Control 
(N=12) 
Estimated Effect 
(95% CI) # 
p-value & 
Demographic information      
Sex (F) 33 7 (21) 12 6 (50) 0.27 (0.06, 1.10)) 0.067 
Age (months) 33 36 (25, 48) 12 15 (12, 21) 22.43 (6.67, 38.20) 0.005 
Weight (kg) 33 18 (14, 24) 12 10 (9, 11) 9.97 (4.69, 15.25) <0.001 
Illness day at T=0 33 4 (3, 4) 12 4 (3, 6) -1.04 (-2.17, 0.09) 0.062 
Admission grade* 32  12  # 0.797 
- 2  0 (0)  3 (25)   
- 2b  19 (59)  9 (75)     
- 3  13 (41)  0 (0)   
Clinical manifestations 
Fever (> 37.50 C) 33 26 (79) 12 11 (92) 0.34 (0.02, 2.23) 0.288 
Tachycardia** 33 7 (21) 12 2 (17) 1.35 (0.27, 10.07) 0.732 
Systolic BP at T=0 33 140 (130, 147) 12 134 (128, 137) 7.04 (-3.43, 17.50)) 0.170 
Diastolic BP at T=0 33 70 (63, 80) 12 64 (60, 69) 6.51 (-1.77, 14.79) 0.110 
Tachypnea for age 29 16 (55) 12 9 (75) 0.41 (0.08, 1.71) 0.227 
Irregular breathing  33 3 (12) 12 2 (18) 0.61 (0.09, 5.25) 0.628 
Skin ANS features*** 33 1 (3) 12 0 (0)  # 0.428 
Laboratory investigations 
WBC (x109/L) 30 12.6 (10.8, 16.1) 10 12.0 (8.8, 14.2)  -2.73 (-5.49, 0.03) 0.045 
Neutrophil (%) 30 58.8 (48.4, 69.4) 10 47.5 (43.8, 58.4)  10.30 (0.06, 20.54) 0.042 
Hb (g/l) 30 11.9 (10.9, 13.1) 10 13.1 (11.9, 13.7) -0.66 (-1.85, 0.53) 0.252 
CK-MB (UI/l) 15 23.9 (20.8, 35.5) 6 36.8 (20.1, 72.6) -28.59 (-57.19, 0.01) 0.038 
Troponin I (pg/ml) 15 11.0 (5.5, 18.0) 6 13.0 (1.2, 65.2) -133.1 (-26.97, 293.23) 0.078 
Glycemia (mg/dl) 25 106 (96, 127) 9 103 (82, 111) 4.67 (-16.91, 26.26) 0.644 
EV-A71 positive  33 23(70) 12 12(100) # 0.007 
Summary statistic is absolute count (%) for categorical variables and median (IQR) for continuous data 
Estimated effect: OR for categorical variables (based on logistic regression model) and mean difference 
(based on linear regression model) 
 *: One case was diagnosed with encephalitis at admission 
**: Heart rate sustained >150 beats/min, adjusted down by 10 for each 1oC of fever above 37.0 oC 
***: Skin manifestations of autonomic nervous system dysregulation 
#: cannot be compared because there was no event in one group 
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The proportion of girls (6/12, 50%) was higher in the control group than in the exposed 
group (7/33, 21%), and the children in the MgSO4 group were significantly older, with 
a median (IQR) age of 36 (25, 48) months versus 15 (12, 21) months in the control 
group, estimated effect size 22.43 (6.67, 38.20), p=0.005. Reflecting this fact, the 
weights of the MgSO4 subjects were also significantly greater than the weights of the 
control group (p<0.001). The illness day at T=0 was similar for the two groups. 
However, regarding clinical severity at hospital admission the control patients were 
generally less severe at this time (no cases were admitted at Grade 3 compared to 
13/33 (41%) of the MgSO4 group), although there was no significant difference overall 
between the groups when assessed using ordered logistic regression.  
A greater degree of family anxiety for the younger children may have resulted in 
earlier presentation to hospital with progression to Grade 3 occurring after 
hospitalization in the control group. With respect to clinical manifestations, there were 
no apparent differences in terms of fever, tachycardia, tachypnea, irregular breathing, 
and skin manifestations of ANS dysregulation between the groups. Systolic and 
diastolic blood were elevated in all patients, consistent with the selection criteria of 
Grade 3 HFMD with Stage 2 hypertension; although the values appear generally higher 
in the MgSO4 group these values are not age adjusted and the control patients were 
much younger than the MgS04 patients.   
There were minor differences of borderline statistical significance in several laboratory 
parameters, in general indicating slightly more abnormal values in the control group 
compared to the MgSO4 group but the differences were small and unlikely to relevant 
clinically.  
Diagnostic swabs were available for all 45 individuals. In 8 cases the enterovirus PCR 
was negative, while in the remaining 37/45 (82%) cases enterovirus infection was 
confirmed by RT-PCR. In the majority of these cases (35/37, 95%), the serotype was 
EV-A71, while in the other 2 cases no specific serotype was identified. All 12 control 
cases had EV-A71 infection compared to 70% of the MgSO4 subjects, probably 
reflecting changes in serotype dominance during the years of the study as discussed in 
Chapter 3.    
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5.3.2 Outcomes: comparison of major events between the groups (Table 5.2)  
No deaths occurred in either group. Two children in the control group required 
invasive ventilation (for 111 and 153 hours respectively) compared to one in the 
MgSO4 group (100 hours) (Table 5.2). The duration of treatment with milrinone and 
the duration of hospitalization, both assessed in relation to T=0, were very similar 
between the groups.  
 
Table 5.2: Comparison of major events occurring in the exposed and control groups  
 
  
n 
MgSO4 
(N=33) 
 
n 
Controls 
 (N=12) 
Estimated effect  
 (95 % CI) 
 
p-value # 
Composite endpoint 33 1 (3.0) 12 2 (16.7) 0.16 (0.01, 1.79) 0.132 
Invasive ventilation 33 1 (3.0) 12 2 (16.7) 0.16 (0.01, 1.79) 0.132 
Duration of milrinone 
treatment (hrs) 
33 45.5 (32.5, 67.5) 12 44.7 (34.8, 58.2) 2.42 (-17.50, 22.35) 0.802 
Duration of 
hospitalization (days) 
33 9.0 (7.0, 10.0) 12 9.0 (7.8, 13.2) -1.65 (-3.79, 0.49) 0.117 
 
Summary statistic is absolute count (%) for categorical variables and median (IQR) for continuous data  
Composite endpoint included death, invasive ventilation, shock, and inotrope requirement. 
Estimated effect: OR for categorical variables (based on logistic regression model) and mean difference 
(based on linear regression model) 
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5.3.3 Comparisons of SPB and MAP between the MgSO4 and control groups within 
the first 24 hours after T=0. 
Development of the multiple imputation model  
One patient (aged 13 years) who was much older than all the others in the MgSO4 
group was not included in the development of the imputation model. All SBP data from 
the other 32 MgSO4 recipients excluding a) SBP values before initiation of milrinone b) 
SBP values after initiation of MgSO4, and c) SBP values below the age-dependent cut-
off for Grade 2 hypertension, were used to develop the model. Estimated parameters 
for the imputation model are shown in the Table 5.3; the likelihood that MgSO4 will be 
given increases with a greater difference between the measured SBP and the Stage 2 
age-adjusted cut-off, and with the milrinone dose >= 0.7 µg/kg/minute 
Table 5.3: Estimated parameters of the imputation model 
Covariate OR (95% CI) p value 
(Systolic BP - cut-off) 1.11 (1.05, 1.18) <0.001 
% (Systolic BP – previous Systolic BP) 1.06 (0.99, 1.13) 0.098 
Milrinone dose (µg/kg/minute)   <0.001 
  <0.6 1.00   
 (0.6, 0.7) 4.24 (0.62, 29.02)  
  >= 0.7 41.89 (9.01, 194.72)  
 
. This model was used to create 20 imputation datasets for the control group patients 
(Table 5.4).  
  Chapter 5 
150 
  
  
Table 5.4: Imputed time points, within the first 24 hours of achieving initial T=0, to start MgSO4 in the control patients (20 imputation 
datasets) 
 Imputation datasets 
ID 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 
MG012 7.00 7.00 5.00 7.00 5.00 7.00 7.00 7.00 7.00 7.00 7.00 5.00 7.00 7.00 5.00 7.00 7.00 7.00 7.00 7.00 
MG037 12.25 12.25 11.42 9.25 11.42 - 12.25 12.25 11.42 - 11.42 12.25 - 6.25 18.25 12.25 - 11.42 6.25 11.42 
MG038 2.75 5.75 1.00 - - 1.00 1.00 6.75 2.75 1.00 1.00 1.00 - 1.00 2.75 1.00 5.75 - 1.00 1.00 
MG042 - - 4.50 4.00 - 4.50 - 4.50 2.00 4.50 4.50 4.50 7.00 4.50 2.00 4.00 11.00 - 4.00 4.50 
MG044 5.50 3.50 1.50 4.50 21.50 3.50 1.50 2.50 2.50 2.50 2.50 1.50 12.50 5.50 2.50 5.50 5.50 1.50 12.50 12.50 
MG046 22.50 18.50 21.50 22.50 18.50 22.50 18.50 19.50 22.50 19.50 22.50 21.50 18.50 18.50 19.50 18.50 18.50 18.50 21.50 18.50 
MG048 - - 35.50 35.50 - - 30.50 35.50 26.50 45.50 35.50 11.50 35.50 35.50 35.50 14.50 35.50 45.50 26.50 20.50 
MG050 8.50 11.50 11.50 8.50 7.50 7.50 7.50 7.50 8.50 7.50 7.50 8.50 11.50 7.50 7.50 7.50 7.50 7.50 7.50 12.50 
MG051 2.50 4.50 0.50 2.50 2.50 3.50 0.50 0.50 2.50 2.50 2.50 9.50 2.50 5.50 3.50 2.50 3.50 2.50 2.50 0.50 
MG054 15.33 12.33 9.33 12.33 12.33 13.33 12.33 16.33 12.33 18.33 13.33 10.33 12.33 15.33 13.33 10.33 12.33 15.33 12.33 15.33 
MG055 19.00 40.00 17.00 15.00 15.00 32.00 32.00 19.00 19.00 - 17.00 19.00 17.00 19.00 17.00 43.00 - 40.00 19.00 32.00 
MG056 2.67 2.67 2.67 3.67 2.67 2.67 2.67 2.67 6.67 2.67 2.67 2.67 2.67 6.67 2.67 12.67 14.67 2.67 4.67 2.67 
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Comparisons of AUCs for SBP and MAP between the two groups 
During the first 24 hours after T=0, SBP and MAP measurements were missing for 
60/300 (20%) potential time-points in the placebo group and for 34/825 (4%) in the 
MgSO4 group, most likely because the treating clinicians stressed the need for very 
careful observation in those receiving the new treatment. However, those missing 
values were imputed when calculating the AUCs. Individual AUCs for the SBP values 
above the Stage 1 hypertension cut-off were calculated and the difference between 
the MgSO4 group and each of 20 imputation datasets for the control group are shown 
in the Appendix. After pooling all 20 imputed datasets and deriving overall estimates 
using Rubin’s rule, the overall difference between the AUCs, after adjustment for the 
“baseline” SBP recorded at the time-point of MgSO4 indication, was -46.70 (-167.77, 
74.37), p= 0.450 (Table 5.5).  
Similar analysis was done for the AUCs for the MAP values in the two groups. In this 
case there was a significant difference between the overall AUCs after pooling the 
results of the comparisons with the 20 imputation datasets, estimate -60.752 (-
113.670, -7.835), p=0.024.   
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Table 5.5: Comparisons of the AUCs for SBP and MAP above the Stage 1 hypertension level between the MgSO4 and the control groups  
 
Description of AUCs for SBP or MAP in each treatment group  Estimates of difference in AUCs between treatment groups 
Groups Median (IQR)  Parameters 
Mean 
difference  
95% CI 
p-value 
Lower Upper 
AUC of SBP above cut-off        
   (Intercept) 140.72 16.66 264.78 0.026 
Magnesium sulfate  317.8 (192.5, 458.5)  Initial SBP above cut-off * 8.27 5.29 11.25 0.000 
Controls  330.5 (195.7, 509.8)  Magnesium sulfate -46.70 -167.77 74.37 0.450 
        
AUC of MAP above cut-off        
   (Intercept) 66.21 16.91 115.50 0.008 
Magnesium sulfate 40.4 (23.5, 71.7)  Initial MAP above cut-off * 7.05 4.99 9.11 0.000 
Controls 44.2 (22.8, 148.2)  Magnesium sulfate -60.75 -113.67 -7.83 0.024 
 
SBP: systolic blood pressure MAP: mean arterial pressure AUC: area under curve 
Results were derived by pooling all 20 imputed datasets and applying Rubin’s rules to calculate overall estimates. 
*: SBP and MAP above cut-off at the time MgSO4 commenced
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Figure 5.4: Progression of SBP (left panel) and MAP (right panel) above the relevant Stage 1 hypertension level for the first 24 hours after 
T=0* 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*: For illustration, the presumptive times for MgSO4 administration (T=0) for the patients selected as controls are the values taken from the 12th dataset out 
of a total of 20 imputed datasets 
SBP: systolic blood pressure MAP: mean arterial pressure AUC: area under curve
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5.3.4 Relationships between Mg/Ca levels and hemodynamic parameters  
Magnesium and Calcium levels in the MgSO4 group 
Baseline plasma Mg/Ca levels (taken within the 24 hours prior to commencing 
treatment) were measured in 18/33 (55%) of the MgSO4 group, and fell within the 
expected normal ranges in the majority of patients. The plasma Mg concentration 
increased during the first 12 hours of the infusion, and then remained fairly stable, 
with median values of 1.65-1.77 mmol/l for the next 48 hours. Meanwhile, plasma Ca 
levels decreased and fluctuated around 1.88-1.96 mmol/l with an inverse relationship 
to the plasma Mg levels (Figure 5.5). A single high Mg value of 3.13 mmol/l was 
recorded, at which there might be concern about respiratory muscle weakness. 
However the child had no respiratory problems and the ECG was normal.  
Figure 5.5: Sequential plasma magnesium and calcium levels in the MgSO4 group. 
 
 
 
 
 
 
 
 
 
 
 
 
 
          
  NB: Boxplots show the median and IQR values, with red dots indicating outliers    
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However, overall the Mg levels were lower than those measured in the Mg RCT. In this 
patient group values below the target concentration, i.e. less than 1.8 mmol/l, 
occurred in 19/32 (59%), 19/33 (58%), and 17/31 (55%) of cases at 12, 24, and 48 
hours, respectively, after commencing MgSO4, while in the MgSO4 trial, the 
corresponding proportions were 2/13 (15%), 1/14 (7%) and 2/11 (18%), respectively. 
These differences likely reflect differences in the dosing regime for MgSO4 (mg/kg/hr) 
in the two studies, with the overall dosing schedule of the patients included in this 
analysis being lower that that of the RCT participants. At the mid-point of the first day 
of treatment, the median (IQR) dose for patients in this cohort was 40 (30, 50) 
mg/kg/hr compared with a dose at a similar time-point after introduction of MgSO4 of 
50 mg/kg/hr in 13/14 patients in the RCT with only one child on 40 mg/kg/hr at this 
time. At the subsequent 24 and 48 hour assessments MgSO4 doses being given to the 
cohort patients were consistently slightly lower than the doses given to the RCT 
patients. 
Relationship with hemodynamic parameters: SBP, MAP 
 
In contrast to the increasing plasma Mg levels described above, SBP and MAP values  
decreased over time (Figure 5.6). The Pearson’s correlation analysis shows that SBP 
was decreasing when MgSO4 level was increasing with the Cor (95% CI) = - 0.23 (- 0.38, 
- 0.07), p =0.004 (figure 5. 6). It is similar when analyzing the relation between MAP 
and MgSO4 levels with Cor (95% CI) = -0.27 (- 0.41, - 0.10), p= 0.002 (Figure 5.7). 
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Figure 5.6: Progress of SBP (Panel A) and MAP (Panel B) over time in the MgSO4 
group  
 
Note: Individual dots represent all SBP and MAP measurements within 72 hours in the 33 cases in the 
MgSO4 group. 
Blue lines represent the regression line of fitted values using a linear regression model  (plus confidence 
intervals in shadowed areas) 
 
Figure 5.7: Relationships between SBP (Panel A) and MAP (Panel B) with plasma Mg 
levels 
 
 
Note: Individual dots represent the SBP and MAP value at each hour when Mg was measured 
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5.4 Discussion 
Because of the small number of patients recruited into the Mg RCT, I designed this 
study aiming to assess the efficacy of MgSO4 using another approach. This was a 
retrospective analysis of all children with HFMD who achieved a certain threshold of 
severity. Having reviewed all the files of patients treated with high dose milrinone, I 
identified 33 children who had received MgSO4 as second line therapy and 12 children 
who had similarly severe hypertension but did not receive MgSO4, and I used these 
individuals as a control group. Most patients in the control group were in PICU during 
2011 and the early part of 2012, while the MgSO4 group were admitted later in 2012, 
by which time there had been a change to the circulating enterovirus serotypes and 
genotypes towards less virulent viruses in general. There were some inequalities 
between the groups in terms of age, weight, EV-A71 status, all of which suggest that 
the control group might be at higher risk for a poor outcome. On the other hand 
however, children in the MgSO4 group were generally more severe than in control 
group at the time of hospital admission, and developed to the severity level for 
inclusion in this analysis about 1 day earlier than their counterparts in the control 
group; Logically, less severe disease on admission and later presentation with major 
complications would suggest that the overall severity might be less in the control 
group, including the severity of the hemodynamic instability/hypertension. However, 
although various of these factors (sometimes opposing each other) may have 
influenced the results, I could not perform a secondary logistic regression adjusting for 
these covariates because of the small number of patients, especially in the control 
group. It is also notable that none of the 6/10 (60%) cases who died in the 2011-2012 
outbreak and presented with hypertension, were eligible for inclusion in this analysis 
because of rapid progressed to pulmonary edema and/or shock before they achieved 
the inclusion criteria for the study. So the findings of this retrospective analysis must 
be interpreted with caution. 
Similar to the MgSO4 trial, we found no evidence of benefit in the group exposed to 
MgSO4 in terms of the primary outcome and most secondary outcomes. However, 
there was a significant difference in the AUCs for mean arterial pressure (MAP) above 
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the Stage 1 threshold, favoring the MgSO4 group, although not for systolic blood 
pressure (SBP). This is only one analysis out of many so may be a random occurrence, 
but there is a physiological rationale to support the effect observed. Magnesium ions 
compete with calcium ions for receptors on vascular muscle cells and can influence 
blood pressure by modulating vascular tone. Magnesium also has an important role in 
the classical pathway of NO release, with changes in extracellular magnesium content 
modifying production and release of NO, resulting in alterations in arterial smooth 
muscle tone. Magnesium also decreases the release of catecholamines after 
sympathetic stimulation. Consequently, there is an overall relaxation of vascular tone, 
with a decrease in the diastolic blood pressure (DBP) rather than SBP noticed in some 
studies [6, 174, 236], which would be more apparent in the MAP analysis rather than 
the SBP analysis. We did find weak negative correlations (but highly significant) 
between plasma magnesium levels and both SBP and MAP, (r= -0.27, p=0.002 and r= -
0.23, p=0.004 respectively). These lines of evidence suggest that MgSO4 may have a 
greater impact on reducing DBP than SBP which could explain the reduction in MAP 
seen in the MgSO4 group compared to the controls.  
It is also important to note that the patients included in this analysis were more severe 
than most of those enrolled in the RCT, and that the Mg concentrations measured 
during the drug infusions were generally lower than the levels achieved in the RCT. So 
a therapeutic effect may be more difficult to achieve in the patients involved in this 
analysis. In studies of MgSO4 use in other conditions, the target therapeutic level has 
varied from 2 mmol/l to 5.5 mmol/l [171, 176, 240]. In the RCT we selected a target 
range of 1.8 – 2.5 mmol/l, with most patients achieving the upper end of this range 
early on, while in the cohort of patients described here the level achieved was lower. 
In fact more than half the patients in this study did not achieve the 1.8 mmol/l lower 
margin, most likely because this was a new intervention in very sick children and the 
clinicians were more cautious during the first year until they developed more 
confidence that serious toxicity did not occur. The data from these two studies are 
important however in showing that potentially toxic levels of Mg very rarely result 
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from the infusion regime used here, although higher levels may be desired in future 
studies to investigate efficacy.   
Given the limitations of this study as mentioned above, the findings can only be 
regarded as very preliminary. However, the reduction in MAP is encouraging, and 
supports the continued use of MgSO4 as an alternative anti-hypertensive drug in 
emergency situations where blood pressure can not be controlled by conventional 
therapy. It still remains desirable however to consider opportunities to develop further 
studies, especially randomized control trials, to formally investigate the efficacy and 
safety of MgSO4 for severe HFMD in future.  
5.5  Conclusion 
In summary, this study provides an overview of the experience of using MgSO4 as the 
rescue therapeutic for severe hypertension in patients who failed to respond to high 
dose conventional therapy, i.e. milrinone. Continuous infusion with a dosage of 30-50 
mg/kg/hr following an loading dose of 50 mg/kg over a 20-minute infusion resulted in 
increased plasma Mg to within the desired therapeutic range in most cases, with the 
measured plasma Mg and Ca levels showing a clear dose response relationship. It was 
very rare to find levels above the level for potential toxicity (3 mmol/l) with this 
regime. Plasma Mg levels showed a weak negative correlation with SBP and MAP 
measurements, and the MAP assessed over 24 hours was significantly lower in the 
MgSO4 group than in the controls assessed as being of similar severity who did not 
receive MgSO4.  
Even though we found no evidence of a beneficial effect in the other outcomes 
assessed, the patient numbers in the two groups were unequal and relatively small 
(especially the control group), and also there were several potential confounders at 
baseline so that it is not possible to say whether the two groups were really 
equivalent. However, the lack of any adverse effects is reassuring and supports the 
continued use of MgSO4 as second line therapy when managing hypertension in 
severe HMFD in clinical practice.  
The original question of whether early intervention with MgSO4 when ANS 
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dysregulation first becomes apparent might control cardiovascular instability more 
effectively than milrinone as currently used, and thus prevent progression to severe 
disease, remains unanswered and a formal RCT is still needed. Alternatively, with the 
evidence on MgSO4 safety from these data, the alternative approach of comparing 
MgSO4 with milrinone directly in a formal RCT could also be considered, in order to 
identify the most effective regimen for children with severe HFMD who develop 
hypertension.  
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Appendix 
 Supplementary Table 5. 1: AUC of Systolic blood pressure above the stage 1 
hypertension cut-off comparison between groups who received MgSO4 and who did 
not for each dataset and overall pooling 
Dataset 
AUC of each dataset 
(Median (IQR) ) 
AUC difference after adjusting for each dataset 
  95 % CI  
Variables Estimate Lower Upper. p 
Imputation 1 317.0 (186.7, 497.0) (Intercept) 127.885 0.177 255.594 0.050 
 
 MgSO4 groups -26.449 -132.594 79.696 0.617 
 
 
Initial SBP 
above cut-off 8.010 4.981 11.040 0.000 
Imputation 2 331.7 (164.0, 498.0) (Intercept) 122.381 1.964 242.799 0.047 
 
 MgSO4 groups -39.943 -144.068 64.183 0.443 
 
 
Initial SBP 
above cut-off 8.684 5.702 11.667 0.000 
Imputation 3 302.4 (202.8, 474.0) (Intercept) 162.211 46.598 277.824 0.007 
 
 MgSO4 groups -59.000 -163.449 45.449 0.261 
 
 
Initial SBP 
above cut-off 7.947 4.784 11.111 0.000 
Imputation 4 333.0 (192.4, 482.7) (Intercept) 141.551 26.313 256.789 0.017 
 
 MgSO4 groups -41.728 -141.669 58.213 0.404 
 
 
Initial SBP 
above cut-off 8.068 5.166 10.969 0.000 
Imputation 5 336.5 (221.0, 510.0) (Intercept) 197.288 75.426 319.150 0.002 
 
 MgSO4 groups -91.147 -201.843 19.549 0.104 
 
 
Initial SBP 
above cut-off 7.843 4.779 10.908 0.000 
Imputation 6 323.2 (220.1, 498.3) (Intercept) 148.085 21.364 274.805 0.023 
 
 MgSO4 groups -42.724 -146.422 60.974 0.410 
 
 
Initial SBP 
above cut-off 7.871 4.884 10.858 0.000 
Imputation 7 333.0 (194.0, 486.7) (Intercept) 125.541 9.392 241.691 0.035 
 
 MgSO4 groups -41.132 -140.882 58.618 0.410 
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Initial SBP 
above cut-off 8.614 5.642 11.586 0.000 
Imputation 8 271.4 (166.2, 475.0) (Intercept) 96.431 -24.326 217.188 0.115 
 
 MgSO4 groups -7.713 -107.666 92.239 0.877 
 
 
Initial SBP 
above cut-off 8.462 5.344 11.579 0.000 
Imputation 9 334.7 (188.2, 470.5) (Intercept) 125.812 11.681 239.942 0.032 
 
 MgSO4 groups -32.023 -127.306 63.259 0.501 
 
 
Initial SBP 
above cut-off 8.282 5.370 11.193 0.000 
Imputation 10 300.1 (217.0, 498.3) (Intercept) 135.409 15.562 255.255 0.028 
 
 MgSO4 groups -49.394 -151.412 52.623 0.334 
 
 
Initial SBP 
above cut-off 8.558 5.609 11.506 0.000 
Imputation 11 289.4 (193.1, 475.0) (Intercept) 118.442 -1.999 238.884 0.054 
 
 MgSO4 groups -15.669 -116.052 84.714 0.754 
 
 
Initial SBP 
above cut-off 7.963 4.904 11.022 0.000 
Imputation 12 314.2 (207.4, 470.9) (Intercept) 185.142 70.973 299.311 0.002 
 
 MgSO4 groups -72.425 -176.780 31.930 0.169 
 
 
Initial SBP 
above cut-off 7.610 4.475 10.745 0.000 
Imputation 13 334.7 (222.5, 498.0) (Intercept) 166.431 48.665 284.196 0.007 
 
 MgSO4 groups -72.070 -174.344 30.205 0.162 
 
 
Initial SBP 
above cut-off 8.261 5.302 11.221 0.000 
Imputation 14 280.6 (199.1, 474.6) (Intercept) 103.081 -11.350 217.512 0.076 
 
 MgSO4 groups -13.945 -107.608 79.718 0.765 
 
 
Initial SBP 
above cut-off 8.447 5.558 11.336 0.000 
Imputation 15 323.2 (192.4, 475.0) (Intercept) 151.834 38.304 265.364 0.010 
 
 MgSO4 groups -61.831 -165.477 41.814 0.235 
 
 
Initial SBP 
above cut-off 8.416 5.237 11.595 0.000 
Imputation 16 322.0 (217.1, 475.6) (Intercept) 143.906 35.548 252.263 0.010 
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 MgSO4 groups -49.855 -146.574 46.863 0.304 
 
 
Initial SBP 
above cut-off 8.272 5.386 11.159 0.000 
Imputation 17 332.2 (198.1, 498.1) (Intercept) 149.191 32.538 265.844 0.013 
 
 MgSO4 groups -56.023 -157.203 45.158 0.270 
 
 
Initial SBP 
above cut-off 8.304 5.426 11.181 0.000 
Imputation 18 317.0 (104.0, 498.3) (Intercept) 122.178 6.917 237.440 0.038 
 
 MgSO4 groups -49.374 -153.539 54.791 0.344 
 
 
Initial SBP 
above cut-off 9.026 6.100 11.953 0.000 
Imputation 19 304.9 (207.4, 474.5) (Intercept) 156.790 54.902 258.679 0.003 
 
 MgSO4 groups -69.264 -160.805 22.276 0.134 
 
 
Initial SBP 
above cut-off 8.504 5.728 11.280 0.000 
Imputation 20 282.7 (217.1, 460.9) (Intercept) 134.908 24.119 245.696 0.018 
 
 MgSO4 groups -42.264 -138.121 53.594 0.379 
  Initial SBP 
above cut-off 
8.322 5.393 11.252 0.000 
Overall pooling  (Intercept) 140.72 16.66 264.78 0.026 
  MgSO4 groups -46.70 -167.77 74.37 0.450 
  
Initial SBP 
above cut-off 
8.27 5.29 11.25 0.000 
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 Supplementary Table 5. 2: AUC of Mean Blood Pressure (MAP) above the stage 1 
hypertension cut-off comparison between MgSO4 group and control group for each dataset 
and overall pooling 
Dataset 
AUC of each dataset 
(Median (IQR)) 
AUC difference after adjusting for each dataset 
  95% CI  
Variables Estimate Lower. Upper p 
Imputation 1 48.6 (18.3, 147.1) (Intercept) 58.171 10.495 105.847 0.018 
 
 MgSO4 groups -50.254 -100.734 0.226 0.051 
 
 
Initial SBP above 
cut-off 6.749 4.796 8.702 0.000 
Imputation 2 50.5 (23.3, 160.3) (Intercept) 74.111 31.118 117.104 0.001 
 
 MgSO4 groups -70.839 -117.717 -23.962 0.004 
 
 
Initial SBP above 
cut-off 7.321 5.464 9.177 0.000 
Imputation 3 39.1 (21.4, 149.0) (Intercept) 75.924 28.353 123.495 0.002 
 
 MgSO4 groups -68.408 -122.665 -14.150 0.015 
 
 
Initial SBP above 
cut-off 6.798 4.433 9.164 0.000 
Imputation 4 44.2 (15.9, 149.9) (Intercept) 52.191 7.211 97.172 0.024 
 
 MgSO4 groups -46.151 -94.374 2.072 0.060 
 
 
Initial SBP above 
cut-off 6.980 5.030 8.930 0.000 
Imputation 5 55.7 (24.0, 148.2) (Intercept) 86.829 31.445 142.213 0.003 
 
 MgSO4 groups -73.339 -133.072 -13.606 0.017 
 
 
Initial SBP above 
cut-off 6.064 3.863 8.265 0.000 
Imputation 6 48.2 (25.1, 147.0) (Intercept) 65.673 18.631 112.714 0.007 
 
 MgSO4 groups -58.994 -109.182 -8.806 0.022 
 
 
Initial SBP above 
cut-off 6.902 4.917 8.886 0.000 
Imputation 7 44.2 (26.8, 145.8) (Intercept) 73.381 33.150 113.611 0.001 
 
 MgSO4 groups -70.650 -115.603 -25.696 0.003 
 
 
Initial SBP above 
cut-off 7.387 5.544 9.230 0.000 
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Imputation 8 32.7 (13.4, 144.6) (Intercept) 55.712 14.178 97.246 0.010 
 
 MgSO4 groups -51.809 -97.968 -5.649 0.029 
 
 
Initial SBP above 
cut-off 
7.243 5.286 9.200 0.000 
Imputation 9 40.2 (20.9, 153.5) (Intercept) 47.652 3.422 91.882 0.035 
 
 MgSO4 groups -41.805 -89.230 5.620 0.082 
 
 
Initial SBP above 
cut-off 
7.004 4.998 9.010 0.000 
Imputation 10 49.6 (25.6, 147.0) (Intercept) 76.246 33.640 118.852 0.001 
 
 MgSO4 groups -73.327 -120.134 -26.521 0.003 
 
 
Initial SBP above 
cut-off 
7.364 5.503 9.225 0.000 
Imputation 11 35.5 (16.7, 144.6) (Intercept) 51.445 7.755 95.135 0.022 
 
 MgSO4 groups -45.353 -93.080 2.374 0.062 
 
 
Initial SBP above 
cut-off 
6.974 4.957 8.990 0.000 
Imputation 12 38.3 (17.2, 144.6) (Intercept) 73.118 24.143 122.092 0.004 
 
 MgSO4 groups -63.442 -118.863 -8.021 0.026 
 
 
Initial SBP above 
cut-off 6.533 4.124 8.942 0.000 
Imputation 13 49.9 (23.1, 160.3) (Intercept) 78.387 34.774 122.000 0.001 
 
 MgSO4 groups -74.356 -122.285 -26.428 0.003 
 
 
Initial SBP above 
cut-off 7.227 5.317 9.137 0.000 
Imputation 14 35.5 (20.5, 153.4) (Intercept) 44.573 3.633 85.513 0.034 
 
 MgSO4 groups -40.758 -84.971 3.455 0.070 
 
 
Initial SBP above 
cut-off 7.254 5.408 9.099 0.000 
Imputation 15 33.8 (22.8, 144.6) (Intercept) 75.198 27.880 122.516 0.003 
 
 MgSO4 groups -67.369 -121.425 -13.312 0.016 
 
 
Initial SBP above 
cut-off 6.760 4.410 9.110 0.000 
Imputation 16 38.3 (21.8, 151.1) (Intercept) 60.611 21.563 99.659 0.003 
 
 MgSO4 groups -56.426 -100.173 -12.679 0.013 
 
 Initial SBP above 7.208 5.405 9.011 0.000 
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cut-off 
Imputation 17 49.5 (23.1, 156.9) (Intercept) 61.656 17.042 106.270 0.008 
 
 MgSO4 groups -56.821 -104.268 -9.374 0.020 
 
 
Initial SBP above 
cut-off 7.128 5.262 8.995 0.000 
Imputation 18 48.6 (23.3, 147.0) (Intercept) 81.944 40.773 123.114 0.000 
 
 MgSO4 groups -79.997 -125.962 -34.032 0.001 
 
 
Initial SBP above 
cut-off 7.483 5.673 9.294 0.000 
Imputation 19 40.2 (21.7, 151.3) (Intercept) 62.192 21.524 102.860 0.004 
 
 MgSO4 groups -58.381 -103.914 -12.848 0.013 
 
 
Initial SBP above 
cut-off 7.254 5.318 9.190 0.000 
Imputation 20 36.9 (23.9, 148.9) (Intercept) 69.201 30.846 107.555 0.001 
 
 MgSO4 groups -66.569 -110.330 -22.809 0.004 
  Initial SBP above 
cut-off 
7.399 5.565 9.234 0.000 
Overall pooling  (Intercept) 66.21 16.91 115.50 0.008 
  MgSO4 groups -60.75 -113.67 -7.83 0.024 
  Initial SBP above 
cut-off 
7.05 4.99 9.11 0.000 
**: Overall pooling 20 dataset are calculated based on the Rubin’s rule 
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Chapter 6 
GENERAL DISCUSSION AND FUTURE RESEARCH PLANS 
HFMD is still a public health issue of major concern in Vietnam and around the Asia-
Pacific region. Disease incidence increased dramatically over a number of years up to 
2011, and despite the recent reduction in case numbers and in clinical severity many 
health care practitioners remain concerned about a possible re-emergence here 
and/or in neighbouring countries.  
Some years ago the Vietnamese MoH released guidelines for management of the 
disease, recommending control methods focused on hand washing as well as other 
ways to prevent disease transmission through the fecal/oral route. Although overall 
numbers have reduced from the major outbreak years of 2011-2014, mild to moderate 
cases continue to be seen with reasonable regularity in the outpatient departments of 
the big hospitals in HCMC and the possibility of a newly emerging epidemic remains 
real. Also, it is well recognized that the severity of disease varies over the years in part 
because the circulating enterovirus serotypes shift over time. If large outbreaks start to 
occur again, peaking over a short period, it is possible that we will again see a number 
of patients with rapid progression to severe disease. There is a lack of knowledge of 
the clinical features among these cases, which can result in an inadequate and 
informal evidence base with respect to management of these severe manifestations, 
particularly ANS dysregulation.  
The first major aim of this thesis was to describe the clinical features of all severe 
HFMD cases seen at HTD during a defined time-period, as well as the range of 
outcomes and management strategies used, and to explore the predictive factors 
associated with severe outcomes. The second major aim was to formally assess the 
potential effects of intravenous MgSO4 in severe cases, focusing on hypertension 
control as the clearest indicator of ANS dysregulation. 
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Even though the clinical features of severe HFMD have been described in a few 
studies, most of these were based on internal classification systems [104, 190, 196, 
197], or described small reviews that were mostly focused on EV-A71 [74, 125, 191, 
192], or were published in local languages and therefore inaccessible to the wider 
scientific community [193-195]. So I focused on describing the clinical features of 
severe HFMD, using the data of all 1272 patients who were managed at our PICU in 
HCMC over 2 years. The data were gathered retrospectively, but because of the MoH 
guidelines that stipulate in great detail how severe HFMD cases should be monitored 
and managed, the data available for most cases in the series were very good, with less 
than 5% missing information for the parameters of interest. However there was some 
evolution in processes over the two-year period, so there was some variation, 
particularly in laboratory investigations and virological diagnostics used during the 
study [83, 147].  
The results show that severe disease is caused not only by EV-A71, but also can be 
caused by CV. The predominant strains were CV-A10 and CV-A6, rather than CV-A16 as 
reported in southern Vietnam in 2005 and 2008, and initially in the 2011 outbreak [89, 
201], and in other countries [241-243]. The shift from EV-A71 to CV infection and also 
in the sub-genogroups of EV-A71 from C4 to B5 [244], may help to explain the change 
in incidence of severe HFMD cases admitted to PICU in 2011 and 2012 compared to 
the overall HFMD cases in HTD. The same association between overall reduced disease 
severity and a shift from EV-A71 to CV species has also been shown in a recent study 
from China [211].  
Skin lesions were more prominent in EV-A71 infection, while mouth ulcers were 
common in CV infection. Neurological involvement, including myoclonic jerks and focal 
neurological signs, were more common in cases associated with EV-A71 than CV, but 
this was not exclusively so. Respiratory distress occurred in one-quarter of severe 
cases associated with EV-A71 compared to 2% in cases related to CV. The ANS 
dysregulation manifestations, mostly hypertension, occurred in 16% of EV-71 cases 
and 2% of CV infected patients. The final stage of severe disease, i.e. pulmonary edema 
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and cardiopulmonary failure, occurred in 1% (PE) and 3% (cardiopulmonary failure) of 
the EV-A71 infections, but none of the CV-associated HFMD cases.  
I also described the evolution of clinical features over time in the patient cohort. The 
persistence of fever for more than 3 days was associated with EV-A71 as opposed to 
CV infection. Other signs and symptoms such as skin lesions and mouth ulcers tended 
to occur concurrently with fever in the first few days of illness, similar to findings 
shown in previous studies [82, 83]. In contrast neurological signs rarely happened on 
the first day, but developed over the second and third days of illness. Subsequently 
manifestations of CNS involvement, particularly respiratory abnormalities, occurred 
from around day 3 and remained present for around 3 days. This clinical course is in 
keeping with the theoretical pathophysiological mechanisms that are thought to 
contribute to the development of severe HFMD [64].  
WHO recommends that early detection and timely management are the best ways to 
reduce morbidity and mortality from HFMD. Some research groups have tried to 
investigate risk factors for progression to severe disease, aiming to identify the best 
strategy for follow-up and management (Table 3.1) [112, 194, 202-208]. However, in 
most of these studies associations with severe disease were identified, as opposed to 
predictive factors, because the timing of evolution of the various features was not 
identified. Only one study formally investigated risk prediction for neurological 
involvement and identified three parameters: fever persisting for 3 days; peak fever 
over 38 C; and a history of lethargy, as risk factors for progression [209].  
As well as carefully identifying the sequence of different clinical features over time, I 
defined strict criteria for severe disease in my cohort and also excluded patients who 
deteriorated rapidly (within 24 hours of PICU admission). Using pre-defined clinical and 
readily available laboratory factors, I found that initial presentation with skin lesions, 
or with tachypnea, were predictive of subsequent deterioration to severe disease. Skin 
lesions are linked to EV-A71 infection, which is already an established factor causing 
severe disease, and was a clear predictor when included in the model. This factor was 
also found to be an indicator for risk of severe disease in the case-control study in 
Singapore [205]. Tachypnea is an early manifestation of respiratory distress, and could 
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also lead to severe outcome. Presentation with mouth ulcers alone was strongly 
associated with CV infection, and was a protective factor for severe outcome. This 
finding is similar to a meta-analysis of studies mainly conducted in mainland China, 
that showed that patients who presented with oral involvement were not at greater 
risk of severe disease [112], In principle, management of severe HFMD relies on early 
supportive care, with careful observation to recognize disease progression [83, 147]. 
Better detection of individuals at risk for progression should be facilitated by the 
results from the observational study, potentially allowing healthcare workers to direct 
their resources towards these high-risk groups.  
Within the severe patient group, management of hypertension, a key manifestation of 
ANS dysregulation, is still controversial. Based on rather limited evidence milrinone has 
become the recommended first choice therapy for blood pressure control in Vietnam 
and other countries in the region [117, 147, 168]. However in 2011, when we were 
experiencing a very high disease burden on PICU with many severe cases, it became 
clear that in a proportion of these patients milrinone was not effective. Other 
therapeutic options were considered, mostly following conventional principles for 
hypertension management, including nicardipine and captopril [224], or alternatively 
based on anecdotal experience, i.e. hemofiltration [153, 154]. In the end, based on 
effective use of magnesium sulfate infusions for control of autonomic dysfunction in 
adults with tetanus [171], and more recently in neonates [230], I tried this therapy in a 
number of severe HFMD cases. Data from use of this agent as second line therapy in 
19 HFMD cases with poorly controlled blood pressure despite high dose milrinone 
looked promising, and I therefore decided to go forward with developing a protocol for 
a randomized double-blind controlled trial to formally evaluate the efficacy and safety 
of this novel intervention for severe HFMD before it became established as the 
standard of care. 
Finding formal evidence to support use of MgSO4 in severe HFMD is essential to fill the 
gaps between theoretical principles and the reality of clinical practice. However 
conducting a randomized blinded trial in severely ill children is a difficult undertaking. 
The trial was designed very carefully to ensure there were no treatment delays for the 
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children and that all possible safety mechanisms were incorporated in the protocol. 
Partly as a result of this, the trial did not actually start until mid-2014, by which time 
the epidemic in the region was waning and the number of severe cases was declining, 
probably partly reflecting a change in local enterovirus epidemiology. Case numbers 
continued to decline throughout 2015 and 2016, and finally only 26 participants out of 
a planned sample size of 190 were enrolled before the trial had to be stopped on the 
grounds of futility.  
With the small number of participants in the trial, we found no evidence of benefit in 
any of the outcomes assessed, but the data were clearly not adequate to address the 
question of efficacy and a much larger trial is still needed to properly evaluate whether 
MgSO4 has a role in controlling hypertension in severe HFMD. Following on from this 
setback I decided to take another approach, and designed a retrospective cohort 
analysis aiming to make the best use of the available data on all the HFMD patients 
who had received MgSO4 in the preceding years, not limited to the trial participants. 
To do this, I identified all patients with Grade 3 HFMD and signs of ANS dysregulation 
with Stage 2 hypertension who had received open-label MgSO4 during the 2011-2012 
outbreak, and compared their cardiovascular responses with similar cases who 
achieved the same basic severity level but for whom MgSO4 was not used. The 
numbers involved were a little larger than in the RCT, but the final results did not show 
any statistical difference in any major endpoints between those patients who did and 
did not receive MgSO4. There was a difference however, in the reduction in the AUC of 
mean arterial pressure, favoring those who received MgSO4. However, with the small 
sample size, I did not have statistical power to determine this effectively.  
In both studies the safety profile of MgSO4 was carefully observed. Very little data is 
currently available about MgSO4 safety profiles in children, particularly in relation to 
measured plasma magnesium and calcium levels. There were no serious adverse 
events linked to magnesium usage in the retrospective cohort analysis, while the 
adverse events I observed in the prospective trial occurred at similar rates in both 
treatment groups. Plasma levels were generally consistent with the dosage titration in 
both studies, and in very few individuals were the plasma Mg levels outside the 
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desired therapeutic window. The data indicate that the dosing regimen we used, with 
the upper limit target of 2.5 mmol/l for plasma Mg, should be suitable for use in 
situations when a therapeutic effect is desired but where safety is a primary concern 
(e.g. in an outbreak situation, when it may not be possible to admit all patients to an 
ICU or DHU), and that repeated checks on plasma Mg are not necessary if there are no 
clinical concerns. However there may be leeway to push the upper limit target to 3 
mmol/l or higher in situations where good safety monitoring is possible, for example in 
ventilated patients or ICU situations. Given the lack of a clear therapeutic effect, albeit 
in a very small study, a higher concentration should be considered, with precaution, in 
any future studies on HFMD. 
Conducting a trial during an unpredictable outbreak is a huge challenge in terms of 
ethical issues, and clinical practice, for both clinical doctors and researchers [245]. As 
in the influenza pandemic in 2009 [246], and the Ebola outbreak in 2014 [247], testing 
a new therapeutic agent in an outbreak situation is often difficult. For example, 
without sufficient clinical information about the disease during the early phase, and 
without well-established study protocols together with the obvious lag time required 
to set up new protocols [248], many factors contribute to lost opportunities to test 
interventions and management strategies before the disease outbreak comes under 
control. We were careful to ensure the MgSO4 trial design was ethically and 
scientifically robust, especially in terms of safety, intending to test this novel treatment 
option during the massive outbreak of highly contagious HFMD, which impacted 
millions of young children. The trial was approved by local, national and institutional 
Ethical Boards, but it took time to obtain these approvals. With detailed operating 
procedures and good compliance from all study team members the trial was 
conducted well, but patient recruitment was low since disease incidence had 
decreased considerably by the time the trial started. Although the study termination 
was disappointing, the experience of developing and setting up the trial was very 
valuable for me and other staff, and there is now a solid foundation including the study 
protocol, standard operating procedures, and some preliminary data that is available 
for use in the future, whether in Vietnam or neighboring countries in the event of 
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another outbreak of HFMD. Alternatively, a modified form of this trial could be re-
started quite quickly in the future. 
For now, we still have a need for alternative medications that can control hypertension 
associated with HFMD when conventional medicines such as milrinone are not 
effective [147, 249]. In such circumstances MgSO4 could still be considered as 
alternative second line therapy. Given its low price, good safety profile, and ease of 
availability [171, 250, 251], the question of whether MgSO4 could still be optimized as 
first line therapy remains an important one, and if further outbreaks do occur in the 
region then a new trial should be considered and ideally implemented quickly.  
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Appendices 
Part A: Magnesium RCT Definitions, Criteria and other information 
Appendix A.1: Definitions for hypertension in the study population 
Hypertension in Children 
The following definitions for hypertension in children are taken from the 2004 (US) 
national high blood pressure education program working group (NHBPEP) [147]. All 
percentiles refer to the relevant value for age, gender and length. 
Normal BP — both systolic and diastolic BP <90th percentile  
Prehypertension — systolic and/or diastolic BP ≥ 90th percentile but <95th 
percentile or if BP exceeds 120/80 mmHg (even if <90th percentile). 
Hypertension:  
o Stage 1 HTN — systolic and/or diastolic BP between the 95th percentile and 5 
mmHg above the 99th percentile. 
o Stage 2 HTN — systolic and/or diastolic BP > 99th percentile plus 5 mmHg. 
o Hypertensive emergency: A severe symptomatic elevation in BP (> 30% 
compared to baseline blood pressure) WITH evidence of acute target organ 
damage defines a hypertensive emergency 
 Brain (seizures, increased intracranial pressure) 
 Kidneys (renal insufficiency)  
 Eyes (papilledema, retinal hemorrhages, exudates) 
 Heart (heart failure) 
Hypertension in infants (6-12 months) [249]:  
Because there are no normative data that describe 95th percentile BP values for 
infants less than one year of age, and the blood pressure is almost unchanged in 
infants from 6 months to 12 months, the following thresholds will be used to identify 
hypertension in infants: 
o An invasive blood pressure measurement of >100/60 will be taken as indicating 
Stage 1 hypertension. (An oscillometric awake BP of > 100/60 is accepted as the 
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level at which follow-up BP monitoring and an evaluation for an underlying 
cause for elevated BP is usually recommended). 
o An invasive blood pressure measurement that is persistently ≥ 110/65 will be 
considered as Stage 2 hypertension. (Treatment is generally initiated for BP 
persistently ≥ 110/65, or sooner if left ventricular hypertrophy is present) 
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BP Levels for Girls by Age and Height Percentile 
Age 
(year) 
BP 
 Percentile 
  SBP, mm Hg    DBP, mm Hg  
  Percentile of Height    Percentile of Height 
5th 10th 25th 50th 75th 90th 95th  5th 10th 25th 50th 75th 90th 95th 
1 50t
h 
83 84 85 86 88 89 90  38 39 39 40 41 41 42 
 90t
h 
97 97 98 100 101 102 103  52 53 53 54 55 55 56 
 95t
h 
100 101 102 104 105 106 107  56 57 57 58 59 59 60 
 99t
h 
108 108 109 111 112 113 114  64 64 65 65 66 67 67 
2 50t
h 
85 85 87 88 89 91 91  43 44 44 45 46 46 47 
 90t
h 
98 99 100 101 103 104 105  57 58 58 59 60 61 61 
 95t
h 
102 103 104 105 107 108 109  61 62 62 63 64 65 65 
 99t
h 
109 110 111 112 114 115 116  69 69 70 70 71 72 72 
3 50t
h 
86 87 88 89 91 92 93  47 48 48 49 50 50 51 
 90t
h 
100 100 102 103 104 106 106  61 62 62 63 64 64 65 
 95t
h 
104 104 105 107 108 109 110  65 66 66 67 68 68 69 
 99t
h 
111 111 113 114 115 116 117  73 73 74 74 75 76 76 
4 50t
h 
88 88 90 91 92 94 94  50 50 51 52 52 53 54 
 90t
h 
101 102 103 104 106 107 108  64 64 65 66 67 67 68 
 95t
h 
105 106 107 108 110 111 112  68 68 69 70 71 71 72 
 99t
h 
112 113 114 115 117 118 119  76 76 76 77 78 79 79 
5 50t
h 
89 90 91 93 94 95 96  52 53 53 54 55 55 56 
 90t
h 
103 103 105 106 107 109 109  66 67 67 68 69 69 70 
 95t
h 
107 107 108 110 111 112 113  70 71 71 72 73 73 74 
 99t
h 
114 114 116 117 118 120 120  78 78 79 79 80 81 81 
6 50t
h 
91 92 93 94 96 97 98  54 54 55 56 56 57 58 
 90t
h 
104 105 106 108 109 110 111  68 68 69 70 70 71 72 
 95t
h 
108 109 110 111 113 114 115  72 72 73 74 74 75 76 
 99t
h 
115 116 117 119 120 121 122  80 80 80 81 82 83 83 
7 50t
h 
93 93 95 96 97 99 99  55 56 56 57 58 58 59 
 90t
h 
106 107 108 109 111 112 113  69 70 70 71 72 72 73 
 95t
h 
110 111 112 113 115 116 116  73 74 74 75 76 76 77 
 99t
h 
117 118 119 120 122 123 124  81 81 82 82 83 84 84 
8 50t
h 
95 95 96 98 99 100 101  57 57 57 58 59 60 60 
 90t
h 
108 109 110 111 113 114 114  71 71 71 72 73 74 74 
 95t
h 
112 112 114 115 116 118 118  75 75 75 76 77 78 78 
 99t
h 
119 120 121 122 123 125 125  82 82 83 83 84 85 86 
9 50t
h 
96 97 98 100 101 102 103  58 58 58 59 60 61 61 
 90t
h 
110 110 112 113 114 116 116  72 72 72 73 74 75 75 
 95t
h 
114 114 115 117 118 119 120  76 76 76 77 78 79 79 
 99t
h 
121 121 123 124 125 127 127  83 83 84 84 85 86 87 
10 50t
h 
98 99 100 102 103 104 105  59 59 59 60 61 62 62 
 90t
h 
112 112 114 115 116 118 118  73 73 73 74 75 76 76 
 95t
h 
116 116 117 119 120 121 122  77 77 77 78 79 80 80 
 99t
h 
123 123 125 126 127 129 129  84 84 85 86 86 87 88 
11 50t
h 
100 101 102 103 105 106 107  60 60 60 61 62 63 63 
 90t
h 
114 114 116 117 118 119 120  74 74 74 75 76 77 77 
 95t
h 
118 118 119 121 122 123 124  78 78 78 79 80 81 81 
 99t
h 
125 125 126 128 129 130 131  85 85 86 87 87 88 89 
12 50t
h 
102 103 104 105 107 108 109  61 61 61 62 63 64 64 
 90t
h 
116 116 117 119 120 121 122  75 75 75 76 77 78 78 
 95t
h 
119 120 121 123 124 125 126  79 79 79 80 81 82 82 
 99t
h 
127 127 128 130 131 132 133  86 86 87 88 88 89 90 
13 50t
h 
104 105 106 107 109 110 110  62 62 62 63 64 65 65 
 90t
h 
117 118 119 121 122 123 124  76 76 76 77 78 79 79 
 95t
h 
121 122 123 124 126 127 128  80 80 80 81 82 83 83 
 99t
h 
128 129 130 132 133 134 135  87 87 88 89 89 90 91 
14 50t
h 
106 106 107 109 110 111 112  63 63 63 64 65 66 66 
 90t
h 
119 120 121 122 124 125 125  77 77 77 78 79 80 80 
 95t
h 
123 123 125 126 127 129 129  81 81 81 82 83 84 84 
 99t
h 
130 131 132 133 135 136 136  88 88 89 90 90 91 92 
15 50t
h 
107 108 109 110 111 113 113  64 64 64 65 66 67 67 
 90t
h 
120 121 122 123 125 126 127  78 78 78 79 80 81 81 
 95t
h 
124 125 126 127 129 130 131  82 82 82 83 84 85 85 
 99t
h 
131 132 133 134 136 137 138  89 89 90 91 91 92 93 
16 50t
h 
108 108 110 111 112 114 114  64 64 65 66 66 67 68 
 90t
h 
121 122 123 124 126 127 128  78 78 79 80 81 81 82 
 95t
h 
125 126 127 128 130 131 132  82 82 83 84 85 85 86 
 99t
h 
132 133 134 135 137 138 139  90 90 90 91 92 93 93 
17 50t
h 
108 109 110 111 113 114 115  64 65 65 66 67 67 68 
 90t
h 
122 122 123 125 126 127 128  78 79 79 80 81 81 82 
 95t
h 
125 126 127 129 130 131 132  82 83 83 84 85 85 86 
 99t
h 
133 133 134 136 137 138 139  90 90 91 91 92 93 93 
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BP Levels for Boys by Age and Height Percentile  
Age 
(yea
r) 
BP Percentile   SBP, mm Hg    DBP, mm Hg  
   Percentile of Height    Percentile of Height 
 5th 10th 25th 50th 75th 90th 95th  5th 10th 25th 50th 75th 90th 95th 
1 50th 80 81 83 85 87 88 89  34 35 36 37 38 39 39 
 90th 94 95 97 99 100 102 103  49 50 51 52 53 53 54 
 95th 98 99 101 103 104 106 106  54 54 55 56 57 58 58 
 99th 105 106 108 110 112 113 114  61 62 63 64 65 66 66 
2 50th 84 85 87 88 90 92 92  39 40 41 42 43 44 44 
 90th 97 99 100 102 104 105 106  54 55 56 57 58 58 59 
 95th 101 102 104 106 108 109 110  59 59 60 61 62 63 63 
 99th 109 110 111 113 115 117 117  66 67 68 69 70 71 71 
3 50th 86 87 89 91 93 94 95  44 44 45 46 47 48 48 
 90th 100 101 103 105 107 108 109  59 59 60 61 62 63 63 
 95th 104 105 107 109 110 112 113  63 63 64 65 66 67 67 
 99th 111 112 114 116 118 119 120  71 71 72 73 74 75 75 
4 50th 88 89 91 93 95 96 97  47 48 49 50 51 51 52 
 90th 102 103 105 107 109 110 111  62 63 64 65 66 66 67 
 95th 106 107 109 111 112 114 115  66 67 68 69 70 71 71 
 99th 113 114 116 118 120 121 122  74 75 76 77 78 78 79 
5 50th 90 91 93 95 96 98 98  50 51 52 53 54 55 55 
 90th 104 105 106 108 110 111 112  65 66 67 68 69 69 70 
 95th 108 109 110 112 114 115 116  69 70 71 72 73 74 74 
 99th 115 116 118 120 121 123 123  77 78 79 80 81 81 82 
6 50th 91 92 94 96 98 99 100  53 53 54 55 56 57 57 
 90th 105 106 108 110 111 113 113  68 68 69 70 71 72 72 
 95th 109 110 112 114 115 117 117  72 72 73 74 75 76 76 
 99th 116 117 119 121 123 124 125  80 80 81 82 83 84 84 
7 50th 92 94 95 97 99 100 101  55 55 56 57 58 59 59 
 90th 106 107 109 111 113 114 115  70 70 71 72 73 74 74 
 95th 110 111 113 115 117 118 119  74 74 75 76 77 78 78 
 99th 117 118 120 122 124 125 126  82 82 83 84 85 86 86 
8 50th 94 95 97 99 100 102 102  56 57 58 59 60 60 61 
 90th 107 109 110 112 114 115 116  71 72 72 73 74 75 76 
 95th 111 112 114 116 118 119 120  75 76 77 78 79 79 80 
 99th 119 120 122 123 125 127 127  83 84 85 86 87 87 88 
9 50th 95 96 98 100 102 103 104  57 58 59 60 61 61 62 
 90th 109 110 112 114 115 117 118  72 73 74 75 76 76 77 
 95th 113 114 116 118 119 121 121  76 77 78 79 80 81 81 
 99th 120 121 123 125 127 128 129  84 85 86 87 88 88 89 
10 50th 97 98 100 102 103 105 106  58 59 60 61 61 62 63 
 90th 111 112 114 115 117 119 119  73 73 74 75 76 77 78 
 95th 115 116 117 119 121 122 123  77 78 79 80 81 81 82 
 99th 122 123 125 127 128 130 130  85 86 86 88 88 89 90 
11 50th 99 100 102 104 105 107 107  59 59 60 61 62 63 63 
 90th 113 114 115 117 119 120 121  74 74 75 76 77 78 78 
 95th 117 118 119 121 123 124 125  78 78 79 80 81 82 82 
 99th 124 125 127 129 130 132 132  86 86 87 88 89 90 90 
12 50th 101 102 104 106 108 109 110  59 60 61 62 63 63 64 
 90th 115 116 118 120 121 123 123  74 75 75 76 77 78 79 
 95th 119 120 122 123 125 127 127  78 79 80 81 82 82 83 
 99th 126 127 129 131 133 134 135  86 87 88 89 90 90 91 
13 50th 104 105 106 108 110 111 112  60 60 61 62 63 64 64 
 90th 117 118 120 122 124 125 126  75 75 76 77 78 79 79 
 95th 121 122 124 126 128 129 130  79 79 80 81 82 83 83 
 99th 128 130 131 133 135 136 137  87 87 88 89 90 91 91 
14 50th 106 107 109 111 113 114 115  60 61 62 63 64 65 65 
 90th 120 121 123 125 126 128 128  75 76 77 78 79 79 80 
 95th 124 125 127 128 130 132 132  80 80 81 82 83 84 84 
 99th 131 132 134 136 138 139 140  87 88 89 90 91 92 92 
15 50th 109 110 112 113 115 117 117  61 62 63 64 65 66 66 
 90th 122 124 125 127 129 130 131  76 77 78 79 80 80 81 
 95th 126 127 129 131 133 134 135  81 81 82 83 84 85 85 
 99th 134 135 136 138 140 142 142  88 89 90 91 92 93 93 
16 50th 111 112 114 116 118 119 120  63 63 64 65 66 67 67 
 90th 125 126 128 130 131 133 134  78 78 79 80 81 82 82 
 95th 129 130 132 134 135 137 137  82 83 83 84 85 86 87 
 99th 136 137 139 141 143 144 145  90 90 91 92 93 94 94 
17 50th 114 115 116 118 120 121 122  65 66 66 67 68 69 70 
 90th 127 128 130 132 134 135 136  80 80 81 82 83 84 84 
 95th 131 132 134 136 138 139 140  84 85 86 87 87 88 89 
 99th 139 140 141 143 145 146 147  92 93 93 94 95 96 97 
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Appendix A.2: Inclusion and exclusion criteria 
1. Inclusion criteria  
 Age 6 months to 15 years 
 Clinical suspicion of HFMD requiring PICU/HDU admission 
 Considered severe enough to warrant invasive blood pressure monitoring by 
PICU/HDU staff 
 Development of hypertension defined as follows:  
 For children aged 1 year and over, at least 3 consecutive systolic blood 
pressure recordings above the 95th centile for age, gender and length (USA 
guidelines for defining Stage 1 hypertension in children, (Appendix A.1)) 
measured invasively over a period of 20 minutes provided the child is not 
distressed or crying [252, 253].  
 For children aged 6 months to 1 year, systolic BP > 100 mm Hg measured 
invasively on at least 3 occasions over a period for 20 minutes provided the 
child is not distressed or crying 
 Plus one or more of the following criteria: 
 Tachypnoea for age  
 Irregular or labored breathing, but with SpO2 above 92% in air and normal 
ABG (pH, pCO2, pO2, HCO3 all within the normal range for the local 
laboratory) 
 Resting heart rate > 150 bpm 
 Mottled skin 
 Profuse sweating 
 Refractory fever  
 Hyperglycemia 
 Informed consent 
2. Exclusion criteria  
 Past history of hypertension, chronic renal, cardiac or pulmonary disease, or 
any neurological disorder 
 Hypertensive emergency 
 Already commenced milrinone or any other inotropic agents 
 Respiratory distress with SpO2<92% in air or PaCO2>45 mm Hg 
 AV block or any arrhythmia 
 Acute renal failure 
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Appendix A.3: Treatment failure criteria 
1. Criteria for discontinuation of study treatment 
If any of the following occur the study treatment will be stopped immediately and 
rescue treatment given as appropriate (Appendix B.3). 
 Serious cardiac arrhythmia (eg atrio-ventricular block, prolonged QT interval) 
 Hypotension: SBP < 70 + (2 X age) mmHg for 15 minutes or more 
 Urine output < 1ml/kg/hr for 4 hours or more  
 Cardiac arrest or any other emergency situation where the treating physician feels 
there is a contra-indication to the study drug.  
In addition, if a patient develops respiratory distress (as defined in Appendix B.3) an 
urgent plasma Mg level will be performed. If intubation and ventilation is needed, or if 
the Mg level is > 3 mmol/L, the study treatment will be stopped and rescue treatment 
will be given as described in Appendix B.3.  
2. Criteria for addition of milrinone  
The study drug will be continued for 72 hours as described in the protocol, unless one of 
the criteria for discontinuation indicated above occurs. Milrinone will be commenced in 
the following circumstances in accordance with the VN MOH guidelines. 
 Hypertensive emergency (Appendix A.1) 
 SBP fails to decrease by 25% over the first 8 hours after enrolment despite maximum 
MgSO4 maintenance infusion  
 For children aged 1 year and over: 
 SBP increases to > 99th percentile plus between 5 -15 mm Hg consistently for 30 
minutes  
 SBP increases to > 99th percentile plus 15 mm Hg consistently for 15 minutes 
 SBP increases to ≥ 40 mm Hg over baseline for 15 minutes, if this value is lower 
than either of the first two cutoffs. The baseline systolic blood pressure is 
defined as the lowest value measured at any time after admission to hospital 
before enrolment in the study. 
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 For children aged 6 months to 1 years: 
 SBP increases to ≥110 mm Hg up to to 120 mmHg consistently for 30 minutes  
 SBP increases to ≥ 120 mm Hg consistently for 15 minutes  
 SBP increases to ≥ 40 mm Hg over baseline for 15 minutes, if this value is lower 
than either of the first two cutoffs. The baseline systolic blood pressure is 
defined as the lowest value measured at any time after admission to hospital 
before enrolment in the study. 
Occasionally the clinical status of a patient may indicate that milrinone is not the best 
inotrope to use – in these cases the treating physician will make management 
decisions appropriate to the situation.  
If the patient’s clinical status remains unstable after starting milrinone additional 
measures including ventilation and/or haemofiltration will be considered in 
accordance with VN MOH guidelines for management of HFMD. If the blood pressure 
remains high (SBP > 99th percentile plus >15 mm Hg) despite maximal doses of 
milrinone and study drug infusion then additional antihypertensive agents may be 
added – e.g. nicardipine, captopril etc. depending on the clinical scenario. 
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Appendix A.4:  Additional study definitions 
Autonomic nervous system (ANS) dysregulation: At least 2 of the following features: 
heart rate of 150-170 beats/min, systolic blood pressure variability with absolute 
values higher than the 95th percentile for age, gender and height, profuse sweating, 
mottled skin, respiratory abnormalities, and hyperglycemia.  
For RCT we will use the following definitions for the inclusion/exclusion criteria: 
Tachypnea: respiratory rate 
 6 – 12 months: ≥50  
 13 – 72 months: ≥40 
 6 – 12 years: ≥ 30 
 13 – 15 years: ≥25 
Refractory Fever: Core temperature > 40oC for at least 4 hours despite antipyretics 
Hyperglycemia: >150 mg/dl (8.3 mmol/l) on a random test [254], or >126 mg/dl (7 
mmol/l) on a fasting test (at least 4 hours after feeding).  
Respiratory distress: if the patient has any one of the following findings: 
 Tachypnea    
 Irregular breathing  
 Wheeze  
 Stridor    
 Cheyne-Stokes breathing    
 Gasp 
 Apnoeic episodes 
Cardiac arrhythmia:  
 Sinus tachycardia is not an exclusion criterion, but any other cardiac arrhythmia 
is, including AV block (Grades I-III) or QT prolonged >0.48 ms 
Acute Renal failure: 
 Serum creatinine > 2mg/dl (176 μmol/l) or urine output < 1ml/kg/hr for 4 hours 
or more 
Prolongation of existing hospitalization: duration of hospitalization > 14 days 
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Appendix A.5: Definition of other variables:  
All variables in the following tables are classified, as binary category and their value are Yes/No 
Variables  Definition  
Heart Rate (bpm) For analysis: the absolute value will be used. Heart rate will be 
justified 10bmp per 1oC above 37oC 
Tachycardia  For inclusion criteria: Any of heart rate > 150 bmp (after justify 
10bmp per 1oC above 37oC 
Shock SBP < 70+ 2n and/or requirement of fluid resuscitation and/or 
vasopressor medicines 
Irregular breathing Irregular pattern of breathing 
Stridor Abnormal inspiration sound 
Wheezing Low respiratory rales during the expiration 
Cheyne-Stoke Irregular breathing with short apnea period (<15s) 
Apnea breathing Apnea lasting over 15 seconds  
Drowsiness GCS <15 or stupor or Legarthy manifestation 
Witnessed myoclonic jerk  A jerk recorded by doctor 
Cerebellar signs Presented any of the following signs: limb tremor, nystasmus, 
ataxia 
Paralysis    Any cranial nerves paralysis or limb paralysis that is assessed on 
discharge 
Brainstem encephalitis Clinical HFMD and present of myoclonus and/or ataxia and/or 
nystagmus and/or oculomotor palsies, and/or bulbar palsy 
and/or brainstems abnormality in MRI and/or abnormal 
respiratory pattern (irregular breathing, labor breathing and 
severe respiratory breathing) 
Pulmonary edema Respiratory distress and tachycardia and tachypnea and/or rales 
and pink frothy secretion and bilateral pulmonary infiltrates 
without cardiomegaly in chest radiograph 
Death Both death or moribund 
Neurological sequelae at 
discharge 
Any neurological sequels still exist at discharge 
Bailey score*  Scales of Toddler and Infant Development III assessed cognitive, 
language and motor functions at discharge and 6 months later in 
cohort.  
*Bayley scores derive: each aspect will be analysed and interpreted separately. The Z-scores of 
each aspect will be calculated by comparing the patient’s score and the mean and standard 
deviation of the score from healthy children who matched by age, sex, maternal education 
level, and stunting status. Analysis using derived z-scores will also be adjusted for 
socioeconomic status of the mother and gender of the child. 
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Appendix A.6: Magnesium sulfate background information 
Pharmacology: 
Magnesium is important as a cofactor in many enzymatic reactions in the body. There 
are at least 300 enzymes that are dependent upon magnesium for normal functioning. 
Actions on lipoprotein lipase have been found to be important in reducing serum 
cholesterol. Magnesium is necessary for the maintaining of serum potassium and 
calcium levels due to its effect on the renal tubule. In the heart, magnesium acts as a 
calcium channel blocker. It also activates sodium potassium ATPase in the cell 
membrane to promote resting polarization and produce arrhythmias. Magnesium 
prevents premature labor by inhibiting myometrium contractions. In the CNS, 
magnesium prevents or controls seizures by blocking neuromuscular transmission and 
decreasing the amount of acetylcholine liberated at the end-plate by the motor nerve 
impulse. It also has a depressant effect on the CNS. 
Safety in clinical practice 
Although there are few formal research studies in young children magnesium sulphate 
is generally considered to be safe, even in neonates. A randomised trial that compared 
magnesium sulphate with placebo for women with pre-eclampsia found that exposure 
to MgSO4 during labor did not effect long term morbidity or mortality among the 827 
children involved in the study; neonatal outcomes were similar in the MgSO4 and 
control patients[255]. In a Cochrane review of four studies using MgSO4 for persistent 
pulmonary hypertension of the newborn (loading dose of 200 mg/kg MgSO4, followed 
by a continuous infusion of 20 to 150 mg/kg/hour lasting for 72 hours), among 40 term 
infants treated, no adverse events were reported except for transient bradycardia 
responsive to dobutamine in one of the studies. [256]. Finally, in a meta-analysis of 5 
randomised controlled trials assessing use of intravenous MgSO4 for treating acute 
asthma (182 children, doses ranging from 25 mg/kg to 75 mg/kg), the treatment was 
well tolerated and only minor side effects were reported, such as epigastric or facial 
warmth, flushing, pain and numbness at infusion site, dry mouth, and malaise [222]. 
Dosage: 
In a randomized trial in neonates focused on management of pulmonary hypertension 
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the following doses were used: A loading dose of 200 mg/kg MgSO4 diluted to 10% in 
sterile water was given intravenously over 20 minutes, followed by a continuous 
infusion of 20 to 150 mg/kg/hour lasting 72 hours, aiming to obtain a concentration of 
serum magnesium from 3.5 to 5.5 mmol/l [257] 
In a randomized trial in adults with severe tetanus: A loading dose of 2g/hour MgSO4 
diluted to 10% in sterile water was given intravenously over 30 minutes, followed by a 
continuous infusion of 40 mg/kg/hour, lasting up to 7 days, aiming for serum 
magnesium levels of 2 to 4 mmol/l [171] 
In severe exacerbations of asthma the following regimen is recommended by the Royal 
Children’s Hospital in Melbourne: A loading dose of 50 mg/kg MgSO4 diluted to 10% in 
sterile water given intravenously over 20 minutes, followed by a continuous infusion of 
30 mg/kg/hour lasting 24 -48 hours [258] 
Side effects [233, 259]:  
Adverse effects with magnesium therapy are primarily related to the serum 
magnesium level. The approximate relation between clinical manifestations and the 
degree of hypermagnesemia can be summarized as follows: 
 Plasma Mg concentration > 1.25 mmol/l – impaired peripheral neuromuscular 
transmission leading to anticonvulsant effects  
 Plasma Mg concentration 2 to 3 mmol/L – nausea, flushing, headache, lethargy, 
drowsiness, and diminished deep tendon reflexes. 
 Plasma Mg concentration 3 to 5 mmol/L – somnolence, hypocalcemia, absent 
deep tendon reflexes, hypotension, bradycardia, and ECG changes. 
 Plasma Mg concentration above 5 mmol/L – muscle paralysis, respiratory 
paralysis, complete heart block, and cardiac arrest. In most cases, respiratory 
failure precedes cardiac collapse. 
Other recognised effects include: 
1. Cardiovascular: Although a Mg level > 5 mmol/l may precipitate cardiac 
arrhythmias, magnesium is also used as a treatment for certain rhythm 
disturbances – such as irregular/polymorphic VT with normal baseline QT interval 
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2. Gastrointestinal: Abdominal cramps, diarrhea, gas formation 
Dosing adjustment in renal impairment:  
Patients in severe renal failure (creatinine clearance below 10ml/minute) should not 
receive magnesium due to toxicity as a result of accumulation. Patients with a 
creatinine clearance of <25 mL/minute receiving magnesium should have serum 
magnesium levels carefully monitored. 
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Appendix A.7: Suggested indications for specific interventions following Vietnamese 
MoH guidelines 
Ventilation criteria:  
 If a patient continues to display any of the following criteria despite 
oxygenation via nasal cannula and cardiac support with inotropic drugs for 
more than 60 minutes.  
o Labored breathing 
o Tachypnea with resting respiratory rate > 70 / minute without fever 
o Hypoxemia and/or fluctuating SpO2  
o Poor tissue perfusion and persistent resting HR > 180 beats/minute 
without fever  
 Or  
o Decorticate or decerebrate rigidity  
o Coma (GCS < 10 ) 
 
Hemofiltration indication criteria: 
 Acute renal failure and one of the following: 
o Severe respiratory distress: Ventilation with FiO2 > 60%, inspiratory 
pressure > 25 cmH2O and PEEP > 10 cm H2O 
o Unstable hemodynamic status despite intensive resuscitation for 3 
hours 
o Coagulopathy (INR> 1,5) 
o Acute hepatic failure 
o GCS < 10 
Or  
 Ventilated patients with one or more of the following 
o Coma and refractory fever  
o Coma and refractory shock (shock status not improved after two hours 
of intensive resuscitation)  
o Heart failure or a positive Troponin I  
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Appendix A.8: Study schedule for all planned investigation 
 Screenin
g 
Enrolmenta   / D 1 
D1 
D 2 D 3 D 4 D 5+ Discharge Disch 
+7 
M6 
Hour from admission T-x T-1 T(-1/2) T0 T12 T24 T48 T72 T96+    
Clinical activities 
Screening assessment             
Informed consent             
History and physical assessment             
Randomization assign and study drug 
preparation 
            
Study drug administration             
Patient assessment         b c (c) c 
Recording/ downloading hemodynamic data  d d d/e d/e d/e d/e d/e     
Research blood test 
Chemistries  0.5 ml  1.5 ml 1 ml 2 ml 2 ml 2 ml     
Specialized additional research blood test 
Serum catecholamine    2 ml  2 ml 2ml 2 ml     
Cytokine profile    1 ml 1 ml 1 ml    1 ml   
Serology 1 ml         1 ml  
Research procedures 
ECG recordingf             
Arterial catheterization             
Blood draw             
Diagnosis swabs             
Additional procedure 
Brain MRI         Just in stable 
conditiong 
  
Urine-Research Laboratory 
Urine Catecholamine             
Total amount of blood 1 ml 7 ml 
13 ml 
5 ml 4 ml 4 ml  2 ml  
Note that additional clinical investigation will be performed as necessary as indication 
Note:   a- Enrollment stage should be done as fast as possible: 30 munite to take informed consent and check exclusion criteria, 30 minutes for drug administration. 
          b- Clinical assessment still be carry out daily until discharge 
            c- Neurological outcome and development will be assessed in this stage. Patients unable to be assessed at discharge will be invited to attend for assessment after 7 day. 
            d- Standard hemodynamic data will be recording/downloading and stored in PC 
            e- Advance hemodynamic data will be downloading from LiDCOrapid and stored in PC 
   f- Standard ECG recording will be performed daily and whenever an abnormality is noted on the monitor  
 g- indicated for 08RS stu
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Appendix A.9: Definitions for laboratory abnormalities  
A laboratory abnormality is one that was: 1) not present at baseline, or 2) was present at baseline and has now worsened; 3) was present at baseline, 
improved for >24 hours, and has now recurred,  If the value varies during any 24 hour period, the worst grade abnormality will be recorded. 
 Grade 1 Grade 2 Grade 3 Grade 4 Grade 5 
Acidosis pH <7.37, but >=7.3 - pH <7.3 
Life-threatening 
consequences 
Death 
Alkalosis 
pH >7.45, but <=7.5 - pH >7.5 
Life-threatening 
consequences 
Death 
Hemoglobin (Hgb) 
 
6months-2yrs: 10.0 - <10.5 g/dl 
>2 yrs: 10.0 - < 11.5 g/dL 
<10.0 - 8.0 g/dL <8.0 g/dL 
Life-threatening 
consequences urgent 
intervention indicated 
Death 
Platelet count decreased <LLN - 75,000/mm3 <75,000 - 50,000/mm3 50,000 - 25,000/mm3 < 25,000/mm3 - 
Cardiac Troponin I increased* 
 
>ULN - 2.5 x ULN >2.5 x ULN - 5 x ULN >5 x ULN - 10 x ULN > 10 x ULN - 
   Before 11Mar2015: ULN: 0.3 
ng/l 
 
> 0.3 - 0.75 > 0.75 - 1.5 >1.5 - 3 > 3  
  From 11Mar2015: ULN: 15.6 
(female), 34.2  (male) pg/l 
>15.6 – 39 (female); 34.2-85.5 
(male) 
> 39– 78 (female); 85.5-171 
(male) 
>79– 156 (female); 171 -
342 (male) 
>156 (female); 342 (male)  
CK-MB 
ULN: 24 UI/l 
>ULN - 2.5 x ULN 
(> 24- 60) 
>2.5 x ULN - 5 x ULN 
(> 60-120) 
>5 x ULN - 10 x ULN 
(>120 – 240) 
> 10 x ULN 
(>240) 
- 
Creatinine increased 
ULN: <4yr : 42.2, / 4-10yr : 
52.2 /  >10-14 yr: 77.8 umol/l 
>ULN -1.5 x ULN >1.5 - 3.0 x ULN >3.0 - 6.0 x ULN >6.0 x ULN - 
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Hyponatremia 
LLN: 135 mmol/l 
<135 - 130 mmol/L - <130 - 120 mmol/L <120 mmol/L Death 
Hypernatremia 
ULN: 145 mmol/l 
>145 - 150 mmol/L >150 - 155 mmol/L >155 - 160 mmol/L >160 mmol/L Death 
Hyperkalemia 
 
>5 - 5.5 mmol/L >5.5 - 6.0 mmol/L >6.0 - 7.0 mmol/L >7.0 mmol/L Death 
Hypokalemia 
 
<3.5 - 3.0 mmol/L - <3.0 - 2.5 mmol/L <2.5 mmol/L Death 
Hypermagnesemia >1 -1.23 mmol/L ->1.23 – 2.5 mmol/L >2.5 – 3.3 mmol/L >3.30 mmol/L Death 
Hypocalcemia: ULN: 2.2 
mmol/l 
(~ Ionized calcium: 1.1) 
Serum calcium of <2.2 - 2 mmol/L 
or 
Ionized calcium of <1.1 - 1 mmol/l 
Serum calcium of <2.0 - 1.8 
mmol/L 
Ionized calcium of <1 - 0.9 
mmol/l 
Serum calcium of <1.8 - 1.5 
mmol/L or 
Ionized calcium of <0.9 - 0.75 
mmol/l 
Serum calcium of <1.5 
mmol/L or 
Ionized calcium of <0.75 
mmol/l 
Death 
Hypoglycemia <60 - 55 mg/dL or 
< 3.33 – 3.05 mmol/l 
<55 - 40 mg/dL or 
< 3.05 – 2.2 mmol/l 
<40 - 30 mg/dL or 
< 2.2 – 1.66 mmol/l 
<30 mg/dL or 
< 1.66 mmol/l 
Death 
Hyperglycemia: ULN: 120 
mg/dl  or 6.7 mmol/l 
Fasting glucose > 120 - 160 mg/dL 
or 
> 6.7  - 8.88 mmol/l 
Fasting glucose >160 - 250 
mg/dL or > 8.88 – 13.88 
mmol/l 
Fasting glucose >250 - 500 
mg/dL or > 13.88 – 27.8 
mmol/l 
Fasting glucose >500 mg/dL   
or 
> 27.8 mmol/l 
Death 
* Note change in lab procedures on 11th Mar 2015, with new normal ranges for Troponi
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Part B. Important Standard Operation Procedures (SOPs) 
Appendix B.1 Screening and enrolment 
PRE-SCREENING 
Identify potential study patients in PICU ->  
 Age 6 months to 15 years 
 Grade 2b and 3 HFMD (clinically suspected) and medical indication for invasive 
blood pressure (IBP) monitoring 
Open the Height Percentile Calculator on the desktop of the ward computer. Enter the 
sex, age (in months) and height of the child to calculate the height percentile. Choose 
the appropriate BP Label from the study binder according to gender, age, and height 
percentile. Have a different person DOUBLE CHECK all values and the chosen label. 
Stick the BP Label on inside cover of the patient’s hospital file. 
 If the software shows the percentile such as 15th or 85th, please choose the 
nearest but lower percentile. 
Provide Screening Number using the next available number from the Screening and 
Enrolment Log.  Complete the Screening & Enrolment Log as the steps below are 
performed  
Ensure that: 
 Arterial line/catheter is in place 
 Backup vein line is available beside the main line 
 Appropriate IBP monitoring system has been established 
 Standard laboratory tests (WBC, CRP, Creatinine) are being performed 
 Blood sugar level is recorded in the hospital observation chart every 6 (+/-2) 
hourly 
Explain study information to the parent/guardian and give them Informed Consent Form 
(ICF) to read. 
Connect the Nihon Kohden/Space Labs monitor to the LidCo rapid monitor - Refer to the 
Operating Monitors SOP. 
Study doctor will set up the alert at 95th percentile (from the BP Label) of SBP on Nihon 
Koden  
Go to menu screen, choose PRESS button. Set the alert to Emergency Signal. The 
monitor will alert if SBP meets the set warning levels 
 Remember to calibrate the monitor before taking readings 
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If patient discharges without developing hypertension as described below, complete the 
Screening & Enrolment Log up to the column on BP. 
SCREENING 
If patient develops hypertension - (Grade 1 = SBP above 95th percentile, Grade 2 = SBP 
above 99th percentile + 5) 
Verify the INCLUSION CRITERIA below with available observations. 
 Development of hypertension defined as follows:  
 For children aged 1 year and over, at least 3 consecutive systolic blood pressure 
recordings above the 95th centile for age, gender and length measured invasively 
over a period of 20 minutes provided the child is not distressed or crying. Note 
the three SPB reading on the hospital file. 
 For children aged 6 months to 1 year, systolic BP > 100 mm Hg measured 
invasively on at least 3 occasions over a period for 20 minutes provided the child 
is not distressed or crying. 
The thermo papers contained these readings will be printed out with signature, date of 
printing, and study number on them. One additional copy will be made followed the 
same procedure. 
 Plus one or more of the following criteria 
 Tachypnea for age 
 Irregular or labored breathing, but with SpO2 above 92% in air and normal ABG 
 Resting heart rate > 150 bpm 
 Mottled skin 
 Profuse sweating 
 Refractory fever  
 Hyperglycemia (>150 mg/dl on a random test, or >126 mg/dl on a fasting test (at 
least 4 hours after feeding)) 
Verify the following EXCLUSION CRITERIA with available observations. 
 Past history of hypertension, chronic renal, cardiac or pulmonary disease, or 
any neurological disorder 
 Hypertensive emergency 
 Already commenced milrinone or any other inotropic agents 
 Respiratory distress with SpO2<92% in air or PaCO2>45 mm Hg 
 AV block or any arrhythmia 
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 Acute renal failure: Creatinine> 2x upper normal range for age* or urine 
output <1ml/kg/hr for 4 hours    
  *UNR = >6<12 mth: 18 - 35 μ/L; >12 mth <12 yrs: 27 – 62 μ/L; >12 yrs: 44 – 88 
μ/L 
If the patient is excluded based on a permanent criteria (something that will not change) 
complete an SCR CRF form and the remaining information in the Screening & Enrolment 
Log. Stop all study related procedures. 
If the patient does not meet inclusion/exclusion criteria due to a clinical criterion that 
may change, continue to follow the patient and re-evaluate criteria regularly. 
If the patient meets all inclusion criteria and does not meet, any exclusion criteria based 
on available information (you may not have an ABG or ECG yet) approach the 
parent/guardian for informed consent. 
INFORMED CONSENT - Study staff will discuss the study with the accompanying 
parent/guardian. If both parents are dead or not actively involved in caring for the child, 
the main long-term carer for the child will be accepted as a guardian and considered 
able to give consent for the study.  
Study staff will describe the purpose, procedures, risks/benefits, rights, responsibilities 
of participants, and alternatives to enrolment. The parent/guardian will be invited to ask 
questions which will be answered by study staff.  
If the parent/guardian agrees for the child to participate, they will be asked to sign and 
date an informed consent form. A copy of the form will be given to them to keep.  
If the parent/guardian is illiterate, the Informed Consent Form will be read to them in 
the presence of a witness who will sign to confirm the parent/guardian’s understanding 
and acceptance.  
The study staff taking consent must also sign and date the ICF. The name of the 
parent/guardian and study staff (and witness if applicable) can be filled in by anyone. 
REFUSAL OF CONSENT - If parents/guardians refuse consent, complete the Screening & 
Enrolment Log and an SCR CRF. 
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AFTER CONSENT IS GIVEN - If an ABG was not done within the previous 120 minutes 
(and showed no abnormality. Otherwise, it needs to redo), take 0.5 ml of blood. Make 
sure results are available as soon as possible (within 30 minutes) and check results 
against inclusion criteria. (Please refer to Sampling SOP)  
If an ECG was not done within the previous 120 minutes, perform a bedside ECG. Check 
results against exclusion criteria. In very rare cases where it is unable to perform a full 
ECG due to the irritability of the child and the commencing time constraint, the study 
doctor will observe on the monitor and check against the exclusion criteria. A full ECG is 
required to perform as soon as possible at later.   
If Creatinine was not done within the previous 4 hours (and showed no abnormality. 
Otherwise, it needs to redo), it needs to perform and check against the inclusion criteria.  
IF THE CHILD IS NOT ELIGIBLE FOR THE STUDY - Inform the parents/guardians of the 
reason for exclusion. Complete the SCR CRF and the Screening and Enrolment Log up to 
the “Enroll” column. Place the SCR CRF in the Failed Screening section of the study 
binder. 
ENROLMENT* 
IF THE CHILD ENROLS TO THE STUDY - Print out the data stored on the HEMODYNAMIC 
PROFILE of each patient for the 2 hours preceding enrolment.  
Take the next sequential treatment pack from the study drug storage cabinet. Write the 
study number from the drug package on the Screening & Enrolment Log and complete 
the rest of the log. Write the study number on the SCR CRF. Place the SCR CRF into a full 
patient file. Write the patient name and weight on the study drug package. Complete the 
Delivery and Return Study Drug form. Give treatment as soon as possible – Refer to 
Medication SOP and Inpatient SOP. 
Take the T0 (Baseline) samples before the first dose of study drug if possible, including:  
1.5-2ml Li-Heparin to HTD Biochemistry lab (Electrolytes, Creatinin, CKMB, Troponin, 
Glycemia). Clinical doctor may decide on the necessity of repeating these tests in the 
case of a very recently available result. 
2 ml EDTA for catecholamine and 1 ml EDTA for serology and cytokine to OUCRU lab. 
Combined nasal/throat swab and rectal swab to. 
Stamp all HTD Lab Request Forms with the 02EI stamp. Refer to Sampling SOP. 
Complete the Patient Contact Sheet in the patient file. 
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Do a full clinical assessment as soon as possible and complete the DEMO, HIST and EXAM 
CRFs.  
 
*Make sure that the maximum time from development of hypertension to commencing study 
treatment is less than 30 mins for patients with Grade 2 hypertension and 60 mins for 
patients with Grade 1 hypertension. These times will be written on the SCR CRF (development) 
and the STUDRG CRF (treatment). 
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Appendix B.2   Sampling 
LABORATORY EQUIPMENT KIT PREPARATION 
Ensure all the blood and tubes and urines aliquot are prepared in advance in a zip lock 
with appropriate label assigned each day. (VTM container for swabs will be stored in 
the fridge) 
Those packages are kept in the study cabinet  
Tubes 
D1 D2 D3 D4 Disc 
Screening T0 T12 T24 T48 T72  
EDTA  1 2 1 2 1 1 1 
Li-Heparin 1  1 1 1 1  
Urinocol   1  1 1 1  
VTM  2      
Preservatives container 
1.5 l 
 1  1 1 1  
Urine-Aliquot 2ml    2 2 2  
The labels for each sample are kept in the study binder. 
BLOOD SAMPLING 
 To comply with the practice, all samples will be taken at 8am/8pm daily 
Ensure every time samples are taken these steps WILL be DONE: 
A label with appropriate randomized number and type of specimen will be stick on the 
every sample tube. Note on the label with time the sample is taken, and fill in the 
“Sample tracking form” 
Study nurse make sure all the necessary tests on the checklist will be ticked when 
performed. If not, remind the doctors immediately to give order. 
During screening (ABG and Blood sugar) 
0.5 ml arterial blood will be drawn from the consented patients for ABG. 
Put a drop of blood from the syringe to perform blood sugar measurement using 
standard ward equipment. 
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Slowly push the rest to the Li-Heparin tube 
Fill with “02EI screening number” on the Label and paste to the tube 
Send it directly to Biochemical Lab with 02EI stamped on the “Hospital indication form” 
as soon as possible by study staff (nurses and medical assistants) 
The Lab staff will receive sample and perform ABG as soon as possible 
The result will be uploaded directly to the Hospital’s network system 
The study doctor will check the result in the PICU computer  
In case the study staff can’t receive the result after 15 minutes, she/he will make a call 
to Lab, mention the screening number and patient name (extension number: 290) 
 If the hospital network system fails, the medical assistants will be waiting at lab 
to collect the result (approximately 10-15 minutes). The results will be informed 
to the study doctors at PICU ward (ext 226) via 02EI, or contact directly the 
study doctor’s hand phone. 
If the ABG has been performed within 120 minutes, it can be used for screening. 
At T0 (enrolment) 
Each enrolled patients will be test: 
 Hospital Lab: 1.5-2ml Li-Heparin for Biochemistry (Electrolytes-including Mg and 
Ca, Creatinin, CKMB, Troponin, Glycemia).  
 OUCRU Lab: 2 ml EDTA for catecholamine, 1 ml EDTA for serology and cytokine.   
*If FBC and CRP have not been done previously, make sure these test will be performed 
Within the first 24 hours, all patients will have blood taken at 8am and 8 pm (either 
one may be first depending on when they are enrolled). For the next 2 days, all 
patients will have an 8 am draw which will be the 48 and 72 hour draws. 
At T12 (if this draw comes less than 6 hour from the enrolment time, it will be 
delayed to the next nearest 8am/8pm draw)  
Ensure each patient will have blood taken on time regard to the enrolment time (+/- 30 
minutes). 
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 For hospital lab: 1 ml Li-Heparin for Biochemistry (Mg, Ca).  
 For OUCRU: 1 ml EDTA. 
 A drop of blood from the syringe will be put to perform blood sugar 
measurement using standard ward equipment. The result will be recorded in 
hospital file. 
 A request for Ca & Mg test will be separated from other forms. On the request 
for Ca &Mg should include MSMD contact with a stamps “Do Not upload this 
result”, and a red stamp “DO NOT RETURN THIS RESULT TO PICU”  
At T24 
Ensure each patient will have blood taken at 8 am, including: 
 For OUCRU: 2 ml EDTA for catecholamine, and 1 ml for cytokine will be taken  
 For hospital routine: 1.5-2ml Li-Heparin for Biochemistry (Electrolytes-including 
Mg and Ca, Creatinine, CKMB, Troponin, Glycemia) 
 A drop of blood from the syringe will be put to perform blood sugar 
measurement using standard ward equipment. The result will be recorded in 
hospital file. 
 A request for Ca & Mg test will be separated from other forms. On the request 
for Ca &Mg should include MSMD contact with a stamps “Do Not upload this 
result”, and a red stamp “DO NOT RETURN THIS RESULT TO PICU”  
At T48, T72 
 For OUCRU: 2 ml EDTA for catecholamine (at T48 ONLY) 
 For hospital routine: 1.5-2ml Li-Heparin for Biochemistry (Electrolytes-including 
Mg and Ca, Creatinine, CKMB, Troponin, Glycemia) 
 Put a drop of blood from the syringe to perform blood sugar measurement 
using standard ward equipment 
 A request for Ca & Mg test will be separated from other forms. On the request 
for Ca &Mg should include MSMD contact with a stamps “Do Not upload this 
result”, and a red stamp “DO NOT RETURN THIS RESULT TO PICU” 
At T96 
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 For OUCRU: 2 ml EDTA for catecholamine 
Sample handling during storage/transport/delivery 
For OUCRU sample 
 Fill in the OUCRU label for the sample 
 Store the samples in the fridge at 4 degree Celsius 
 02EI Study nurse or PICU medical assistant will collect all samples and 
deliver to the Biochemistry lab no later than 8am/8pm every. 
 Record the sample information into the “Specimen Tracking Log”. 
 Biochemistry lab technician will handle the samples within 30 minutes 
 Blood will be centrifuged at 3000 rpm for 5 minutes. 
Separate plasma and cell into different tubes: 1 tube for cytokine, 1 tube 
for serology, 1 tube for cells 
 Note the date on the provided label and stick to the aliquots. 
 Record the sample information into the “Specimen Tracking Log”. 
OUCRU lab will collect the aliquots together with “Specimen Tracking Log” every day. 
URINE SAMPLING 
During the study 
Urine will be taken at 6 am and sent to OUCRU Lab at 8 am everyday 
Equipment preparation: 
 Five 1.8 liters of urine collecting bottle contain 10 ml of 6M HCL (will be 
prepared in OUCRU Lab and send to the PICU in advance). 
 Aliquot 10 ml of 6N HCL solution and pour to five 1.5 liter bottles 
and store at OUCRU lab by Ms Duyen 
 Check pH every month to make sure the preservative solution is 
stable. If the pH changes, replace new solution in the prepared 
bottles. 
 Study nurse will maintain to ensure there are always five bottles 
available at PICU 
  Make sure to shake the bottle before using. 
Urine collection: 
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 Take one bottle and paste the label with correct time and put at bedside 
 Attach the urine collecting bag to the patients (Urinocol- B/Braun) 
 Make sure the study nurse will take the urine out of the collecting bag 
when it is nearly full. 
 Empty the urine bag to the sample urinal jug with measurement. 
 Measure the volume of urine at least every 4 hours and then pour the 
urine into the collecting bottle and shake regularly 
 Record the total volume at the end of the 24 hour period on the Nursing 
Chart 
 Take 2 aliquots of urine (1.5 ml), fill in the OUCRU label for the sample 
and “Sample Tracking Form” and then send to the OUCRU lab (EVI 
group) every day for storage at -70oC. 
Upon completing, study nurse will the collecting bottle and handing to the OUCRU to 
clean and reused.  
DIAGNOSTIC SPECIMENS 
After enrolment- The throat swab and a rectal swab for PCR diagnostics are taken. 
The study nurse will maintain and prepare the swabs when the count is low 
If the swabs: 
 Are taken before 4 pm 
 Fill in the OUCRU label for the sample 
 02EI Study nurse or PICU medical assistant will deliver OUCRU lab (EVI 
group). 
 EVI technician will handle the samples  
 Record the sample information into the “Specimen Tracking Log”. 
 Are taken after 4 pm 
 Fill in the OUCRU label and date for the sample 
 Store the samples in the PICU’s fridge at 4 degree 
 Record the sample information into the “Specimen Tracking Log”. 
The study nurse will deliver the sample to virology lab at 8 am (+/-2) next day (EVI 
group-lab staff will be in charge) in the morning every day. 
SAMPLING SCHEDULE 
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 D1 D2 D3 D4 D5 Disc 
Hour T0 T12 T24 T48 T72 T96  
B
ic
h
em
is
tr
y 
(L
i-
H
ep
ar
in
) 
Cre, Na, K, Cl, Ca&Mg( 
separated request form), 
TnI, CK-MB, Glucose: 1.5 ml 
     
 
 
Mg/Ca only: 1ml        
ABG (heparin): 0.5ml        
OUCRU 
3ml 
(EDTA) 
2ml for catecholamine        
1ml for cytokine      
 
 
Serology        
Urine output 5ml        
Diagnostic specimens (nasal/throat 
and rectal swabs) 
     
 
 
Amount of blood needed (ml) 5 ml 2 ml 5 ml 
4 
ml 
2 
ml 
2 ml 
2ml 
Total (day) 7 ml 5 ml 4 ml 2 ml  2ml 
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Appendix B.3 Medication 
Study doctor will set up the alert threshold of SBP on Nihon Koden  
1. Go to menu screen, choose PRESS button, set up the upper and lower range of SBP 
based on the BP label that is attached in the hospital file 
 A> If the patients enrolled at hypertension stage 1 (>95th percentile, <99th % 
+5), the upper alarm will be set at 99th percentile + 5 mmHg, the lower alarm 
will be set at 70 + 2*Age. 
 B> If the patients enrolled at hypertension stage 2 (>99th + 5 mmHg), the upper 
alarm will be set at 99th percentile + 15 mmHg, the lower alarm will be set at 70 
+ 2*Age. 
2. Set the alert to Emergency Signal. The monitor will alert if SBP meets the set warning 
levels  
Study doctor will write order in the hospital file (“Phiếu điều trị”): 
 Study drug: 45 ml 
 0.5 ml x weight (kg) infuse in 20 minutes 
 then infuse with 0.3 ml x weight (kg)/hr continuously.   
Dose will be adjusted according to clinical scenarios below and noted in hospital file as they 
occur. 
Prepare study drug as follows: 
 Mix 3 study drug vials (10 ml) and 15 ml NaCl 0.9% in a 50 ml syringe to obtain 45 ml of 
final preparation 
 Calculate the Loading Dose according to the patient’s weight 
Study drug Volume Infusion time Rate (ml/hr) 
Loading dose 0,5 ml x weight (kg)  20 minutes 0,5 x weight x 3 
 Set the rate of the infusion of the pump. 
 Start infusion and set pump alarm to alert after 20 minutes. 
(Prepare the calculation below before the 20 minute alarm alerts) 
 Calculate the Maintenance Dose according to the patient’s weight 
Study drug Rate (ml/hr) Infusion time 
Maintenance dose 
(continuous) 
0,3 ml x weight (kg) Up to 72 hours 
 
Study drug is constantly infused following the doctor’s order. The study nurse will write down 
in the hospital file (“Phiếu thực hiện thuốc”) and record any new dose on the “Nursing chart”. 
The study staff will monitor closely drug’s volume and prepare the new dose in advance when 
the remaining volume in the syringe is around 2 ml. 
 If the study bottle is broken, the study nurse will prepare the new final solution and 
note on the Drug Delivery and Returning form of number vial broke. 
DOSE ADJUSTMENT 
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In addition to the study scheduled blood pressure monitoring, study nurses will monitor the 
blood pressure each hour and during acute changes according to clinical care. The study doctor 
will be available at the bed side to decide the dose adjustment according to the following: 
 During the 72 hours  
  Dose adjustment 
SBP status Value  Without MSMD 
advices 
With MSMD advices* 
if SBP is 
decreasing 
> 90th and ≤95th 
percentiles 
No Change Increase: follow if not 
on maximum dose. 
Decrease: follow 
No change: follow 
≤ 90th percentile and ≥ 
70th percentile +2n 
Decrease 0.1 ml/kg 
for every 15 minutes 
 
Increase: don’t 
follow. 
Decrease: follow if 
not at the minimum 
dose (0.1 ml/kg) 
No change: don’t 
follow 
rapidly more than 25% 
over 15 minutes 
Decrease 0.1 ml/kg 
for every 15 minutes 
Increase: don’t 
follow. 
Decrease: follow 
No change: don’t 
follow 
but fails to decrease by 
25% over the first 8 hours 
despite maximum dose 
achieved 
Add milrinone Increase: don’t 
follow. 
Decrease: follow 
No change: follow 
If SBP is stable or  
unsignifically  
increasing 
 
 > 95th percentile and ≤ 
99th centile +5 and dose is 
less than 0.5 ml/kg/hr) 
 
increase 0.1 ml/kg 
for every 15 minutes 
Increase: follow if not 
on maximum dose. 
Decrease: follow 
No change: don’t 
follow if not on 
maximum dose 
If SBP is 
increasing 
significantly 
between 99th centile +5-15 
mmHg within 30 mins 
increase 0.1 ml/kg 
for every 15 minutes 
Increase: follow if not 
on maximum dose. 
Decrease: follow 
No change: don’t 
follow if not on 
maximum dose 
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between 99th centile +5-15 
mmHg for > 30 mins 
 Continue to 
increase 0.1 
ml/kg for every 
15 minutes if 
dose is less than 
0.5 ml/kg/hr 
 And add 
milrinone  
Increase: follow if not 
on maximum dose. 
Decrease: follow 
No change: don’t 
follow if not on 
maximum dose 
SBP > 99th centile +15 
mmHg within 15 mins 
increase 0.1 ml/kg 
for every 15 minutes 
Increase: follow if not 
on maximum dose. 
Decrease: follow 
No change: don’t 
follow if not on 
maximum dose 
SBP > 99th centile +15 
mmHg for >15 mins 
 Continue to 
increase 0.1 
ml/kg for every 
15 minutes if 
dose is less than 
0.5 ml/kg/hr 
 And add 
milrinone 
Increase: follow if not 
on maximum dose. 
Decrease: follow 
No change: don’t 
follow if not on 
maximum dose 
If SBP is 
increasing 
rapidly and there 
are evidences of 
acute target 
organ damage 
SBP > baseline + 40 mmHg   Continue to 
increase 0.1 
ml/kg for every 
15 minutes if 
dose is less than 
0.5 ml/kg/hr 
 And add 
milrinone 
Increase: follow if not 
on maximum dose. 
Decrease: follow 
No change: don’t 
follow if not on 
maximum dose 
 
 If patients are currently on both study drug and milrinone, when need to adjust 
the dose, please be noticed: 
 Increase the dose: Increase the dose of milrinone first until reaching the 
maximum dose (0,75 μg/kg/minute). If SBP still not be controlled, please inform 
and discuss with PI before considering unblinding. 
 Decrease the dose: decrease the dose of milrinone first until reaching the 
minimal dose (0,4 μg/kg/ minute), followed by decreasing the dose of study 
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drug 
 If a patient is treated with the maximum dose of milrirone as well as the 
maximum dose of study Mg/Placebo and the blood pressure is not controlled: 
study doctors may consider to unblind the study medication to ensure the patient 
is receiving magnesium sulfate. Please discuss all decisions to unblind with PI, and 
follow the Unblinding Procedure below.             
Please note:  
Hypertensive emergency- A severe symptomatic elevation in BP (> 30% compared to baseline 
blood pressure) WITH evidence of acute target organ damage defines a hypertensive 
emergency 
 Brain (seizures, increased intracranial pressure, paralysis) 
 Kidneys (renal insufficiency)  
 Eyes (papilledema, retinal hemorrhages, exudates) 
 Heart (heart failure) 
 Dose stopping after 72 hours of study: - Patients who complete the 72 hour study 
drug treatment at a dose of: 
 0.3 ml/kg/hr or less may stop study drug if their clinical condition permits 
 >0.3 <0.5 ml/kg/hr should have the study drug tapered to 0.3 ml/kg/hr then 
stopped. Tapering should be done according to the patient's clinical condition 
and completed within 6 hours when possible. 
*In rare cases, if study doctor is not available at the bed side when a clinical decision is 
needed, study nurse will contact the study doctor by phone to discuss the patient 
parameters. The study doctor will make a decision based on the pulse, RR, BP, Sp02 and 
other required clinical information. If the doctor decides to change the medication, the 
nurse will note this in the nursing record and the doctor will note this in the hospital file 
when s/he returns to the ward. 
EMERGENCY SITUATION 
If the emergency situation occurs as describe as below, the study drug will be stopped 
immediately, the unblinding procedures must be followed and rescue management should be 
applied: 
1. Cardiac arrest, AV block, QT >0.48ms  
2. Urine output < 1ml/kg/hr > 4 hrs with evidence of acute renal failure in ultrasound and 
creatinine result  
3. SBP < 70 mmHg 
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4. Intubation / ventilation 
1.1 Prolonged the QT interval or any cardiac arrhythmia: 
When plasma Mg level is high, usually above 5 mmol/l, this may result in prolongation of the 
QT interval (> 0.48 ms) and this could precipitate an arrhythmia. An ECG will be done at 
baseline and then daily and the QT interval will be measured as a routine. In addition if any 
arrhythmia is noted on the cardiac monitor the following actions will be taken.  
 Assess the patient clinically, perform a full ECG, check plasma Mg and Ca level and 
discuss the clinical situation with the site PI. 
 If the QT interval is above 480 mms, the study drug will be stopped immediately.  
 Any other serious cardiac arrhythmia will be managed according to APLS guidelines  
 The results of the Mg/Ca levels will go to the independent doctor for review. He/she 
will discuss the situation with the treating doctor. If the clinician has any clinical 
concerns the independent doctor will release the blood results so that the treating 
doctor can take any necessary action immediately. However, if the treating doctor and 
the site PI consider that the arrhythmia is minor (e.g occasional SVE’s) and there are no 
other clinical issues of concern, then the blood results will not be released. The 
independent doctor may recommend adjustments to the study drug infusion according 
to the blood test results, but sham adjustments will also be made to the placebo arm 
to maintain blinding.  
 However, if the calcium level < 0.9 mmol/l, the independent doctor will inform 
the treating doctor of this result specifically so that a rescue dose of 0.5ml/kg of 
calcium gluconate 10% can be given. 
1.2 Cardiac arrest 
In the event of a cardiac arrest the following actions will be taken: 
 Stop study drug infusion immediately 
 Emergency resuscitation will be started immediately according to APLS guidelines  
 Plasma Mg and Ca levels will be checked urgently and the results will be returned 
directly to the ward clinicians. 
 A rescue dose of 0.5ml/kg of calcium gluconate 10% will be given while awaiting the 
results if other attempts including CPR and conventional resuscitation drugs fail to 
restore sinus rhythm and effective cardiac output. 
 The plasma Mg/Ca results may unblind the clinical team to the randomization 
arm and the fact that an urgent level has been reported to the ward doctors 
will be recorded in the CRF. 
 Further intensive intervention will be done according to the Vietnamese MOH 
guidelines for HFMD management and APLS resuscitation guidelines. 
2. Urine output < 1ml/kg/hr: - define as urine output < 1ml/kg/ hr over 4 hours. 
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If the urine output is < 1ml/kg/ hr over 4 hours the following actions will be taken: 
 A bedside ultrasound will be performed to check whether there is any urine in the 
bladder 
 A urethral catheter will be inserted to monitor the urine output closely, and the plasma 
creatinine will be checked urgently 
 If the creatinine has increased to twice the baseline value, the study drug will be 
stopped and hemofiltration/dialysis will be performed according to the MOH 
guidelines regardless of the plasma Mg level. 
 If the creatinine is in the normal range but the bladder is empty, then the urine output 
will be monitored closely for 4 hours more. If the urine output is increasing during this 
time the study drug will be continued, but if there is no improvement the study drug 
will be stopped and hemofiltration/dialysis will be performed according to the MOH 
guidelines regardless of the plasma Mg level. 
 If the creatinine is in the normal range and there is urine in bladder, the urine output 
will be monitoring hourly for at least the next 24 hours 
3. Hypotension: - Development of hypotension could be the natural progression of severe 
disease or a side effect of MgS04, especially if the plasma Mg level is above 3 mmol/l. If 
hypotension occurs, defined as a drop in systolic blood pressure to below 70mmHg + 2 X the age 
in years lasting for 15 minutes, the follow actions will be taken:  
 Study drug will be stopped immediately 
 Assess the patient clinically, check plasma Mg/Ca levels and creatinine, and discuss the 
clinical situation with the site PI  
 Start with a fluid challenge of 5ml/kg of Lactate Ringers or NaCl 0.9% over 15 mins 
 Access the central venous pressure (CVP) and titrate the rate of fluid infusion based on 
CVP measurements and the clinical response. 
 Start inotropes or vasopressors (such as dobutamine, noradrenaline or adrenaline), 
and continue with interventions following the Vietnamese MOH guideline. 
 The results of the Mg/Ca levels will go directly to the ward clinicians. If the calcium 
level is < 0.9 mmol/l, regardless of the plasma Mg level, a rescue dose of 0.5ml/kg of 
calcium gluconate 10% will be given.  
 The plasma Mg/Ca results may unblind the clinical team to the randomization arm and 
the fact that an urgent level has been reported to the ward doctors will be recorded in 
the CRF. 
 If the creatinine level is increasing and the treating doctor suspects a diagnosis of acute 
renal failure, there may be a risk of toxicity due to Mg accumulation. Hemofiltration 
will be commenced according to MOH guidelines regardless of the plasma Mg level. 
4. Respiratory muscle weakness - defined as new signs and symtomps of respiratory distress 
and plasma Mg level is above 3 mmol/l. This is a very rare side effect of magnesium therapy 
and can be suggested by elevation in Plasma Mg level and the presence of respiratory distress  
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If the patient develops new or worsening signs and symptoms of respiratory distress the follow 
actions will be taken:  
 Assess the patient clinically including deep tendon reflexes, check the plasma Mg and 
Ca levels and an arterial blood gas and discuss the clinical situation with the site PI.  
 If the patient meets the MOH ventilation criteria as indicated above, (or the treating 
doctor thinks that the patient needs to be intubated for any reason) the study drug will 
be stopped immediately,  
o The results of the Mg/Ca levels will go directly to the ward clinicians. If the calcium 
level is < 0.9 mmol/l, regardless of the plasma Mg level, a rescue dose of 0.5ml/kg of 
calcium gluconate 10% will be given.  
o The plasma Mg/Ca results may unblind the clinical team to the randomization arm 
and the fact that an urgent level has been reported to the ward doctors will be 
recorded in the CRF. 
 If the patient does not meet the MOH ventilation criteria and the treating doctor and 
site PI agree that immediate intervention/respiratory support is not needed the patient 
will be observed closely for at least 60 minutes. 
o The results of the Mg/Ca levels will go to the independent doctor for review as soon 
as possible. If the Mg level is above 2.5 mmol/l but below 3 mmol/l, the treating 
doctor will be informed to reduce the infusion dose as described in the protocol. 
Similar sham adjustments can also be made to the placebo arm to maintain 
blinding.  
o If the Mg level is 3 mmol/l or above, the independent doctor will release the result 
and inform the study doctor to stop the study drug infusion.  
o If the Ca level is < 0.9 mmol/l the treating doctor will be informed so that a rescue 
dose of 0.5ml/kg of calcium gluconate 10% can be given if appropriate. 
o If the patient subsequently meets the criteria for intubation, or the PaCO2 rises >45 
mmHg, the intubation steps described above will be acted upon. 
 Any further interventions will be performed according to the Vietnamese MOH 
guidelines for HFMD management 
EMERGENCY UNBLINDING PROCEDURE 
If there is any question about whether the participant should be unblinded or not, the 
investigator is encouraged to contact one of the Principal Investigators at: 
Dr. Phan tu Qui – Tel: 0942555202 , Email: phantuqui@gmail.com  
Dr. Truong Huu Khanh – Tel: -----, Email: truonghuukhanh@gmail.com  
When considering unblinding due to an Adverse Event all of the following three criteria should 
be met in order to unblind the participant’s randomization: 
1. The Adverse Event must be a Serious Adverse Event as defined in the protocol and 
duplicated above. 
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2. The Serious Adverse Event must be thought to be probably or definitely related to the 
study drug as defined in the protocol and duplicated above. 
3. The treating clinician states that knowledge of the treatment arm may change the 
therapy provided to the participant or improve the patient’s outcome. 
UNBLINDING PROCEDURE 
 The contact person will verify that the participant has met the criteria for unblinding 
and provide the unblinding information to one of the site PIs. 
 One of the PIs must confirm that a serious adverse event has occurred. 
 One of the PIs will review the above criteria for emergency unblinding and confirm that 
knowing the treatment arm of the study will aid or change the clinical management of 
the participant. 
 One of the PIs will complete the SAE Report Form and submit to the Data and Safety 
Monitoring Committee, to the manufacturers of the therapy (if the patient is 
randomized to the Magnesium arm of the study) and to Dr. Nguyen Van Vinh Chau, 
Director of HTD or Dr Nguyen Thanh Hung, Vice director of Ch1, within 24 hours of 
becoming aware of the event, then send reports to MOH as the above procedure.  
 The PI will call the study pharmacist to request the unblinding information. The PIs will 
be responsible for ensuring that the unblinding is recorded in the study file by the 
study nurse. 
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Appendix B.4                        Monitoring and Reporting AEs And SAEs 
Definitions: 
Adverse Event : An unfavourable or unexpected sign, including an abnormal laboratory finding 
that is temporally associated with the use of an investigational product, whether or not 
considered related to the product. Events will be considered Adverse Events if they occur after 
the first infusion of study drug commences. Pre-existing conditions that worsen after the first 
infusion of study drug commences will also be reported as Adverse Events.  
 
Serious Adverse Events (SAE): In this study, an AE is a Serious Adverse Event if it results in any 
of the following outcomes: 
 Results in death or 
 Is life-threatening (i.e. the patient was at risk of death at the time of the AE) or 
 Requires prolongation of existing hospitalization or 
 Requires new inpatient hospitalization or 
 Results in persistent or significant disability/incapacity 
 
LABORATORY EVENTS: 
All laboratory parameters will be included in the analysis, with cutoffs identifying significant 
abnormalities defined in the database (see section above). Significant laboratory 
abnormalities will be entered on an AE form only if they meet one or more of the following 
conditions: 
 Accompanied by clinical symptoms 
 Leading to a change in the study drug (dose modification or withdrawal) 
 Requiring a change in concomitant therapy (e.g. dose adjustment or discontinuation) 
 Note: Laboratory abnormality only needs to be recorded as a clinical adverse event if it is 
associated with an intervention 
Adverse event recording 
All directly observed or spontaneously reported AEs will be recorded in the participant’s 
medical records and in the CRF and entered on the database, together with the Study 
Physician’s assessment of the relation to the study drug. One of the PI’s will be informed as 
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soon as possible. 
Please refer to the “AE Scale Classification” specifically modified for 02EI to justify and record 
when event occur. 
Adverse event reporting 
 Serious Adverse Event need to be entered on the separate SAE reporting form. One of the 
PIs must be informed as soon as possible. 
 All SAEs will be reported to the Sponsor (OUCRU), the local Research Ethics Committee 
(HTD or Children Hospital 1) as soon as possible. 
o For SAEs results death or threatens life 
 PI will write an initial report and send to coordinator within 2 days of the 
onset of event. Trial coordinator will submit the initial report to the 
sponsor and local IRB for comment and to office of MOH Research Ethics 
Committee (MOH REC) as soon as possible within 7 days.  
 The final report with comment from hospital IRB, will be sent to office of 
MOH Research Ethics Committee (MOH REC) within 14 days regardless 
the SAE has been resolved.   
o For other SAEs 
PI will write an initial report and send to coordinator within 2 days of the onset of event. Trial 
coordinator will submit the initial report to the sponsor and local IRB.   
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Appendix B.4 Mg Safety Monitoring Doctor 
Overview 
The main responsibilities of MSMD are recording and monitoring closely the Mg/Ca value of 
the randomized patients and indicate if there’s need to adjust the study dose following this 
SOP 
List of MSMD: 
1 –Dr Nguyen Minh Nguyet – phone number:  
2 –Dr Tran Thi Van Thinh - phone number: 0907481915 
3-  Dr. Nguyen Thi Hoang Mai – phone number: 0989698860 
A schedule of assigned MSMD (one main MSMD, and one for the substitute) will be posted in 
the ward. The study nurse will maintain the schedule and make arrangements with the MSDS 
to ensure that each MSDS is available and the responsibilities transfer smoothly. The assigned 
MSMD will rotate each week on Monday. Weeks should be arranged to avoid travel or leave. 
Backup: If the lab/PICU cannot contact the assigned MSMD within 15 minutes of the 
scheduled time, they will contact the substitute with accordance to the number provided 
each week. 
An optional tablet will be available for MSMD if needed 
System set up 
The CliRes system will be established by the OUCRU IT. It will contain the randomized 
allocation of each patient and randomized dose adjustments for patients who receive 
placebo.   
Access to the CliRes will be strictly controlled.    
ACCESS 
Each assigned MSMD will be provided with a username and password to access to this CliRes 
database. The MSMD who is in charge each week will be responsible to entry the data on 
CliRes. 
For new Patient: 
Study nurse will inform MSMD about study number and patient name for any new enrolled 
patients 
Upon receiving result of Mg/Ca, MSMD filled the click “NextPatient” to take the correct study 
number 
For ongoing patient: 
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MSMD will fill in correct study number in “PatientNo” box and click “search” 
 
MSMD will enter the value on all the required fields (i.e., date, time, Mg, Ca value, etc.), then 
hit the “Save” button. 
CliRes can be access on any devices, and a tablet with internet access will be provided if 
request for a MSMD who is on duty. In case of problems with the CliRes please contact Mr. 
Hien, OUCRU-IT at tel: 0988084391. 
ON THE WARD -   
Mg/Ca levels will be checked upon enrolment, 8 am or 8 pm for the after 12 hours, and at 8 
am on the next 2 sequential days.  
Mg/Ca levels may be checked at any point in the case of an emergency. 
Mg/Ca tests will be requested and reported separately from other Biochemistry tests. Study 
staff will verify the schedule to know which MSMD is on duty that day and will apply a label 
with the name and phone number of the assigned MSMD on the request form for Mg and Ca 
test. The label will also include the instruction “Do not upload this result”. 
IN THE LAB – Mg/Ca tests with study labels will be processed as soon as possible. The lab staff 
will text and then call the number on the label to inform the result of Mg/Ca and the 
correlated study number to the MSMD who is in charge at that time 
Lab staff who enters the lab result will make sure the Mg/Ca is not uploaded onto computer. 
For the scheduled tests: 
 If the Ca < 0.9 mmol/l the lab technical will inform the MSMD immediately. The 
MSMD will call the study/ward doctor immediately to inform them of the result. 
 If the Mg>3.0 mmol/l the lab technical will inform the MSMD immediately. The 
MSMD will call the study/ward doctor immediately to decrease the dose. 
 For any other Ca/Mg results, the lab technical will inform the MSMD no later than 10 
am daily for 8 am draws and no later than 10 pm for 8 pm draws (note that this will only 
occur at 8 pm on days when new patients are enrolled). 
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MSMD 
MSMD will receive message and calls from the lab according to the study schedule. The study 
nurse will support the MSMD to track patient schedules to know approximately when the 
scheduled tests/calls will occur.   
When a result is received from the lab, the MSMD will repeat the result, time point and 
patient number back to the lab to double check the results. The MSMD will then enter the 
result for the appropriate patient number and time point on CliRes and enter their 
recommended dose adjustment (for active Mg arm only – see decision criteria below). 
After receiving the schedule result, the MSMD will ring the ward and inform the guideline no 
later than 11 am daily or 11 pm for evening draws.   
When enrolled patients are within the first 48 hours of treatment, if the MSMD does not 
receive a call from the lab by 10 am/pm, s/he will call the lab at 290. 
MSMD will make a decision regarding the recommended dose adjustment as follows: 
For patients on the placebo arm:  
 Call the study doctor and recommend that the dose be decreased, maintained or increased 
as shown on the CliRes system unless the current dose is already the maximum (when 
increase is shown) or minimum (when decrease is shown). In these cases, the 
recommendation should be No Change. 
For patients on the active Mg arm: 
If serum Mg <1.8 mmol/l - tell study doctor to increase dose  
If serum Mg >2.5 mmol/l – tell study doctor to decrease dose.  
If serum Mg 1.8 - 2.5 mmol/l – tell study doctor not to change the dose 
In emergency circumstances: 
o If knowing the Mg/Ca test results is relevant to affect patient care, the study/treating 
doctor will discuss the emergency circumstance with site PI immediately. If the study 
doctor/treating doctor has any clinical concerns, the result will be release immediately to the 
ward and the lab technician will inform the MSMD, then MSMD will complete the Mg Safety 
Monitor Log 
o If not, the MSMD will follow the instruction as above 
On the last recommendation (Day 4- T72): before giving the recommendation, MSMD will 
ask the study doctor/ clinical doctor who is on duty:  
o If the study patient is still on study drug: follow the above procedure 
o If the study patient completed the study drug course: no further 
recommendation is required. Complete the CliRes.  
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